Identification of novel protein kinase regulators of TGFβ signalling by Hutchinson, Luke
                                                                          
University of Dundee
DOCTOR OF PHILOSOPHY
Identification of novel protein kinase regulators of TGF signalling
Hutchinson, Luke
Award date:
2019
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jan. 2021
Identification of novel protein kinase 
regulators of TGFb signalling 
Luke Daniel Hutchinson 
A thesis submitted for the degree of Doctor of Philosophy (PhD) 
MRC Protein Phosphorylation and Ubiquitylation Unit 
University of Dundee 
May 2019 
2 
TABLE OF CONTENTS 
DECLARATIONS .................................................................................................................. 6 
ACKNOWLEDGEMENTS ...................................................................................................... 7 
THESIS SUMMARY ............................................................................................................. 8 
LIST OF FIGURES AND TABLES .......................................................................................... 10 
ABBREVIATIONS .............................................................................................................. 13 
AMINO ACID CODE .......................................................................................................... 23 
PUBLICATIONS ................................................................................................................. 24 
1 INTRODUCTION ........................................................................................................ 25 
1.1 TRANSFORMING GROWTH FACTOR-β (TGFβ) SIGNALLING ........................................... 25 
1.1.1 The TGFβ cytokines ...................................................................................................................... 25 
1.1.2 Signalling receptors of the TGFβ family of ligands ...................................................................... 31 
1.1.3 SMAD proteins – the mediators of the canonical TGFβ signalling pathway .............................. 35 
1.1.4 Transcriptional control by SMAD proteins .................................................................................. 40 
1.1.5 SMAD-independent signalling by TGFβ family members ........................................................... 42 
1.2 THE REGULATION OF TGFβ SIGNALLING ....................................................................... 48 
1.2.1 Regulation of TGFβ signalling by reversible post-translational modification (PTM) ................. 48 
1.2.2 Regulation of TGFβ receptors by reversible protein phosphorylation ....................................... 48 
1.2.3 Regulation of TGFβ receptors by reversible protein ubiquitylation ........................................... 49 
1.2.4 Regulation of SMADs by reversible protein phosphorylation .................................................... 53 
1.2.5 Regulation of SMADs by reversible protein ubiquitylation ........................................................ 56 
1.3 CELLULAR FUNCTIONS OF TGFβ FAMILY CYTOKINES .................................................... 59 
1.3.1 The importance of cellular context ............................................................................................. 59 
1.3.2 Immune regulation ...................................................................................................................... 60 
1.3.3 Cellular proliferation .................................................................................................................... 61 
1.3.4 Epithelial-mesenchymal transition (EMT) ................................................................................... 66 
1.3.5 Apoptosis ..................................................................................................................................... 69 
1.4 TGFβ SIGNALLING IN HUMAN PATHOLOGIES ............................................................... 73 
1.4.1 TGFβ signalling in cancer ............................................................................................................. 73 
1.4.2 TGFβ-induced fibrosis .................................................................................................................. 75 
1.4.3 Pharmacological intervention of TGFβ-associated human pathologies ..................................... 77 
3 
1.5 AIMS OF THE PHD THESIS ............................................................................................ 81 
2 MATERIALS AND METHODS ...................................................................................... 83 
2.1 MATERIALS .................................................................................................................. 83 
2.1.1 Antibodies .................................................................................................................................... 83 
2.1.2 Cytokines ...................................................................................................................................... 83 
2.1.3 Small-molecule pharmacological inhibitors ................................................................................ 84 
2.1.4 RT-qPCR primers .......................................................................................................................... 84 
2.1.5 Small interfering RNA (siRNA) oligonucleotides ......................................................................... 85 
2.1.6 Recombinant proteins ................................................................................................................. 86 
2.2 METHODS .................................................................................................................... 87 
2.2.1 Mammalian cell culture ............................................................................................................... 87 
2.2.2 Cryopreservation of mammalian cell lines .................................................................................. 87 
2.2.3 Transformation of primary MEFs ................................................................................................ 88 
2.2.4 Pharmacological screen ............................................................................................................... 89 
2.2.5 Treatment of cells with cytokines and small-molecule inhibitors .............................................. 89 
2.2.6 Transfection of cells with siRNA .................................................................................................. 89 
2.2.7 Mammalian cell lysis .................................................................................................................... 90 
2.2.8 Protein concentration measurement .......................................................................................... 91 
2.2.9 Endogenous CRTC3 immunoprecipitation (IP) ............................................................................ 92 
2.2.10 Covalent conjugation of antibodies to protein G agarose ..................................................... 92 
2.2.11 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) ............................. 93 
2.2.12 Western immunoblotting ....................................................................................................... 94 
2.2.13 Quantitative reverse transcription polymerase chain reaction (RT-qPCR) ........................... 95 
2.2.14 Luciferase transcriptional reporter assay ............................................................................... 95 
2.2.15 Cellular fractionation (cytoplasmic/nuclear) ......................................................................... 96 
2.2.16 Annexin V staining assay ......................................................................................................... 97 
2.2.17 Crystal violet cellular viability assay ....................................................................................... 97 
2.2.18 Cellular proliferation assay ..................................................................................................... 98 
2.2.19 Removal of GST affinity tag from purified recombinant proteins ......................................... 99 
2.2.20 In vitro protein kinase assay ................................................................................................... 99 
2.2.21 Statistical analysis ................................................................................................................. 100 
3 RESULTS ................................................................................................................. 101 
3.1 SMALL-MOLECULE INHIBITOR SCREEN IN ENDOGENOUS TGFb-RESPONSIVE 
TRANSCRIPTIONAL REPORTER CELL LINE ................................................................................. 101 
4 
3.1.1 Introduction ............................................................................................................................... 101 
3.1.2 Characterisation of endogenous TGFb transcriptional reporter cell line ................................. 103 
3.1.3 Identification of putative hits obtained from the pharmacological screen ............................. 106 
3.1.4 Discussion ................................................................................................................................... 114 
3.2 CHARACTERISATION OF SIK INHIBITORS IN THE CONTEXT OF TGFb SIGNALLING ........ 115 
3.2.1 Introduction ............................................................................................................................... 115 
3.2.2 Two structurally distinct SIK inhibitors suppress TGFb-induced luciferase transcriptional 
reporter activity ....................................................................................................................................... 119 
3.2.3 SIK inhibitors attenuate phosphorylation of CRTC3 in U2OS osteosarcoma cells ................... 121 
3.2.4 Analysis of SIK inhibitors on receptor-mediated SMAD3 phosphorylation ............................. 123 
3.2.5 In vitro protein kinase analysis of SIK isoforms against SMAD2 and SMAD3 .......................... 125 
3.2.6 MRT199665 does not affect the TGFb-dependent nuclear accumulation of SMAD2 or SMAD3
131 
3.2.7 Discussion ................................................................................................................................... 132 
3.3 VALIDATION OF SIK INHIBITION AS A REGULATOR OF TGFb-INDUCED GENE 
TRANSCRIPTION ...................................................................................................................... 135 
3.3.1 Introduction ............................................................................................................................... 135 
3.3.2 The small-molecule inhibitor MRT199665 suppresses TGFb-induced target gene expression135 
3.3.3 Discussion ................................................................................................................................... 139 
3.4 GENETIC EVIDENCE FOR THE INVOLVEMENT OF SIK ISOFORMS IN THE MODULATION OF 
TGFβ SIGNALLING ................................................................................................................... 141 
3.4.1 Introduction ............................................................................................................................... 141 
3.4.2 Overexpression of catalytically active LKB1 potentiates the TGFβ-mediated induction of PAI-1 
expression ................................................................................................................................................ 141 
3.4.3 The RNAi-mediated depletion of SIK isoforms attenuates TGFβ-mediated upregulation of PAI-
1 expression ............................................................................................................................................. 144 
3.4.4 The genetic inactivation of SIK isoforms attenuates TGFβ-mediated transcriptional induction 
of PAI-1 146 
3.4.5 Discussion ................................................................................................................................... 150 
3.5 THE CLINICALLY APPROVED SMALL-MOLECULE INHIBITORS BOSUTINIB AND DASATINIB 
INHIBIT SIK ISOFORMS AND REGULATE TGFβ SIGNALLING ...................................................... 152 
3.5.1 Introduction ............................................................................................................................... 152 
3.5.2 Bosutinib and dasatinib are potent inhibitors of SIK isoforms in vitro and in cultured cell lines
155 
3.5.3 Bosutinib and dasatinib both negatively regulate TGFβ-dependent gene transcription ........ 158 
5 
3.5.4 Discussion ................................................................................................................................... 159 
3.6 THE EFFECT OF SIK INHIBITION ON TGFβ-MEDIATED PHYSIOLOGICAL RESPONSES ...... 163 
3.6.1 Introduction ............................................................................................................................... 163 
3.6.2 MRT199665 enhances the upregulation of the cyclin-dependent kinase inhibitors p21CIP1 and 
p27KIP1 163 
3.6.3 NMuMG murine mammary epithelial cells undergo TGFβ-induced apoptosis ....................... 167 
3.6.4 Treatment of NMuMG cells with MRT199665 enhances the proteolytic cleavage of caspase-3 
and PARP in response to TGFβ stimulation ............................................................................................. 171 
3.6.5 Treatment of NMuMG cells with MRT199665 increases the percentage of apoptotic cells and 
reduces cellular viability .......................................................................................................................... 173 
3.6.6 Treatment of NMuMG cells with bosutinib enhances the proteolytic cleavage of caspase-3 and 
PARP in response to TGFβ stimulation .................................................................................................... 179 
3.6.7 Discussion ................................................................................................................................... 181 
4 CONCLUSIONS AND FUTURE PERSPECTIVES ............................................................ 184 
REFERENCES ................................................................................................................... 191 
6 
DECLARATIONS 
I declare that the following thesis is based upon experimental investigations conducted by 
myself, and that this thesis is of my own composition. Research other than my own is 
indicated by reference to the relevant publications or researchers. Furthermore, this 
dissertation has not previously been submitted for a higher degree. 
Luke Daniel Hutchinson 
I certify that Luke Daniel Hutchinson has completed the equivalent of at least nine terms in 
research work in the Medical Research Council (MRC) Protein Phosphorylation and 
Ubiquitylation Unit within the School of Life Sciences at the University of Dundee and that he 
has fulfilled the conditions of the Ordinance General No. 14 of the University of Dundee and 
is qualified to submit the accompanying thesis in application for the degree of Doctor of 
Philosophy (PhD). 
Dr. Gopal P. Sapkota 
7 
ACKNOWLEDGEMENTS 
First and foremost, I wish to thank my supervisor Gopal Sapkota for providing me the 
opportunity to conduct my PhD research project under his supervision. I am extremely 
grateful for his guidance, encouragement and persistence throughout my time in the lab. 
I also wish to thank the past and present members of the Sapkota lab, in particular 
Tim, Polyxeni, Fulchie for invaluable scientific (and non-scientific…) discussions. It was a 
pleasure to work alongside you and I am forever appreciative that the lab was such an 
enjoyable place to work (despite Fulchie’s innumerable bad puns over the years). In addition, 
I also wish to thank the many friends I made throughout the MRC PPU. Although too many to 
mention individually, I wish to specifically thank Lambert for the intense discussions regarding 
Catalan independence and the many weekend mornings spent on the squash court. Also, I 
am incredibly grateful to Ana, George and Gerrit, my original lab mates when I first moved to 
Dundee and whose help throughout the difficult times adjusting to PhD life was 
immeasurable. I also wish to thank Dominika, whose friendship, advice and company over the 
previous three years has been one of the highlights of my time spent in Dundee. 
I would like to acknowledge and thank all the technical and administrative support 
staff within the MRC PPU, without whom it would be a much more difficult place to work. In 
particular, I wish to thank Jennifer Moran (for compiling the small-molecule inhibitor library), 
Dr. Rosie Clarke (for technical advice and assistance with performing the flow cytometric 
analyses) and Nicola Wood (for all the cDNA cloning). 
I also wish to thank Dr. Nicola Darling, for providing me with the SIK inactive KI MEF 
cell lines which have contributed invaluably towards this thesis project and for her advice and 
knowledge regarding the SIKs. In addition, I also wish to thank Prof. Philip Cohen for his advice 
and input at times during the project. 
Finally, I wish to thank my parents and sister for their unwavering support throughout 
my PhD, without which it would not have been possible. I would like to dedicate this thesis to 
my grandfathers, who have been the most influential people in my life and whom I hope 
would be proud. 
8 
THESIS SUMMARY 
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) 
family of cytokines perform critical functions during embryonic development and adult tissue 
homeostasis. Accordingly, TGFβ family members are involved in the regulation of a diverse 
array of cellular processes including epithelial-mesenchymal transition (EMT), differentiation, 
cellular proliferation, extracellular matrix (ECM) production and apoptotic cell death. Hence, 
genetic malfunctions in the TGFβ-induced signalling pathways are implicated in the 
pathogenesis of multiple somatic and inherited human pathologies, most notably fibrosis and 
tumourigenesis and metastasis. Accumulating evidence has illuminated the context-
dependent nature of TGFβ signalling and provided a molecular framework by which to explain 
how a conceptually simple signal transduction pathway is able to control diverse cellular 
responses. Thus, further elucidation of the molecular basis underlying the contextual 
determinants of TGFβ signalling will evidently provide a greater understanding of how TGFβ 
signalling operates in different cellular contexts and inform research focused on 
pharmacologically targeting the pathway effectively. 
This thesis project began by conducting a pharmacological screen using an 
endogenous TGFβ-dependent transcriptional reporter cell line in order to identify potential 
novel regulatory components of the TGFβ signalling pathway. From this screen and 
subsequent validation experiments, I observed that three structurally unrelated small-
molecule inhibitors that target the salt-inducible kinases (SIKs) are able to attenuate the 
TGFβ-mediated transcriptional regulation of specific target genes. Moreover, this 
transcriptional attenuation occurred without affecting the receptor-mediated 
phosphorylation of the R-SMAD transcription factors SMAD2 or SMAD3 nor the ability of 
activated SMAD transcriptional complexes to translocate into the nucleus. 
The SIKs, of which there are three isoforms, are serine-threonine specific protein 
kinases that belong to the AMPK-related family of kinases. To date, the reported cellular 
functions of SIK isoforms are primarily in the control of innate immune signalling and 
metabolic regulation. The SIKs primarily function by phosphorylating and hence regulating 
the activity of the transcriptional coregulators CREB-regulated transcriptional coactivators 
(CRTCs) and the class IIa histone deacetylases (HDACs) HDAC4 and HDAC5. From the research 
conducted during this thesis project, it is now evident that SIKs also function to modulate 
9 
TGFβ-dependent transcriptional responses. However, the precise molecular mechanisms 
underlying this observation remain to be elucidated. 
In addition to small-molecule kinase inhibition of SIK isoforms, I have demonstrated 
that genetic inactivation of SIK2 and SIK3 results in the attenuation of TGFβ-dependent 
transcriptional induction of the target gene PAI-1. Moreover, both PAI-1 transcript and 
protein expression are attenuated in cells which are deficient in the endogenous expression 
of LKB1, the upstream activating kinase of SIK isoforms. Crucially, restoration of wild type, but 
not kinase inactive LKB1, potentiates both basal and TGFβ-induced PAI-1 expression. The 
effect of small-molecule SIK inhibitors was also investigated in the context of the TGFβ-
dependent cellular proliferation and apoptotic responses. Inhibition of SIKs was sufficient to 
enhance the anti-proliferative response in certain cell lines. Furthermore, treatment of cells 
with small-molecule SIK inhibitors potentiated TGFβ-mediated apoptotic cell death. 
Collectively, these findings not only identify SIK isoforms as novel regulators of TGFβ signalling 
but also imply that inhibiting SIKs might sensitise certain cancers for TGFβ-mediated 
apoptosis. 
10 
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TM transmembrane 
TNF tumour necrosis factor 
TP53 cellular tumour antigen p53 
TRAF6 TNF receptor-associated factor 6 
Treg regulatory T cell 
Tris tris(hydroxymethyl)methylamine 
u-PA urokinase-type plasminogen activator 
Ub ubiquitin 
UC ulcerative colitis 
UCH ubiquitin carboxy-terminal hydrolase 
US FDA United States Food and Drug Administration 
USP ubiquitin-specific proteases 
V volt 
v/v volume to volume ratio 
VEGF vascular endothelial growth factor 
w/v weight to volume ratio 
WT wild type 
WW tryptophan-tryptophan 
ZEB zinc finger E-box-binding homeobox 
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ZO-1  zonula occludens-1 
µ  micro- 
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AMINO ACID CODE 
Amino acid Three-letter code Single-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
Any amino acid Xaa X 
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1 INTRODUCTION 
 
1.1 TRANSFORMING GROWTH FACTOR-β (TGFβ) SIGNALLING 
 
The signalling pathways initiated by the transforming growth factor-β (TGFβ) family of 
cytokines are amongst the most prevalent and diverse in metazoan biology. TGFβ cytokines 
are known to regulate a multitude of cellular processes including cell proliferation and 
differentiation, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) 
production, immune regulation and apoptosis, in a context-dependent manner. Therefore, 
perturbations in the signalling pathway have been implicated in the development of many 
pathological conditions such as tumorigenesis and metastasis, fibrotic disorders, congenital 
diseases and dysregulation of the immune system (Elliott and Blobe, 2005; Gordon and Blobe, 
2008). 
 
 
1.1.1 The TGFβ cytokines 
The TGFβ family of structurally related cytokines are encoded by 33 genes in the human 
genome and includes the three prototypical TGFβ members, Nodal, left-right determination 
factor 1 and 2 (LEFTY1 and LEFTY2), inhibin-a, four inhibin-β chains (heterodimers of which 
form activin isoforms), bone morphogenetic proteins (BMPs), anti-Muellerian hormone 
(AMH, alternatively referred to as Muellerian-inhibiting substance; MIS) and growth and 
differentiation factors (GDFs). These members can be further divided into sub-families; the 
TGFβ/activin/nodal subfamily and the BMP/GDF/MIS subfamily. This subdivision is based on 
a number of structural and functional considerations including sequence similarity, 
preferences for different cell surface receptors and differences in downstream SMAD 
activation (Shi and Massagué, 2003). 
 All of the 33 genes for TGFβ and BMP cytokines encode large precursor polypeptides 
with similar sequence organisation, consisting of an amino-terminal secretion signal peptide, 
a large, approximately 250 residue precursor segment (termed prodomain or prosegment) 
and a carboxy-terminal polypeptide that confers the biological activity of the mature dimeric 
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form of the protein. The amino-terminal secretion signal peptide is cleaved during 
translocation of the polypeptide into the lumen of the rough endoplasmic reticulum (RER) 
(Morikawa, Derynck and Miyazono, 2016). The amino acid sequence of the carboxy-terminal 
polypeptide defines the structural similarity of TGFβ cytokines, whereas the sequence of the 
prodomain polypeptide is divergent amongst the family members, varying in both length and 
sequence homology (Derynck et al., 1988). In order to generate the biologically active 
signalling proteins, the inactive precursor polypeptides of TGFβ/BMP members undergo 
proteolytic processing. For example, the 55 kDa pro-TGFβ1 polypeptide requires 
endoproteolytic cleavage conducted by the serine proprotein convertase furin, resulting in 
the separation of the 44 kDa prodomain from the 12.5 kDa mature TGFβ1 monomer (Dubois 
et al., 1995). Similarly, the precursor polypeptides of Nodal and BMP4 can be proteolytically 
processed by either furin or another proprotein convertase termed PACE4 (alternatively 
referred to as proprotein convertase subtilisin/kexin type 6; PCSK6) (Constam and Robertson, 
1999). The importance of this endoproteolytic regulation is highlighted by the dysregulation 
of anteroposterior and left-right axis formation that occurs during early embryonic 
development in PACE4-deficient mouse embryos (Constam and Robertson, 2000). 
Interestingly, TGFβ isoforms are secreted from cells in a biologically inactive form termed 
latent TGFβ, which consists of the mature TGFβ homodimer non-covalently associated with 
the previously cleaved prodomain polypeptide. In this context, the prodomain is 
subsequently referred to as the latency-associated peptide (LAP) (Miyazono et al., 1988; 
Wakefield et al., 1988). The LAP protein is itself dimeric, resulting from the formation of 
intermolecular disulphide bonds between monomers, and functions to prevent the mature 
TGFβ homodimer from interacting with cognate cell surface receptors. This latent TGFβ 
complex is further associated with latent TGFβ-binding proteins (LTBPs) which assist with 
correct complex formation and may define the extracellular localisation of the latency 
complex (Miyazono et al., 1991). The liberation of the active TGFβ cytokine from the latency 
complex is therefore an important regulatory event in the TGFβ signalling pathway and can 
be achieved through a variety of mechanisms. A number of different proteases have been 
reported to be involved in the proteolytic activation of latent TGFβ including the serine 
protease plasmin (Lyons, Keski-Oja and Moses, 1988) and matrix metalloprotease-9 (MMP-9) 
(Yu and Stamenkovic, 2000). 
 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A. The TGFβ family of cytokines 
(A) The human genome encodes 33 genes of the transforming growth factor β (TGFβ) family 
of cytokines including 3 TGFβ isoforms, 4 inhibin-β subunits, 10 bone morphogenetic proteins 
(BMPs) and 11 growth and differentiation factors (GDFs). All members of the TGFβ cytokine 
family are synthesised as large precursor polypeptides that require proteolytic processing by 
proprotein convertase (PC) enzymes either intracellularly or extracellularly. The family 
includes a number of antagonistic ligands: left-right determination factor 1 and 2 (LEFTY1 and 
LEFTY2) antagonise Nodal, inhibin antagonises activins and BMP3 antagonises other BMP 
members. The following members have alternative names indicated in parentheses: BMP15 
(GDF9B), GDF2 (BMP9), GDF5 (BMP14), GDF6 (BMP13), MSTN (GDF8), GDF10 (BMP3B) and 
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GDF11 (BMP11). GDF15 is a distant member of the TGFβ family and signals through glial-
derived neurotrophic factor receptor a-like (GFRAL). (B) Phylogenetic tree derived from the 
protein sequence alignment of the TGFβ family precursor polypeptides. Multiple sequence 
alignment was performed in Jalview (version 2.10.5) software (Waterhouse et al., 2009) using 
the Clustal Omega sequence alignment programme. The phylogenetic tree was calculated 
using the neighbour-joining (NJ) method (Saitou and Nei, 1987). Abbreviations: AMH (Anti-
Muellerian hormone), inhibin-a (INHA), inhibin-β (INHB), MSTN (Myostatin). 
 
 
 Ligands of the TGFβ family, along with those of the nerve growth factor (NGF) and 
platelet-derived growth factor (PDGF) families all share a similar, unique structural motif 
known as a cysteine knot (Sun and Davies, 1995). The presence of this cysteine knot motif 
occurs due to the formation of intramolecular disulphide bonds between pairs of highly 
conserved cysteine residues. In addition to these, a single intermolecular disulphide bond is 
formed between corresponding cysteine residues present within each monomer that enables 
dimer formation. Sequence alignment of the three different TGFβ isoforms (TGFβ1-3) 
encoded in the mammalian genome determines that they share over 70 percent sequence 
identity and reveals the presence of nine highly conserved cysteine residues in each 
polypeptide chain. Elucidation of the crystal structure of the TGFβ2 isoform revealed that 
eight of these invariant cysteine residues form four intramolecular disulphide bonds between 
Cys7 and Cys16, Cys15 and Cys78, Cys44 and Cys109 and between Cys48 and Cys111. The 
ninth cysteine residue, Cys77, forms an intermolecular disulphide bond with the 
corresponding cysteine residue of another TGFβ2 monomer, and along with hydrophobic 
interactions, is responsible for stabilisation of the active TGFβ2 homodimer (Daopin et al., 
1992; Schlunegger and Grütter, 1992). The majority of the other members in the TGFβ family 
possess seven conserved cysteine residues that correspond to those present in the TGFβ 
isoforms, however they lack the two amino-terminal residues and thus only form three 
intramolecular disulphide bonds. 
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Figure 1B. Sequence alignment of all 33 members of the TGFβ family of cytokines 
All the members of the TGFβ family of cytokines share a distinctive structural motif referred 
to as a cysteine knot, which occurs due to the formation intramolecular disulphide bonds 
between pairs of highly conserved cysteine residues. In addition, a single intermolecular 
disulphide bond is also formed between corresponding cysteine residues present within each 
monomer that facilitates dimer formation. The three prototypical TGFβ isoforms contain nine 
invariant cysteine residues, eight of which participate in the formation of four intramolecular 
disulphide bonds and one which contributes to the intermolecular disulphide bond. The 
majority of the other TGFβ family members possess seven conserved cysteine residues that 
correspond to those present within the TGFβ isoforms and as a consequence only form three 
intramolecular disulphide bonds. Exceptions to this are the four inhibin-β monomers which 
contain the nine conserved cysteine residue arrangement as observed in the TGFβ isoforms 
and five family members (BMP15, GDF3, GDF9, LEFTY1 and LEFTY2) which only contain six 
conserved cysteine residues. As a result, it is uncertain whether these four members form 
dimers in order to be biologically active. The asterisks denote the seven conserved cysteine 
residues present within the prototypical TGFβ isoforms and the majority of other members 
(with exceptions detailed above). Multiple sequence alignment was performed in Jalview 
(version 2.10.5) software (Waterhouse et al., 2009) using the Clustal Omega sequence 
alignment programme. 
 
 
The fourth cysteine in each monomer participates in disulphide-linked dimerisation. 
Exceptions to this are the four inhibin-β monomers (A, B, C and E), which have the 
corresponding nine cysteine residue arrangement as observed in the TGFβ isoforms. 
Furthermore, some TGFβ family members (specifically BMP15, GDF3, GDF9, LEFTY1 and 
LEFTY2) only possess six conserved cysteine residues, compared with the usual seven-cysteine 
or nine-cysteine arrangement. In these instances, the members lack the fourth cysteine 
involved in ligand dimerisation and it is therefore uncertain as to whether they form 
disulphide-bonded dimers or utilise an alternate means to do. As such, the exact physiological 
functions of these six-cysteine TGFβ family members requires further investigation. 
As previously alluded to, biologically active TGFβ family members exist as dimers and 
have been predominantly studied as homodimers. An exception to this is the inhibin 
subfamily, members of which form heterodimers consisting of an a subunit covalently 
associated with a β subunit via a disulphide bond. Inhibin A is a heterodimer of the inhibin a 
and inhibin βA monomers, whereas Inhibin B is composed of inhibin a and inhibin βB 
monomers. In contrast, the three activin isoforms, activin A, activin B and activin AB, exist as 
homodimers of inhibin β monomers (composed of βA/βA, βB/βB and βA/βB respectively) 
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(Namwanje and Brown, 2016). The binding of active TGFβ cytokines to cognate receptors 
present on the cell surface initiates the intracellular signalling pathway. 
 
 
1.1.2 Signalling receptors of the TGFβ family of ligands 
The TGFβ family of cytokines elicit their biological function by binding to a family of 
structurally related transmembrane receptors that are classified as either type I or type II 
receptors. Compared with other broad classes of transmembrane signalling receptors, such 
as the multipass G-protein-coupled receptors (GPCRs) that transduce signals from Wnt or 
Hedgehog ligands (Frizzled, Patched and Smoothened families respectively) or single pass 
transmembrane receptor tyrosine kinases (RTKs) that transduce signals from a diverse array 
of cytokines including epidermal growth factor (EGF), insulin and insulin-like growth factors 
(IGFs) and fibroblast growth factors (FGFs), the TGFβ type I and type II receptors are unique 
in that they possess serine-threonine protein kinase activity. This family of serine-threonine 
kinase receptors represents the only known signalling receptors for TGFβ family members 
and no other cytokines have been reported to signal through these receptors. Interestingly, 
both the type I and type II receptors have also been reported to exhibit tyrosine kinase 
activity. In the case of the type II receptor, it is able to autophosphorylate three tyrosine 
residues (Tyr259, Tyr336 and Tyr424) within its cytoplasmic domain, although the levels are 
considerably lower compared with autophosphorylation on serine and threonine residues. 
Mutation of these tyrosine residues to phenylalanine residues inhibited the kinase activity of 
the type II receptor in vitro, suggesting that autophosphorylation of tyrosine residues may 
have an autoregulatory function (Lawler et al., 1997). In addition, the type I receptor has been 
shown to phosphorylate tyrosine residues on substrate proteins and this is important for non-
canonical TGFβ signalling (discussed in further detail in section 1.2.5) (Lee et al., 2007). 
The human genome encodes 12 members of the serine-threonine kinase receptors, 
seven type I receptors and five type II receptors. The seven type I receptors are comprised of 
TGFβR1 (ALK5), ACVR1B (ALK4), ACVR1C (ALK7), ACVRL1 (ALK1), ACVR1A (ALK2), BMPR1A 
(ALK3) and BMPR1B (ALK6). The five type II receptors include TGFβR2, ACVR2, ACVR2B, 
BMPR2 and AMHR2 (Schmierer and Hill, 2007). This TGFβ family of signalling receptors 
represents a distinct family (termed STRK) within the tyrosine kinase-like (TKL) group of the 
human kinome (Manning et al., 2002). 
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 The type I and type II receptors are both glycoproteins that consist of approximately 
500 amino acid residues, comprising a relatively short (~150 amino acid residues) amino-
terminal extracellular domain, a single transmembrane domain and a carboxy-terminal 
intracellular serine-threonine kinase domain (Shi and Massagué, 2003). Although the type I 
and type II receptors are both serine-threonine kinases, they share only 30 to 40 percent 
sequence homology in their intracellular domains (Ebner et al., 1993). In addition, the type I 
receptors possess unique features that are not present in type II receptors, notably a highly 
conserved 30 amino acid glycine-serine repeat sequence (SGSGSG; termed the GS domain) 
located immediately amino-terminal to the intracellular kinase domain (Wrana et al., 1994; 
Massagué, 1998). 
 The TGFβ family of ligands initiate intracellular signalling pathways by inducing the 
formation of heterotetrameric complexes of transmembrane serine-threonine kinase 
receptors, however two different mechanisms of receptor activation have been identified 
depending on the ligand involved. TGFβ and activin ligands exhibit high affinity for the type II 
receptor but do not interact with isolated type I receptors. Therefore, ligand-binding to type 
II receptors occurs first, followed by interaction with the type I receptor to form a large 
heteromeric complex containing the ligand dimer and homodimers of the type II and type I 
receptors. By contrast, receptor activation induced by members of the BMP subfamily, such 
as BMP-2 and BMP-4, occurs via an alternate mechanism. In this case, the BMP ligands display 
a higher affinity for the extracellular ligand-binding domain of the type I receptor compared 
to that of the type II receptor. The assembled type I receptor-ligand dimer complex 
subsequently has a higher binding affinity for the type II receptor (Shi and Massagué, 2003). 
In both cases, the ligand functions to bring specific pairs of type I and type II receptors in close 
proximity. The type II receptor is believed to be a constitutively active kinase and when in 
proximity to the type I receptor it is able to phosphorylate multiple serine and threonine 
residues within the TTSGSGSG sequence of the intracellular GS domain (Wrana et al., 1994). 
Phosphorylation of residues within the GS domain of the type I receptor is critical for its 
activation and ability to propagate signals from TGFβ family cytokines (Wieser, Wrana and 
Massagué, 1995). Furthermore, along with the residues within the GS domain, the type II 
receptor can also phosphorylate an additional serine residue (Ser165) located in the 
juxtamembrane region of the type I receptor. This phosphorylation event was demonstrated 
to modulate specific TGFβ-induced cellular responses in a positive or negative manner 
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(Souchelnytskyi et al., 1996). In addition to phosphorylation, the activation of the type I 
receptor is also regulated by the binding of an inhibitory protein, the immunophilin FK506-
binding protein 12 (FKBP12) (Wang, Donahoe and Zervos, 1994). In the absence of TGFβ 
ligands, FKBP12 binds to the unphosphorylated GS domain of the type I receptor and 
subsequently dissociates when ligand-induced, type II receptor-mediated phosphorylation of 
the type I receptor occurs (Wang et al., 1996). The unphosphorylated GS domain adopts a 
helix-loop-helix structure in which the regulatory phosphorylation sites are located within the 
loop between the two helices (termed the GS loop). The crystal structure of the type I 
receptor in complex with FKBP12 revealed that the receptor adopts a kinase inactive 
conformation which is maintained by interactions between the unphosphorylated GS loop 
and the amino-terminal lobe (N-lobe) of the kinase domain. FKBP12 binds directly to two 
highly conserved leucine residues (Leu195 and Leu196) within one of the GS domain helices 
and maintains the GS loop in an ordered inhibitory conformation (Huse et al., 1999). In the 
absence of FKBP12, the GS loop region is flexible and incapable of adopting this inhibitory 
conformation (Huse and Kuriyan, 2002). In addition to stabilising the inactive conformation 
of the type I receptor kinase domain, the binding of FKBP12 to the GS domain also obscures 
the type II receptor kinase phosphorylation sites. Therefore, it has been proposed that the 
function of FKBP12 is to impede the activation of heteromeric TGFβ receptor complexes that 
may occur in the absence of TGFβ ligands due to the innate affinity exhibited by type I and 
type II receptors towards one another, thereby preventing any spontaneous ligand-
independent signalling (Chen, Liu and Massague, 1997). 
 Additional non-catalytic accessory receptors have been identified that regulate the 
interaction of certain TGFβ family ligands to cognate type I and type II receptors. A prominent 
example is the accessory receptor betaglycan (alternatively referred to as the TGFβ type III 
receptor), a membrane-anchored proteoglycan that mediates the binding of TGFβ isoforms 
to the type II receptor (López-Casillas et al., 1991; Wang et al., 1991). Betaglycan is composed 
of a large extracellular domain which is modified by multiple glycosaminoglycan chains 
followed by a transmembrane domain and short intracellular domain. It is structurally related 
to another TGFβ family accessory receptor endoglin, a glycoprotein that is expressed at high 
levels in endothelial cells and is able to bind to a number of heteromeric receptor complexes. 
However, unlike betaglycan, it was initially reported that endoglin is unable to bind the ligand 
on its own, requiring the presence of a ligand-binding type II receptor in order to do so. 
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Endoglin does not appear to alter the formation or ligand-binding affinity of the receptor 
complexes, nor does it affect the kinase activity of the receptor complex (Barbara, Wrana and 
Letarte, 1999). Recent research has determined the crystal structure of the extracellular 
domain of endoglin in complex with the BMP-9 homodimer and proposed that endoglin may 
function to secure a pool of BMP-9 ligands at the plasma membrane where it can 
concomitantly bind the type I receptor ALK1 and subsequently interact with a type II receptor 
(Saito et al., 2017). However, further research is required to investigate the mechanisms by 
which endoglin interacts with other TGFβ ligands and receptors and thus determine its precise 
function in TGFβ signalling. Although betaglycan is able to bind all TGFβ isoforms, it appears 
to be most important for TGFβ2, particularly during embryonic development (Brown et al., 
1999; Stenvers et al., 2003). It has been postulated that the cell-type-specific expression of 
accessory receptors may determine whether a cell can or cannot respond to specific TGFβ 
ligands that require accessory receptors in order to activate their cognate heterotetrameric 
receptor complex (Schmierer and Hill, 2007). 
Once activated by type II receptor-mediated phosphorylation, the type I receptors are 
able to propagate the signals of TGFβ ligands via the phosphorylation of downstream 
substrates. 
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Figure 1C. Overview of the core components of SMAD-dependent TGFβ signalling 
The binding of TGFβ ligands to cognate cell surface receptor serine-threonine kinases initiates 
the signalling pathway by inducing the formation of heterotetrameric receptor complexes 
consisting of type I receptor dimers and type II receptor dimers. In close proximity, the type 
II receptor is able to phosphorylate and hence activate the type I receptor. The activated type 
I receptor kinase subsequently phosphorylates two serine residues within the conserved 
carboxy-terminus of the R-SMAD proteins SMAD2 and SMAD3. Phosphorylated R-SMADs 
form heteromeric complexes with the mediator SMAD4 and translocate into the nucleus, 
where they co-operate with additional transcription factors or chromatin modifying enzymes 
to regulate target gene transcription. TGFβ induces the transcription of inhibitory SMAD 
proteins (SMAD6/SMAD7) which participate in a feedback mechanism by competing with R-
SMADs for receptor binding or directing E3 ubiquitin ligases and/or DUBs to the activated 
receptor complex. 
 
 
1.1.3 SMAD proteins – the mediators of the canonical TGFβ signalling pathway 
The SMAD proteins are a family of structurally related transcription factors which function as 
the predominant intracellular mediators of the TGFβ signalling pathway (N.B. the SMAD-
dependent pathway is referred to as the canonical TGFβ signalling pathway). The 
nomenclature SMAD is a portmanteau derived from the fact that they are the vertebrate 
 36 
homologs of mothers against decapentaplegic (MAD) and Sma (referring to smaller than wild 
type phenotype) identified as the intracellular signal transducers of TGFβ family cytokines in 
Drosophila melanogaster (Raftery et al., 1995; Sekelsky et al., 1995) and Caenorhabditis 
elegans (Savage et al., 1996) respectively. The mammalian genome encodes eight SMAD 
proteins, designated SMAD1 to SMAD8 (which is also referred to as SMAD9), which can be 
classified into three subfamilies based on a number of structural and functional 
considerations. Five SMAD proteins (SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8) are 
substrates for the type I serine-threonine kinase receptors and are thus collectively referred 
to as receptor-regulated SMADs (R-SMADs). SMAD4 functions as a common mediator of the 
R-SMADs and is therefore known as a co-SMAD. Both SMAD6 and SMAD7 function as 
inhibitory SMAD proteins (I-SMADs) and can antagonise the signalling pathway in a number 
of different ways, including binding to the type I receptor, recruiting E3 ubiquitin-protein 
ligases to the receptor complex or by interfering in the formation of the R-SMAD-SMAD4 
complex (Hata and Chen, 2016). 
Amongst the R-SMAD proteins, SMAD2 and SMAD3 are primarily phosphorylated by 
the type I receptors for the TGFβ subfamily (TGFβR1, ACVR1B and ACVR1C), whereas SMAD1, 
SMAD5 and SMAD8 are mainly phosphorylated by type I receptors for BMP subfamily ligands 
(ACVRL1, ACVR1A, BMPR1A and BMPR1B) (David and Massagué, 2018). The division of the 
pathway into TGFβ members signalling via SMAD2 and SMAD3, and BMP members signalling 
via SMAD1, SMAD5 and SMAD8 is relatively useful distinction, however more recent research 
has revealed a greater complexity to the system. For example, in a number of different 
mammalian epithelial cell lines, it has been demonstrated that TGFβ1 can induce the 
phosphorylation of SMAD1/SMAD5 in addition to SMAD2/SMAD3 and that this may result in 
the formation of mixed R-SMAD complexes. It was proposed that this is mediated by the 
formation of novel heteromeric receptor complexes containing homodimeric type II 
receptors associated with heterodimeric type I receptors (Daly, Randall and Hill, 2008). 
Recent research from the same group aimed at further elucidating the mechanism and 
functional relevance of this non-canonical form of TGFβ-induced SMAD1/SMAD5 
phosphorylation suggested that the kinetics of TGFβ-induced SMAD1/SMAD5 
phosphorylation appears to be different to that of SMAD2/SMAD3 phosphorylation, requiring 
the serine-threonine kinase activity of two different type I receptors, TGFβR1 and ACVR1 
(ALK5 and ALK2 respectively). Interestingly, it was observed that TGFβ-activated TGFβR1 
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could phosphorylate and activate ACVR1, which subsequently phosphorylated SMAD1. 
Furthermore, the phosphorylated SMAD1/SMAD5 complexes formed in response to TGFβ 
stimulation appear to be transcriptionally competent and required for TGFβ-induced 
epithelial-mesenchymal transition (EMT) (Ramachandran et al., 2018). This presents a new 
paradigm for TGFβ receptor activation and enhances the complexity of the signalling 
pathway. Whether these observations are restricted to specific cell types or contexts or are 
more pervasive is an area of ongoing research. 
The R-SMADs are comprised of approximately 500 amino acid residues and consist of 
highly conserved globular amino-terminal MAD homology 1 (MH1) and carboxy-terminal 
MAD homology 2 (MH2) domains connected via a less conserved linker region. At the amino-
terminus, within the MH1 domain, are putative nuclear localisation signal (NLS) motifs 
consisting of lysine-rich sequences. At their extreme carboxy-terminus the R-SMADs contain 
a conserved Ser-Ser-Xxx-Ser (SSXS) motif that is phosphorylated on the last two of the serine 
residues by the activated type I receptor kinase (Hata and Chen, 2016). The co-SMAD SMAD4 
is similar to the R-SMADs, containing the conserved MH1 and MH2 domains, however it does 
not possess the SSXS motif and thus cannot be phosphorylated by the type I receptor kinases. 
The MH1 domain of the R-SMADs and SMAD4 facilitates DNA binding and the crystal 
structures of SMAD1, SMAD3 and SMAD4 MH1 domains reveal that it consists of four a-
helices and three sets of antiparallel β-hairpin strands (β1-β4, β2-β3 and β5-β6) (Macias, 
Martin-Malpartida and Massagué, 2015). The interaction of the MH1 domain with DNA is 
mediated by a conserved 11-amino acid residue β-hairpin loop structure formed by the β2 
and β3 strands that interacts with the major groove of DNA in a base-specific manner (Shi et 
al., 1998). An exception to this is SMAD2, the most abundant isoform of which contains an 
insertion (encoded by exon 3) that perturbs DNA binding (Massagué, Seoane and Wotton, 
2005). Interestingly, an alternative splice variant of SMAD2 in which exon 3 has been deleted 
(SMAD2Dexon3) exhibits DNA-binding and transcriptional activity similar to that of SMAD3 
(Yagi et al., 1999). Early research into the sequence specificity of SMAD MH1 domains 
identified the eight base-pair palindromic sequence 5’-GTCTAGAC-3’ (termed the CAGA 
motif) as the preferred binding sequence of SMAD3 and SMAD4, albeit with relatively low 
affinity (Zawel et al., 1998). Furthermore, R-SMADs that transduce signals from BMP family 
ligands, namely SMAD1 and SMAD5, were shown to preferentially bind to GC-rich sequences 
within the promoter regions of BMP target genes (Kusanagi et al., 2000; Morikawa et al., 
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2011). Therefore, these collective observations resulted in the paradigm that the CAGA motif 
functions as a SMAD binding element (SBE) for TGFβ subfamily ligands, whereas GC-rich 
sequences present within target gene promoter regions function as BMP responsive elements 
(BRE) for BMP subfamily ligands. However, given the identical sequence of the DNA-binding 
β-hairpin loop present in all the R-SMADs (Shi et al., 1998; Macias, Martin-Malpartida and 
Massagué, 2015) and subsequent observations that SMAD3 and SMAD4 can bind to GC-rich 
sequences that do not contain the CAGA motif, this dichotomy of R-SMAD-DNA binding is 
somewhat misleading. Indeed, recent structural analysis demonstrated that TGFβ-activated 
SMAD3, BMP-activated SMAD1/SMAD5 and SMAD4 all recognise the common consensus 
sequence GGC(G/C)(C/G) (Martin-Malpartida et al., 2017). Clusters of these five base-pair 
sequences, termed the 5GC SBE motif, are highly represented in the promoter and enhancer 
regions of both TGFβ and BMP target genes. Therefore, it is proposed that both TGFβ-
activated SMAD2/SMAD3 and BMP-activated SMAD1/SMAD5 both recognise common DNA 
sequences, and it is the differential binding of SMAD2/SMAD3 and SMAD1/SMAD5 to 
different transcription co-factors that determines target gene specificity (David and 
Massagué, 2018). 
The MH2 domain is a highly conserved globular domain present within all SMAD family 
members and is responsible for mediating protein-protein interactions. The crystal structure 
of the SMAD2 MH2 domain in complex with the SMAD-binding domain (SBD) of SMAD anchor 
for receptor activation (SARA) revealed that it consists of a central β-sheet structure with an 
amino-terminal loop-helix region and carboxy-terminal three-helix bundle (Wu et al., 2000). 
In the context of R-SMADs, the MH2 domain is responsible for interaction with the type I 
receptors. A pocket of basic residues within the R-SMAD MH2 domain interacts with 
phosphorylated serine residues within the GS domain of the activated type I receptor kinase 
(Massagué, Seoane and Wotton, 2005). The specificities of this interaction are determined by 
the L45 loop sequences in the receptor and the loop-helix sequence in the R-SMAD MH2 
domain. A series of contiguous hydrophobic regions (termed the hydrophobic corridor) on 
the surface of the R-SMAD MH2 domain mediate interaction with cytoplasmic retention 
proteins, such as SARA, and DNA-binding transcriptional co-regulators (discussed in further 
detail in the subsequent section). 
As previously mentioned, the conserved MH1 and MH2 domains of SMAD proteins 
are connected via a divergent linker. This linker region contains a proline-tyrosine (PPXY) 
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motif which binds to specific E3 ubiquitin-protein ligases as well as multiple regulatory 
phosphorylation sites. Thus, the linker region is critical for the regulation of SMADs and 
integration of crosstalk from other intracellular signalling pathways (discussed in further 
detail in section 1.3.4). 
The inhibitory SMADs (SMAD6 and SMAD7) possess the conserved carboxy-terminal 
MH2 domain however they do not contain the MH1 domain found in R-SMADs and SMAD4. 
In addition, they lack the carboxy-terminal SSXS motif and are therefore not subject to type I 
receptor-mediated phosphorylation. The expression of I-SMADs can be induced by both TGFβ 
(Nagarajan et al., 1999; Denissova et al., 2000) and BMP family ligands (Ishida et al., 2000; 
Benchabane and Wrana, 2003) to provide negative feedback mechanisms. Negative 
regulation of TGFβ family signalling by I-SMADs occurs through a number of different 
mechanisms and at various stages of the signalling pathway. For example, SMAD7 can directly 
bind to the activated type I receptor kinases, thereby interfering with the interaction between 
the activated receptor complex and R-SMADs and preventing their phosphorylation. Four 
basic residues (Lys312, Lys316, Lys401 and Arg409) within the MH2 domain of human SMAD7 
appear to be crucial for interaction with the L45 loop of the activated type I receptor 
(Mochizuki et al., 2004). Furthermore, SMAD6 can compete with SMAD4 for binding to 
receptor-activated SMAD1 and thereby inhibit BMP signalling through the formation of an 
inactive heterotrimeric SMAD1-SMAD6 complex (Hata et al., 1998). Moreover, research has 
also demonstrated that the homologous to E6-AP carboxyl terminus (HECT) E3 ubiquitin-
protein ligase SMURF1 can both directly and indirectly, via interaction with SMAD6, associate 
with SMAD1/SMAD5 to induce their ubiquitylation and subsequent proteasomal degradation 
(Zhu et al., 1999; Murakami et al., 2003). SMAD7 has been shown to interact with both 
SMURF1 (Ebisawa et al., 2001) and SMURF2 (Kavsak et al., 2000) to induce the ubiquitylation 
and degradation of activated receptor complexes via proteasomal and lysosomal pathways. 
In addition to the SMURF E3 ubiquitin-protein ligases, SMAD7 has also been shown to interact 
with growth arrest and DNA damage protein 34 (GADD34), a regulatory subunit of the protein 
phosphatase 1 (PP1) holoenzyme, to promote the dephosphorylation of the activated TGFβR1 
receptor kinase (Shi et al., 2004). GADD34 functions to recruit the catalytic subunit of PP1 
(termed PP1c) and recruitment of the GADD34-PP1c complex to activated TGFβR1 receptor 
by SMAD7 induces its dephosphorylation and hence inactivation. 
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Therefore, SMAD6 and SMAD7 function to antagonise the TGFβ signalling pathway 
through different mechanisms including competition with R-SMADs for receptor interaction, 
proteasomal degradation of activated receptor complexes and R-SMADs by SMURFs and 
dephosphorylation of activated type I receptors by PP1. The regulation of TGFβ signalling by 
reversible protein phosphorylation and ubiquitylation will be discussed in greater detail in the 
subsequent sections 1.3.4 and 1.3.3 respectively. 
Once phosphorylated at their carboxy-terminal SSXS motif by the type I receptor 
kinases, R-SMADs interact with their common binding partner SMAD4 to form heterotrimeric 
complexes, comprising two R-SMADs and SMAD4. The R-SMAD-SMAD4 complexes 
subsequently accumulate in the nucleus, where they bind to regulatory regions of target 
genes to either activate or repress gene transcription. 
 
 
 
1.1.4 Transcriptional control by SMAD proteins 
Signalling by TGFβ family cytokines can elicit a diverse array of cellular responses by regulating 
programmes of gene expression. However, the precise molecular basis of how a conceptually 
simple signal transduction pathway can regulate a broad range of responses depending on 
cell type or context has remained an open question. Research over the previous two decades 
has provided new insights into how SMAD proteins cooperate with sequence-specific DNA-
binding transcription factors or modifiers of chromatin structure in a highly contextual 
manner. These insights have provided a unified model of how signalling through TGFβ ligands 
and SMAD transcription factors initiates diverse and specific responses depending on the 
biological context. 
 The DNA-binding affinity of SMADs is relatively weak (Shi et al., 1998; Chai et al., 2003) 
and the binding of SMADs to short DNA sequences (5GC SBE motifs) is not particularly specific, 
therefore the interaction of SMADs with additional transcription factors is proposed as the 
principal determinant of high-affinity and high-specificity recruitment of SMADs to DNA (Hill, 
2016). However, the function of these SMAD-cooperating transcription factors may occur 
through different mechanisms. For example, they may be fundamentally required to recruit 
activated SMAD complexes to DNA, as demonstrated by the transcription factor forkhead box 
protein H1 (FOXH1). FOXH1, previously known as forkhead activin signal transducer 1 (FAST1), 
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was the first SMAD-interacting transcription factor to be identified and is required for the 
recruitment of SMAD2-SMAD4 complexes in response to activin stimulation in Xenopus laevis 
embryos (Chen, Rubock and Whitman, 1996; Chen et al., 1997). FOXH1 mediates the 
recruitment of an activated SMAD2-SMAD4 complex to the activin-responsive element (ARE) 
within the promoter region of Mix.2, an immediate-early response gene, during early Xenopus 
embryogenesis. In this way, FOXH1 functions as an archetypal lineage-determining 
transcription factor (LDTF) for SMADs, which are signal-driven transcription factors (SDTFs). 
LDTFs are defined as cell type-specific transcription factors which dictate the binding of SDTFs 
at specific genomic loci in order to establish gene expression patterns that define cell identity 
and function (David and Massagué, 2018). 
Activated SMAD complexes can regulate the transcription of other transcriptional 
regulators which in turn bind to the SMAD complex to regulate the transcription of other 
target genes (Hill, 2016). An example of this self-enabling transcriptional response occurs with 
the transcriptional repressor activating transcription factor 3 (ATF3). In the context of 
epithelial cells, TGFβ-activated SMAD3 can directly induce the expression of ATF3, which 
subsequently forms a complex with SMAD3 that directly represses the transcription of DNA-
binding protein inhibitor ID-1 (Kang, Chen and Massagué, 2003). Downregulation of ID-1 
contributes to the cytostatic effect observed in certain epithelial cell lines in response to 
TGFβ. 
In addition to DNA-binding transcription factors, SMADs can also interact with various 
coactivators and corepressors that regulate the transcriptional response by modifying 
chromatin structure. Transcriptionally permissive promoter regions are associated with high 
levels of acetylation on conserved lysine residues of histone proteins. Activated R-SMAD-
SMAD4 complexes have been shown to interact with the histone acetyltransferases (HATs) 
E1A-associated protein p300 (EP300; previously known as p300) (Feng et al., 1998) and GCN5 
(Kahata et al., 2004) and these interactions are required for TGFβ-induced gene transcription. 
Further evidence for the role of chromatin modification in SMAD-mediated gene transcription 
was obtained from an in vitro transcription system using recombinant phosphorylated 
SMAD2-SMAD4 complexes. The phosphorylated SMAD2-SMAD4 complex was unable to 
induce transcription from naked DNA templates, however they could efficiently activate 
transcription from chromatin templates, suggesting that transcriptional regulation mediated 
by activated SMAD complexes involves, at least in part, modification of chromatin structure 
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(Ross et al., 2006). SMAD complexes can also mediate transcriptional repression by removing 
histone acetylation modifications at promoter regions of target genes via the enzymatic 
action of histone deacetylases (HDACs). Research has demonstrated that TGFβ-activated 
SMAD3 can directly associate with the class IIa HDACs 4 and 5 to deacetylate histone H4 at 
the promoter for osteocalcin, a protein required for osteoblast differentiation (Kang et al., 
2005). Osteocalcin is a target gene for the osteoblast-specific transcription factor runt-related 
transcription factor 2 (RUNX2) (also known as CBFA1). Previous research demonstrated that 
SMAD3 interacts directly with RUNX2 and represses its transcriptional activity (Alliston et al., 
2001). Therefore, SMAD3-mediated recruitment of HDAC4 and HDAC5 to SMAD3-RUNX2 
complexes inhibits the transcriptional function of RUNX2 and consequently represses the 
transcription of RUNX2 target genes during osteoblast differentiation. 
 
 
 
1.1.5 SMAD-independent signalling by TGFβ family members 
As previously alluded to, the interaction of the TGFβ family of cytokines with cognate 
transmembrane serine-threonine kinase receptors and subsequent activation of intracellular 
SMAD transcription factors constitutes the canonical TGFβ signal transduction pathway. 
However, in addition to SMAD-mediated signalling, it has become increasingly appreciated 
that signalling through SMAD-independent pathways represents an important contribution 
to cellular responses elicited by TGFβ family cytokines. Research has indicated that activated 
TGFβ receptor complexes can signal through other signal transducers including mitogen-
activated protein kinase (MAPK) pathways, phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K) and Rho family GTPases (Zhang, 2017). These are collectively referred to as non-
canonical TGFβ signalling pathways and may function alone or in conjunction with canonical 
SMAD signalling to mediate the cellular response to TGFβ ligands. 
Initial evidence for the role of MAPK pathways in TGFβ signalling came from the 
observation that TGFβ stimulation of epithelial cells resulted in the rapid activation of the 
small GTPase Ras (Mulder and Morris, 1992). Further research demonstrated that TGFβ is 
capable of activating three different MAPK pathways: extracellular signal-regulated kinase 
(ERK) MAPK, c-Jun N-terminal kinase (JNK) MAPK and p38 MAPK (Derynck and Zhang, 2003). 
TGFβ stimulation can result in the sequential activation of the serine-threonine protein 
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kinases RAF (a MAPKKK), MEK1/2 and ERK1/2, however this occurs at lower levels compared 
to cytokine stimulation through receptor tyrosine kinases (Mulder, 2000). Upon TGFβ 
stimulation, the activated type I receptor directly interacts and phosphorylates the adaptor 
protein ShcA on serine and tyrosine residues (Lee et al., 2007). Phosphorylation of ShcA 
induces its association with another adaptor protein, growth factor receptor-bound protein 
2 (GRB2), and the guanine nucleotide exchange factor (GEF), son of Sevenless (SOS). The ShcA-
GRB2-SOS complex converts Ras into its active guanosine-5’-triphosphate (GTP)-bound 
conformation which ultimately results in the activation of ERK1 and ERK2 (Dhillon et al., 
2007). 
 
 
 
 
Figure 1D. Overview of SMAD-independent TGFβ signalling pathways 
In addition to the activation of SMAD transcription factors (referred to as the canonical TGFβ 
pathway), the binding of TGFβ family cytokines to their cognate cell surface receptor kinases 
can also induce the activation of a number of additional signal transduction pathways 
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(collectively referred to as non-canonical TGFβ pathways). These non-canonical TGFβ 
signalling pathways primarily include the phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways. The non-canonical TGFβ 
signalling pathways may operate independently or in conjunction with canonical SMAD-
dependent TGFβ signalling to mediate the cellular responses to TGFβ cytokines. 
 
 
TGFβ can induce the rapid and transient activation of JNK and p38 MAPKs through the 
activation of the MAP kinase kinases (MKKs) MKK4 and MKK3/MKK6 respectively (Zhang, 
2017). MKKs require activation by upstream protein kinases termed MAP kinase kinase 
kinases (MKKKs). TGFβ-activated kinase (TAK1) was identified as an MKKK that becomes 
activated in response to TGFβ stimulation and capable of mediating the activation of p38 
MAPK (Yamaguchi et al., 1995). Moreover, TAK1 was also shown to be required for activation 
of JNK MAPK in response to TGFβ. Stimulation of wild type mouse embryonic fibroblasts 
(MEFs) with TGFβ resulted in rapid phosphorylation of JNK, however JNK phosphorylation was 
abrogated in TAK1-deficient MEFs (Shim et al., 2005). Activation of TAK1 can also be induced 
by signalling through the interleukin-1 (IL-1R) and Toll-like receptors (TLRs) (Wu and Arron, 
2003) and requires the formation of Lys63-linked polyubiquitin (K63-Ub) chains, mediated in 
part by the E3 ubiquitin-protein ligase tumour necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) (Cohen and Strickson, 2017). Similarly, activation of TAK1 by TGFβ requires 
TRAF6, which interacts with a consensus binding motif present within the TGFβ type I 
receptor. Interaction of TRAF6 with the type I receptor results in autoubiquitylation of TRAF6 
and subsequent K63-linked polyubiquitylation of TAK1 on Lys34, resulting in its activation and 
subsequent activation of downstream JNK and p38 MAPKs (Sorrentino et al., 2008; Yamashita 
et al., 2008). However, the exact requirement for TAK1 in mediating TGFβ-induced 
phosphorylation of p38 MAPK remains somewhat uncertain. Recent research observed that 
TGFβ-induced phosphorylation of p38 MAPK still occurred in TAK1-deficient MEFs. By 
contrast, phosphorylation of p38 MAPK induced by IL-1 was completely abolished in the 
absence of TAK1 and restored upon expression of wild-type but not a catalytically inactive 
form of TAK1 (Sapkota, 2013). As with SMAD-dependent signalling, the nature of SMAD-
independent pathways may be contingent on cell type or context. 
In certain cell contexts, evidence suggests that TGFβ-induced activation of MAPK 
pathways occurs independently of SMAD activation (Yu, Hébert and Zhang, 2002; Itoh et al., 
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2003). For example, the kinase activity of the TGFβ type I receptor is dispensable for the ability 
of TRAF6 to activate TAK1, whereas the interaction with the type I receptor and E3 ubiquitin 
ligase activity of TRAF are both required for TAK1 activation. Furthermore, SMAD-
independent activation of MAPK pathways was demonstrated using a mutated form of the 
TGFβ type I receptor that is unable to activate SMAD2 or SMAD3 but retains its kinase activity. 
The L45 loop is situated within the kinase domain of the type I receptors and facilitates 
binding to R-SMADs, however mutation of three residues (Asn265, Asp267 and Asn268) 
abolished the SMAD-binding ability of the receptor. Despite this, the mutated type I receptor 
kinase was sufficient to activate p38 MAPK and induce phosphorylation of its substrate, cyclic 
AMP-dependent transcription factor ATF-2. A constitutively active form of the L45 loop 
mutant type I receptor was able to induce apoptosis in murine mammary epithelial cells 
however it was not sufficient to induce EMT (Yu, Hébert and Zhang, 2002). Furthermore, 
TGFβ-induced activation of p38 MAPK was also shown to promote apoptosis in a prostate 
cancer cell line (Edlund et al., 2003). This suggests that TGFβ-induced p38 MAPK activation is 
sufficient for TGFβ-mediated apoptosis, however induction of EMT requires contribution 
from the SMAD-dependent pathway. 
In addition to activation of MAPK pathways, research has also indicated that TGFβ 
family cytokines may also signal through class I PI3K and its downstream effector, the serine-
threonine protein kinase AKT (otherwise known as protein kinase B; PKB) (Zhang, 2009). 
TGFβ1 stimulation can induce the phosphorylation of AKT at serine 473, which is prevented 
upon treatment with a PI3K inhibitor (Bakin et al., 2000) and occurs independent of SMAD 
activation (Wilkes et al., 2005). Similar to SMAD-dependent and MAPK pathways, TGFβ 
stimulation of the PI3K pathway appears to be cell-context dependent, occurring in some 
epithelial cell lines but not others. PI3K was found to be constitutively associated with the 
TGFβ type II receptor via its regulatory subunit p85, whereas association with the TGFβ type 
I was transient, requiring TGFβ stimulation (Yi, Shin and Arteaga, 2005). However, although 
the association between PI3K and the TGFβ receptors does not occur directly, it does require 
the kinase activity of the receptors. Expression of a kinase inactive, dominant negative form 
of the type II receptor inhibited the ligand-induced association between the p85 subunit and 
type I receptor and concomitant TGFβ stimulation of PI3K kinase activity. Moreover, 
overexpression of a constitutively active form of the type I receptor enhanced PI3K kinase 
activity, which was subsequently blocked by the use of a type I receptor kinase inhibitor (Yi, 
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Shin and Arteaga, 2005). Activation of the PI3K-AKT pathway by TGFβ results in activation of 
mammalian target of rapamycin (mTOR) during TGFβ-induced EMT. Activation of mTOR 
complex 1 (mTORC1) by TGFβ results in the phosphorylation of the downstream mTORC1 
effectors ribosomal protein S6 kinase beta-1 (S6K1, also knowns as p70-S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4E-BP1), which are direct regulators of 
translation initiation. The translational regulation resulting from TGFβ-mediated activation of 
mTORC1 and phosphorylation of S6K1 and 4E-BP1 enhanced cell size and protein content, 
and contributed to cell invasion, during TGFβ-induced EMT (Lamouille and Derynck, 2007). 
Subsequent research has also demonstrated that, in addition to activation of mTORC1, TGFβ 
can also induce the activation of mTOR complex 2 (mTORC2) during EMT. RNA interference 
(RNAi)-mediated depletion of rapamycin-insensitive companion of mTOR (RICTOR), a subunit 
of mTORC2 (Sarbassov et al., 2004), prevented mTORC2 activation by TGFβ and also 
suppressed the expression of the transcription factor Snail (also termed zinc finger protein 
SNAI1). Snail expression is upregulated in response to TGFβ and functions to repress the 
transcription of E-cadherin, a fundamental event during EMT. Depletion of RICTOR 
attenuated the TGFβ-induced expression of Snail and resulted in the incomplete 
downregulation of E-cadherin, thereby contributing to the inhibition of TGFβ-induced EMT 
observed in RICTOR-depleted cells (Lamouille et al., 2012). Therefore, although the activity of 
mTORC2 is not required for maintenance of an epithelial cell phenotype, TGFβ-induced 
mTORC2 activation is required for epithelial cells to transition to a mesenchymal, invasive 
phenotype. 
PI3K-AKT signalling can also impact TGFβ-induced gene transcription by 
phosphorylating SMAD-interacting partners. For example, AKT can phosphorylate the 
transcription factor forkhead box protein O3 (FOXO3, previously known as FKHRL1), resulting 
in its association with 14-3-3 proteins and retention in the cytoplasm, thereby inhibiting the 
ability of FOXO3 to induce transcription of target genes (Brunet et al., 1999). In response to 
TGFβ stimulation, FOXO transcription factors cooperate with SMAD3 to mediate the 
transcriptional activation of the cyclin-dependent kinase (CDK) inhibitor p21CIP1, thereby 
contributing to the TGFβ-mediated cytostatic response. Treatment of cells with a PI3K 
inhibitor enhanced the nuclear localisation of endogenous FOXO3 and augmented the 
induction of p21CIP1 in response to submaximal concentrations of TGFβ (Seoane et al., 2004). 
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Therefore, by regulating the subcellular location of FOXO transcription factors, PI3K-AKT 
signalling can negatively regulate SMAD-dependent gene transcription. 
Collectively, these observations suggest complex regulatory interplay between TGFβ-
induced SMAD-dependent and SMAD-independent pathways, which are important for 
cellular responses mediated by TGFβ cytokines such as apoptosis, EMT and cytostasis. 
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1.2 THE REGULATION OF TGFβ SIGNALLING 
 
1.2.1 Regulation of TGFβ signalling by reversible post-translational modification (PTM) 
TGFβ cytokines control many different cellular responses in a context-dependent manner and 
therefore complex mechanisms have developed to regulate the pathway and thus modulate 
the signalling outcome. One of the most prevalent mechanisms by which intracellular 
signalling pathways are regulated is through reversible post-translational modification (PTM) 
of proteins. It is therefore not surprising that a plethora of research has uncovered many ways 
in which reversible PTM can regulate components of the TGFβ signalling pathway, in 
particular protein phosphorylation and ubiquitylation. For the purpose of this section, I will 
focus the discussion on the reversible protein phosphorylation and ubiquitylation of TGFβ 
receptors and SMAD proteins. 
 
 
1.2.2 Regulation of TGFβ receptors by reversible protein phosphorylation 
As introduced in section 1.2.2, the type II TGFβ receptor is constitutively active 
transmembrane serine-threonine protein kinase that upon binding of a cognate extracellular 
TGFβ ligand, forms a heterotetrameric complex with the type I TGFβ receptor. The formation 
of this receptor complex enables the type II receptor to phosphorylate multiple serine and 
threonine residues within the cytoplasmic GS domain of the type I receptor (Wrana et al., 
1994; Wieser, Wrana and Massagué, 1995). This phosphorylation relieves inhibition mediated 
by the inhibitory protein FKBP12 (Chen, Liu and Massague, 1997; Huse et al., 2001) and 
facilitates interaction between the type I receptor and the MH2 domain of R-SMAD proteins, 
allowing the activated type I receptor to phosphorylate two serine residues within the 
carboxy-terminal SSXS motif of the R-SMADs. The phosphorylation of the type I receptor can 
be reversed by the serine/threonine-protein phosphatase PP1 (Shi et al., 2004). The 
regulatory subunit of PP1, termed GADD34, interacts with SMAD7, which facilitates 
recruitment to the activated type I receptor and promotes dephosphorylation of the receptor 
by the PP1 catalytic subunit (referred to as PP1c) (previously discussed in section 1.2.3). 
SMAD7 is upregulated in response to TGFβ (Nakao et al., 1997) and thus its ability to facilitate 
receptor dephosphorylation represents one of its inhibitory functions and constitutes an 
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important negative feedback mechanism to modulate TGFβ signalling. Furthermore, in 
endothelial cells, it has been reported that TGFβ signalling through the type I receptor ACVRL1 
(ALK1) can transcriptionally induce the PP1a isoform, which is subsequently recruited to 
ACVRL1 via interaction with SMAD7 (Valdimarsdottir et al., 2006). SMAD7 can function to 
inhibit ACVRL1-mediated SMAD1/SMAD5 phosphorylation and therefore one of the proposed 
mechanisms by which this can occur is through PP1a-mediated dephosphorylation of the 
receptor. 
 
 
1.2.3 Regulation of TGFβ receptors by reversible protein ubiquitylation 
In addition to dephosphorylation, ubiquitin-mediated degradation of activated receptor 
complexes is another fundamental mechanism by which cells ensure a balanced response to 
TGFβ signals (Izzi and Attisano, 2004; Al-Salihi, Herhaus and Sapkota, 2012). Protein 
ubiquitylation involves the covalent conjugation of the 76-amino acid polypeptide ubiquitin 
to lysine residues of substrates via the sequential action of E1 ubiquitin-activating enzymes, 
E2 ubiquitin-conjugating enzymes and E3 ubiquitin-ligating enzymes in an ATP-dependent 
process (Hershko and Ciechanover, 1998; Kerscher, Felberbaum and Hochstrasser, 2006). This 
enzymatic cascade results in the formation of an isopeptide bond between the carboxy-
terminal glycine residue of ubiquitin (G76) and the e-amino group of a target lysine residue 
or the extreme amino terminus of a polypeptide. Furthermore, an isopeptide bond can also 
be formed between the ubiquitin G76 residue and the e-amino group of a lysine residue 
within another ubiquitin molecule, thereby enabling the formation of polyubiquitin chains on 
substrate proteins. Ubiquitin contains seven internal lysine residues (K6, K11, K27, K29, K33, 
K48 and K63) allowing the generation of seven possible homotypic chain types or numerous 
heterotypic (i.e. branched or mixed) linkage chain types (Dikic, Wakatsuki and Walters, 2009). 
Additionally, ubiquitin molecules can also be linked between the carboxy-terminal G76 
residue and the amino-terminal methionine residue resulting in the formation of linear (M1) 
polyubiquitin chains. Therefore, ubiquitin modification of protein substrates may involve the 
conjugation of a single ubiquitin moiety (i.e. monoubiquitylation) or the formation of 
homotypic or heterotypic polyubiquitin chains resulting in a highly complex post-translational 
regulatory system. 
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The process of protein ubiquitylation can be reversed by the enzymatic action of 
deubiquitylating (DUB) enzymes, a large family of proteases which remove ubiquitin from 
substrate proteins by catalysing the hydrolysis of peptide or isopeptide bonds (Komander, 
Clague and Urbé, 2009). There are approximately 100 DUBs encoded in the human genome 
which can be classified into six subfamilies based on the structure of their catalytic domains 
(Clague et al., 2013; Leznicki and Kulathu, 2017). The following five subfamilies are all cysteine 
proteases; ubiquitin-specific proteases (USPs), ubiquitin carboxy-terminal hydrolases (UCHs), 
ovarian tumour proteases (OTUs), Machado-Joseph disease proteases (MJDs; alternatively 
referred to as Josephins) and the recently identified motif interacting with ubiquitin (MIU)-
containing novel DUB family (MINDY). These all possess a triad of conserved amino acid 
residues (Asp/Asn-His-Cys) that are critical for their catalytic activity. In contrast, a sixth 
subfamily, termed JAB1/MPN/MOV34 (JAMMs, also known as MPN+) are zinc-dependent 
metalloproteases (Clague et al., 2013). DUBs can hydrolyse polyubiquitin chains from either 
the distal or proximal end (exo-cleavage) or within the chain (endo-cleavage). Whether a 
particular DUB catalyses exo- or endo-cleavage is dependent on the DUB family to which it 
belongs, the chain linkage type and hence how the DUB recognises polyubiquitin chains 
(Mevissen and Komander, 2017). 
 The negative regulation of TGFβ signalling by the inhibitory SMAD proteins includes 
controlling the activity and stability of TGFβ receptor complexes by ubiquitylation. SMAD7 
can directly interact with and hence recruit the E3 ubiquitin-protein ligases SMURF1 and 
SMURF2 (SMAD ubiquitylation regulatory factor 1 and 2) to the activated TGFβ receptor 
complexes resulting in their ubiquitin-mediated proteasomal degradation (Kavsak et al., 
2000; Ebisawa et al., 2001). SMURF1 and SMURF2 belong to the neural precursor cell 
expressed developmentally down-regulated protein 4 (NEDD4) family of homologous to the 
E6AP carboxyl-terminus (HECT) E3 ubiquitin ligases and are characterised by the presence of 
an amino-terminal C2 domain, multiple tryptophan-tryptophan (WW) domains (SMURF1 and 
SMURF2 contain two and three WW domains respectively) and a carboxy-terminal catalytic 
HECT domain (Rotin and Kumar, 2009; Morreale and Walden, 2016). Structural analysis has 
revealed that SMAD7 constitutively associates with SMURF1 and SMURF2 and that this 
interaction is dependent on the binding of WW protein domains of SMURF1/2 (WW2 and 
WW3 domains respectively) to the proline-rich PY (Pro-Pro-Xxx-Tyr) motif present within the 
linker region of SMAD7 (Aragón et al., 2012). Furthermore, the HECT E3 ubiquitin-protein 
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ligase ITCH (alternatively referred to as atrophin-1-interacting protein 4, AIP4), which also 
belongs to the NEDD4 family (Morreale and Walden, 2016), has also been reported to inhibit 
TGFβ signalling (Lallemand et al., 2005). However, unlike SMURF1 and SMURF2, this appears 
to be via a ubiquitylation-independent mechanism. Although ITCH can induce the 
ubiquitylation and proteasomal degradation of SMAD7, it also unexpectedly inhibited TGFβ 
signalling without affecting the expression levels of either the receptors or R-SMADs. It 
appears that the inhibitory function occurs as a result of the ability of ITCH to stabilise the 
interaction between SMAD7 and type I TGFβ receptor. 
 The process of protein ubiquitylation is reversible and therefore a number of 
deubiquitylating (DUB) enzymes have been identified that mediate the removal of 
polyubiquitin chains from the type I TGFβ receptor and thus antagonise the function of the 
E3 ubiquitin ligases discussed previously. Three DUBs belonging to the USP family, USP4, 
USP11 and USP15 were independently discovered as DUBs that target the type I TGFβ 
receptor for deubiquitylation using contrasting experimental approaches (Herhaus and 
Sapkota, 2014). In a genome-wide gain-of-function screen using a SMAD3-SMAD4-dependent 
transcriptional luciferase reporter system, USP4 was identified as an important regulatory 
component of TGFβ signalling (Zhang et al., 2012). USP4 directly interacts and deubiquitylates 
the type I receptor, thereby stabilising receptor levels at the cell membrane. Overexpression 
of wild-type USP4, but not a catalytically inactive mutant form, enhanced the ability of breast 
cancer cells to undergo TGFβ-induced EMT. Furthermore, it was found that USP4 is subject to 
phosphorylation at serine 445 by the serine-threonine protein kinase AKT (also knowns as 
protein kinase B, PKB). This AKT-mediated phosphorylation at S445 results in redistribution 
of USP4 from the nucleus to the cytoplasm and cell membrane, as well as affecting its stability 
and ability to deubiquitylate the type I receptor (Zhang et al., 2012). Thus, USP4 may serve as 
an important intersection for crosstalk between the TGFβ and the PI3K/AKT signalling 
pathways. 
 By contrast, USP11 was identified as a specific interactor of SMAD7 in a proteomic 
analysis and subsequently revealed as another DUB that regulates TGFβ signalling (Al-Salihi 
et al., 2012). USP11 directly interacted with SMAD7 but not the R-SMADs SMAD1 and SMAD3 
or co-SMAD SMAD4. Similar to USP4, USP11 is able to interact with and deubiquitylate the 
type I receptor, thereby preventing its proteasomal degradation. Overexpression of USP11 
enhanced TGFβ-responsive luciferase reporter activity whereas RNAi-mediated depletion 
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suppressed the transcription of the TGFβ target genes plasminogen activator inhibitor 1 (PAI-
1) and growth arrest and DNA damage-inducible protein 45 (GADD45B). Consistent with this, 
depletion of USP11 also inhibited the ability of murine mammary epithelial cells to undergo 
TGFβ-induced EMT (Al-Salihi et al., 2012). 
 USP15 was identified in an RNAi loss-of-function screen as a DUB whose depletion 
resulted in the suppression of a TGFβ-responsive luciferase transcriptional reporter (Eichhorn 
et al., 2012). Modulation of USP15 levels via RNAi-mediated depletion or overexpression 
resulted in reduced or enhanced phosphorylation of SMAD2 respectively, without affecting 
the total levels of either SMAD2 or SMAD4. Furthermore, it was found that USP15 forms a 
complex with SMAD7 and the E3 ubiquitin ligase SMURF2 and is thus also recruited to the 
type I receptor, where it facilitates the deubiquitylation and hence stability of the type I 
receptor. Furthermore, in patient-derived glioblastoma neurospheres which exhibited 
aberrantly high levels of USP15, short hairpin RNA (shRNA)-mediated USP15 depletion 
suppressed the oncogenic potential of the neurospheres when injected into 
immunocompromised mice, thus implicating a role for USP15-dependent regulation of TGFβ 
signalling in glioblastoma pathogenesis. Subsequent research has elucidated additional 
catalytic functions of USP15 in the context of TGFβ pathway regulation. In addition to directly 
targeting the type I receptor for deubiquitylation, USP15 can also directly deubiquitylate the 
SMURF2 E3 ubiquitin ligase and this appears to be an important mechanism to modulate the 
catalytic activity of SMURF2 (Iyengar et al., 2015). Using a proteomic approach, the authors 
identified multiple lysine residues within SMURF2 which were deubiquitylated by USP15 and 
further analysis revealed that lysine 734 (K734), located within the carboxy-terminal catalytic 
HECT domain, was critical for SMURF2 function. This was demonstrated by the observation 
that overexpression of K734R mutant form of SMURF2 substantially impeded the ability of 
SMURF2 to downregulate the type I receptor. Therefore, ubiquitylation of SMURF2 at lysine 
734 is required for the ubiquitylation and subsequent proteasomal degradation of the type I 
TGFβ receptor and USP15-mediated deubiquitylation at this residue inhibits the catalytic 
activity of SMURF2 and promotes stability of the type I receptor (Iyengar et al., 2015). 
 In addition to the three USP family members discussed above, the DUB UCH37 (also 
knowns as UCHL5) has also been reported to regulate TGFβ receptor ubiquitylation (Wicks et 
al., 2006; Herhaus and Sapkota, 2014). The UCH subfamily of DUBs comprises four members 
including UCHL1, UCHL3, UCH37 (UCHL5) and breast cancer type I susceptibility protein 
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(BRCA1)-associated protein 1 (BAP1). UCH family DUBs have been described as ubiquitin chain 
trimmers and UCH37 itself has been initially characterised as a proteasome-associated DUB 
that functions to remove ubiquitin moieties from substrates that are destined for 
proteasomal degradation (Lee et al., 2011). However, more recent research has expanded the 
physiological functions of the UCH family members (Leznicki and Kulathu, 2017) and 
consequently highlighted important roles in tumorigenesis and metastasis (Fang and Shen, 
2017). UCH37 has been implicated in regulating both TGFβ receptors and R-SMADs (Wicks et 
al., 2006; Nan et al., 2016). UCH37 was found to interact with SMAD7 and also with SMAD2 
and SMAD3 albeit with substantially lower affinity (Wicks et al., 2005). The interaction with 
SMAD7 facilitates recruitment to the activated receptor complex and enables UCH37 to 
deubiquitylate and thus enhance the stability of the type I receptor. In addition, 
overexpression of UCH37 is sufficient to enhance TGFβ-dependent transcriptional luciferase 
reporter and moreover, expression of UCH37 also attenuates SMURF2-mediated inhibition of 
TGFβ transcriptional responses (Wicks et al., 2005). Furthermore, inducible shRNA-mediated 
depletion of UCH37 results in suppression of certain TGFβ-dependent early response genes, 
and although UCH37 depletion does not appear to affect TGFβ-induced cell proliferation or 
EMT, it does prevent TGFβ-induced cell migration (Cutts et al., 2011). 
 
 
1.2.4 Regulation of SMADs by reversible protein phosphorylation 
As discussed in section 1.2.3, the phosphorylation of two serine residues with the carboxy-
terminal SSXS motif of R-SMADs by the activated type I receptor serine-threonine kinase is a 
fundamental event in the transduction of TGFβ signals. Therefore, the dephosphorylation of 
these residues by protein phosphatases represents an effective method of maintaining an 
appropriately balanced TGFβ signalling response (Bruce and Sapkota, 2012). However, due in 
part to the understudied nature of protein phosphatases compared with protein kinases, the 
knowledge of phosphatases responsible for dephosphorylation of R-SMAD SSXS motif 
remains somewhat limited. 
Protein phosphatase 1A (PPM1A; also known as protein phosphatase 2C isoform 
alpha, PP2Ca) was the first reported SMAD2/SMAD3 C-terminal phosphatase (Lin et al., 
2006). PPM1A is a Mg2+/Mn2+-dependent protein serine-threonine phosphatase (PS/TP) that 
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was observed to be predominantly localised in the nucleus where it directly interacts with 
both SMAD2 and SMAD3. Overexpression or shRNA-mediated depletion of PPM1A resulted 
in suppression or enhancement of SMAD2/SMAD3 C-terminal phosphorylation respectively. 
Moreover, PPM1A depletion increased transcription of the cyclin-dependent kinase (CDK) 
inhibitors p15INK4B and p21 in response to TGFβ stimulation and thereby enhanced the TGFβ-
induced cytostatic response in human immortalised keratinocyte cells. However, subsequent 
research observed that endogenous PPM1A localised exclusively to cytoplasmic fractions in 
multiple human and murine cell lines (Bruce et al., 2012), thus contradicting the apparent 
nuclear localisation of PPM1A reported in the previous study. Furthermore, the cytoplasmic 
localisation of PPM1A remained unaffected by TGFβ stimulation. This indicates that the 
identification of a legitimate nuclear-localised protein phosphatase responsible for reversing 
type I receptor mediated phosphorylation of SMAD2/SMAD3 C-terminal residues remains to 
be elucidated. 
In the same study mentioned above, the serine/threonine-specific protein 
phosphatase 5 (PP5) was identified in a proteomic screen as an interactor of SMAD2/SMAD3. 
Moreover, the interaction between PP5 and SMAD2 and SMAD3 was confirmed at the 
endogenous level and overexpression of PP5 resulted in enhanced SMAD3 C-terminal 
dephosphorylation. In mouse embryonic fibroblasts (MEFs) derived from PP5-/- mice, SMAD3 
phosphorylation was higher compared with wild-type control MEFs following stimulation with 
TGFβ stimulation. However, this may be accounted for by higher levels of total SMAD3 protein 
observed in PP5-/- MEFs. Although the messenger RNA (mRNA) expression of SMAD3 was not 
affected by PP5 deletion, the catalytic activity of PP5 appears to be required for modulation 
of SMAD3 protein expression (Bruce et al., 2012). 
As previously discussed in section 1.2.3, R-SMAD proteins have a globular structure 
comprised of an amino-terminal MH1 domain and carboxy-terminal MH2 domain connected 
via a flexible divergent linker region (Massagué, Seoane and Wotton, 2005). This linker region 
contains multiple residues that are subject to phosphorylation by proline-directed protein 
kinases which can modulate the localisation, transcriptional ability and stability of R-SMADs. 
Therefore, the linker region functions to integrate regulatory inputs from multiple signalling 
pathways that ultimately influence the TGFβ cellular response (Bruce and Sapkota, 2012). 
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Figure 1E. The phospho-regulation of TGFβ-activated SMAD2 and SMAD3 
Schematic diagram of SMAD2 and SMAD3 indicating the principal sites of regulatory 
phosphorylation and the relevant protein kinases and protein phosphatases responsible. The 
majority of phosphorylation sites are located within the linker region between the MH1 DNA-
binding domain and the MH2 protein-protein interaction domain. Protein kinases which 
promote SMAD-dependent signalling are indicated in green whereas kinases which attenuate 
SMAD function are denoted in red. Abbreviations: calcium/calmodulin-dependent protein 
kinase 2 (CAMK2); casein kinase 1 isoform gamma-2 (CK1γ2); cyclin-dependent kinase (CDK); 
glycogen synthase kinase 3 (GSK3); β-adrenergic receptor kinase 1 (also referred to as G-
protein coupled receptor kinase 2, GRK2); mitogen-activated protein kinase (MAPK; also 
referred to as extracellular signal-regulated kinase, ERK); maternal embryonic leucine zipper 
kinase (MELK; also referred to as murine protein serine-threonine kinase 38, MPK38); small 
carboxy-terminal domain phosphatases, SCPs). 
 
 
At present, the only protein phosphatases identified to dephosphorylate 
serine/threonine residues within the linker region of SMAD2 and SMAD3 are the small C-
terminal domain phosphatases (SCPs) 1-3 (alternatively termed carboxy-terminal domain 
RNA polymerase II polypeptide A small phosphatase, CTDSP) (Sapkota et al., 2006; Wrighton 
et al., 2006). RNAi-mediated depletion of SCP1 and SCP2 enhances the linker phosphorylation 
of SMAD2 in response to TGFβ stimulation, resulting in decreased TGFβ-dependent gene 
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transcription (Sapkota et al., 2006). This observation is consistent with the notion that 
SMAD2/SMAD3 linker phosphorylation functions as an inhibitory mechanism. However, 
further research is required in order to dissect the functional consequences of proline-
directed phosphorylation/dephosphorylation of specific serine/threonine residues within the 
linker region (Bruce and Sapkota, 2012). 
 
 
1.2.5 Regulation of SMADs by reversible protein ubiquitylation 
As discussed in the preceding section, the linker region of R-SMAD proteins is subject 
to sequential regulatory phosphorylation events which, in addition to forming high affinity 
binding sites for transcriptional partners, also mediates interaction with E3 ubiquitin-protein 
ligases and thus targets the R-SMADs for proteasomal degradation. In the case of SMAD3, 
phosphorylation of residues within its linker region promotes binding to the transcriptional 
partner peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) and the HECT E3 
ubiquitin ligase NEDD4L, which binds to the SMAD3 PY motif via its WW protein-protein 
interaction domain (Kuratomi et al., 2005; Gao et al., 2009; Aragón et al., 2011). Furthermore, 
the HECT E3 ubiquitin ligases SMURF2 and NEDD4-like E3 ubiquitin-protein ligase WWP1 (also 
known as TGIF-interacting ubiquitin ligase 1, Tiul1) have also been reported to catalyse the 
ubiquitylation and subsequent proteasomal degradation of SMAD2 and SMAD3 (Lin, Liang 
and Feng, 2000; Seo et al., 2004). 
Although several E3 ubiquitin ligases have been identified that facilitate the 
polyubiquitylation and subsequent proteasomal degradation of R-SMADs, to date no 
deubiquitylating enzymes have been identified that reverse this process and hence prevent 
R-SMAD degradation. However, prior to the elucidation of its role in the deubiquitylation of 
the type I TGFβ receptors and the E3 ubiquitin ligase SMURF2, USP15 was reported to interact 
with and deubiquitylate monoubiquitylated R-SMADs (Inui et al., 2011). Using a loss-of-
function siRNA screen, USP15 was identified as a DUB required for TGFβ signalling. Although 
siRNA-mediated depletion did not appear to affect SMAD3 phosphorylation, it did enhance 
the mono- and diubiquitylation of SMAD3. The monoubiquitylation sites were mapped and 
found to be predominantly located within the MH1 domain of SMAD3. In particular, the lysine 
residue at position 81 appeared to be critically important as mutation to an arginine residue 
(K81R) resulted in a pronounced attenuation of SMAD3 monoubiquitylation levels. As 
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previously discussed in section 1.2.3, the MH1 domain of R-SMADs participates in DNA-
binding (Massagué, Seoane and Wotton, 2005) and the K81 residue is positioned in close 
proximity to the highly conserved β-hairpin structure that contacts the major groove of DNA. 
In silico modelling of K81 monoubiquitylated SMAD3 revealed that it is incompatible with DNA 
recognition and this was subsequently confirmed experimentally using DNA pulldown assays 
(Inui et al., 2011). Therefore, monoubiquitylation of R-SMADs within their MH1 domain 
impedes their DNA-binding ability and thus prevents their association with the promoter 
regions of target genes. However, USP15-mediated removal of this monoubiquitylation 
promotes the ability of R-SMADs to bind to DNA and hence induce the transcription of target 
genes (Dupont, Inui and Newfeld, 2012). 
More recent research has identified the involvement of a fourth member of the USP 
subfamily of DUBs in the regulation of TGFβ signalling. USP26 has been reported as a DUB 
that can reverse the K48-linked polyubiquitylation of the inhibitory SMAD7, thereby 
enhancing its stability and promoting the downregulation of the type I receptor (Kit Leng Lui 
et al., 2017). Overexpression of wild type USP26, but not a catalytically inactive form USP26 
C/A, enhanced the degradation of the type I receptor, whereas USP26 depletion promoted 
the downregulation of SMAD7, thereby decreasing receptor ubiquitylation and promoting its 
stability. Moreover, a significant negative correlation was observed between USP26 
expression and SMAD2 phosphorylation in glioblastoma patients, and patients exhibiting 
lower USP26 levels had reduced overall survival compared with patients expressing high 
levels of USP26. This indicates that USP26 loss enhances TGFβ signalling and confers a poor 
prognosis in glioblastoma patients (Kit Leng Lui et al., 2017). 
Research has also revealed a role for OTU domain-containing ubiquitin aldehyde-
binding protein 1 (OTUB1), a cysteine protease that belongs to the OTU family of 
deubiquitylating enzymes, in the regulation of TGFβ signalling (Herhaus et al., 2013). A 
proteomic screen identified OTUB1 as a novel interactor of SMAD3 and subsequent co-
immunoprecipitation analysis revealed that it interacts with TGFβ-activated SMAD2/SMAD3-
SMAD4 complex and that this interaction is dependent on phosphorylation of 
SMAD2/SMAD3. RNAi-mediated depletion of OTUB1 suppressed TGFβ-induced transcription 
of the target genes PAI-1 and connective tissue growth factor (CTGF) however it was found 
OTUB1 is unable to directly deubiquitylate polyubiquitylated SMAD3 in vitro. Instead, OTUB1 
prevents the ubiquitylation of SMAD3 by interacting with and inhibiting the E2 ubiquitin-
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conjugating enzymes UBE2D1 and UBE2N. Therefore, OTUB1 can prevent the proteasomal 
degradation of SMAD3 by inhibiting the efficient transfer of ubiquitin moieties from E2 
ubiquitin-conjugating enzymes to E3 ubiquitin-ligating enzymes and thus functions to 
enhance TGFβ using a mechanism that is independent of its catalytic activity (Herhaus et al., 
2013; Herhaus and Sapkota, 2014). 
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1.3 CELLULAR FUNCTIONS OF TGFβ FAMILY CYTOKINES 
 
1.3.1 The importance of cellular context 
Since the discovery and characterisation of TGFβ cytokines during the 1980s, research 
conducted over the following decades has defined the core molecular components of the 
pathway as well as identifying ancillary components and regulators that function to modulate 
the signalling pathway. However, it became evident that TGFβ can exert different, sometimes 
opposite, effects depending on cell type and context (Massagué, 2012a). Consequently, the 
question of how a conceptually simple ligand-receptor-SMAD signal transduction pathway 
could regulate a diverse array of cellular processes remained somewhat enigmatic. 
More recent and current research has made considerable progress towards 
understanding how context determines the nature of the cellular response to TGFβ signals. 
These contextual determinants that define the TGFβ response can be broadly classified into 
three types, which are often interconnected; those which function at the level of signal 
transduction, the factors which co-operate with SMADs to regulate target gene transcription 
and those which define the epigenetic status of the cell. 
The TGFβ signal transduction pathway is subject to both extracellular and intracellular 
regulation which contributes to determining the context-dependent cellular response to 
TGFβ signals. Examples include the abundance and activity of different TGFβ family members, 
the presence of ligand traps that regulate the access of ligands to cell-surface receptors and 
facilitate the formation of ligand gradients (particularly important during embryonic 
development), the combinations of type I and type II receptors and requirement for co-
receptors, proteins which regulate the stability of receptors and SMADs and the influence of 
cross-talk from other signalling pathways. 
At the level of transcriptional regulation, a unifying paradigm has been revealed 
involving collaboration between SMADs, signal-driven transcription factors (SDTFs) that are 
directly activated by TGFβ receptors and lineage-determining transcription factors (LDTFs) 
which differ depending on cell type (David and Massagué, 2018). The co-operation of LDTFs 
with SMADs determines the binding of activated SMAD complexes to specific genomic loci 
and whether the expression of target genes will be either positively or negatively regulated. 
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The epigenetic status of a cell dictates whether the chromatin conformation is in an 
‘open’ permissive state in which the promoter regions of target genes are accessible to TGFβ-
activated SMAD complexes or in a ‘closed’ repressive state which is not accessible for 
transcriptional regulation. The epigenetic status is particularly important in the context of 
stem cell pluripotency and differentiation. Under conditions which promote self-renewal of 
embryonic stem cells (ESCs), genes required for pluripotency are in an open conformation 
that permits transcriptional activation in response to TGFβ signals, whereas genes involved in 
differentiation remain in a repressive chromatin conformation and are thus refractory to 
these signals (Massagué, 2012a). The involvement of TGFβ in regulating stem cell 
pluripotency and differentiation is discussed in more detail in section 1.4.3. 
 
 
1.3.2 Immune regulation 
Members of the TGFβ family of cytokines have critical and pleiotropic immunoregulatory 
functions. TGFβ1 is the predominant member expressed in the immune system and can 
function in both autocrine and paracrine modes to control the differentiation, proliferation 
and activation of leukocyte lineage cells including lymphocytes, macrophages and dendritic 
cells (Letterio and Roberts, 1998). Disruption of TGFβ signalling components in mice leads to 
the development of numerous immunopathological phenotypes, providing further evidence 
of the importance of TGFβ signalling in the regulation of immune responses (Chen and ten 
Dijke, 2016). 
 The pleiotropic nature of TGFβ action in the immune system is particularly evident in 
the regulation of T lymphocytes, and it has become apparent that TGFβ is a critical regulator 
of thymic T lymphocyte development in addition to contributing to peripheral T lymphocyte 
homeostasis (Gorelik and Flavell, 2002; Li and Flavell, 2008; Tu, Chia and Chen, 2014). The 
important function of TGFβ in regulating the specification of various T lymphocyte subtypes 
is predominantly mediated via the cooperation of SMADs with different lineage-determining 
transcription factors (LDTFs) (David and Massagué, 2018). For example, TGFβ can promote 
the differentiation of naive CD4+ (T-cell surface glycoprotein CD4) T cells into regulatory T 
(Treg) cells in peripheral lymphoid organs (Yamagiwa et al., 2001; Zheng et al., 2004). CD4+ Treg 
cells develop from naive CD4+ T cells in both the thymus and periphery and participate in the 
maintenance of immunological self-tolerance. One of the principal functions of CD4+ Treg cells 
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in the periphery is to suppress the activation and proliferation of potentially harmful self-
reactive T cells that have evaded thymic clonal deletion (Josefowicz, Lu and Rudensky, 2012). 
The lineage-determining transcription factor forkhead box protein P3 (FOXP3) is a principal 
determinant of the CD4+ Treg cell phenotype (Hori, Nomura and Sakaguchi, 2003) and the 
induction of FOXP3 expression in peripheral CD4+ naive T cells is predominantly mediated by 
TGFβ signalling (Chen et al., 2003; Selvaraj and Geiger, 2007). Subsequent research 
demonstrated that TGFβ-mediated regulation of peripheral Treg cell differentiation requires 
cooperation with other signal-driven transcription factors (SDTFs). It was demonstrated that 
TGFβ-activated SMAD3 and the transcription factor nuclear factor of activated T-cells (NFAT) 
bind to conserved sequences within a 5’ enhancer element for the FOXP3 gene (Mantel et al., 
2006; Tone et al., 2008). Furthermore, the binding of both SMAD3 and NFAT to the FOXP3 
enhancer is required for histone acetylation of the enhancer region and concomitant 
induction of FOXP3 expression (Tone et al., 2008). 
Research has also indicated a critical requirement for interleukin-2 (IL-2) signalling in 
the TGFβ-mediated induction of FOXP3 expression that results in the differentiation of 
peripheral CD4+ naive T cells into CD4+ Treg cells (Josefowicz, Lu and Rudensky, 2012). This is 
demonstrated by the observation that TGFβ stimulation is unable to induce the expression of 
FOXP3 in peripheral CD4+ naive T cells derived from IL-2-deficient mice. However, treatment 
with exogenous IL-2, but not IL-7 or IL-15 (cytokines which signal through IL-2 receptor 
subunit gamma (IL-2Rg) and IL-2Rg and IL-2Rβ subunits respectively), was sufficient to restore 
the ability of TGFβ to induce FOXP3 expression (Davidson et al., 2007; Zheng et al., 2007). 
 
 
1.3.3 Cellular proliferation 
TGFβ cytokines were initially identified in crude acid-ethanol extracts from sarcoma and 
carcinoma-derived cell lines and were found to be acid-stable, soluble polypeptides with the 
ability to stimulate the growth of normal (i.e. untransformed) rat renal fibroblasts (Roberts et 
al., 1980), hence their designation as ‘transforming growth factors.’ However, subsequent 
research using purified TGFβ demonstrated that it could also elicit strong anti-proliferative 
effects in certain cell types (Roberts et al., 1985). Research over the following three decades 
has revealed that TGFβ is a multifunctional cytokine that can regulate diverse cellular 
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processes including cellular proliferation and differentiation, EMT, cell death and modulation 
of the cell microenvironment and that TGFβ signalling is highly dependent on cellular context. 
The cytostatic effect of TGFβ has been widely investigated due to its major contribution to 
the tumour suppressive function of TGFβ (Massagué, 2008a) and represents a paradigm of 
TGFβ-mediated cellular response. 
 The molecular mechanisms underlying the cytostatic effect of TGFβ were 
predominantly delineated using epithelial cell types, however the ability of TGFβ to negatively 
regulate cellular proliferation has been observed in multiple cells types including endothelial, 
neuronal and cells of the immune system (Siegel and Massagué, 2003). The eukaryotic cell 
cycle is divided into four sequential phases: G1 phase, S (DNA synthesis) phase, G2 phase and 
M (mitosis) phase. Early research indicated that TGFβ induces cell-cycle arrest at the G1 phase 
(Laiho et al., 1990; Geng and Weinberg, 1993; Polyak, Kato, et al., 1994) and this research 
contributed to the identification of the restriction (R)-point transition that occurs in mid-late 
G1 phase (Planas-Silva and Weinberg, 1997). The R-point represents a specific period during 
which cells perceive and interpret extracellular signals and decide whether or not to proceed 
through the cell cycle. Once a cell progresses through the R-point transition, it is committed 
to completing the remainder of the cell cycle and is no longer competent to regulation by 
extracellular signals. Thus, the addition of TGFβ to cells which have progressed through the 
R-point transition does not inhibit the ongoing cell cycle. 
 The cytostatic response exerted by TGFβ on epithelial cells involves the regulation of 
two distinct classes of cell-cycle regulators that both function to promote cell proliferation; 
the repression of certain growth-promoting transcription factors and the induction of cyclin-
dependent kinase (CDK) inhibitors. Transcriptomic profiling of the TGFβ-mediated cytostatic 
response in three epithelial cell lines derived from different human tissues revealed the 
minimal general features of the cytostatic programme, involving the up-regulation of the CDK 
inhibitors p15INK4B (also termed cyclin-dependent kinase 4 inhibitor B, CDKN2B) and p21CIP1 
(also termed cyclin-dependent kinase inhibitor 1A, CDKN1A) and the repression of the 
transcription factors c-MYC, ID-1, ID-2 and ID-3 (Kang, Chen and Massagué, 2003). 
 Progression through the cell cycle is controlled by the actions of cyclin-dependent 
kinases (CDKs). CDKs are the catalytic subunits of heterodimeric serine-threonine protein 
kinases which require the binding of a regulatory subunit (termed cyclin) as well as 
phosphorylation of a threonine residue within the activation loop of the kinase subunit in 
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order to be completely active (Hochegger, Takeda and Hunt, 2008). The cyclin D-dependent 
kinases CDK4 and CDK6 control progression through the G1 phase of the cell cycle by 
phosphorylating retinoblastoma protein (pRb; also known as p105), retinoblastoma-like 
protein 1 (RBL1; also known as p107) and retinoblastoma-like protein 2 (RBL2; also known as 
p130) (Malumbres and Barbacid, 2005). The cyclin D-CDK4 and cyclin D-CDK6 complexes are 
both specifically inhibited by p15INK4B, the expression of which is rapidly induced by TGFβ in 
epithelial cells (Hannon and Beach, 1994; Reynisdóttir et al., 1995). p15INK4B belongs to the 
inhibitors of CDK4 (INK4) family of cyclin-dependent kinase inhibitors which also includes 
p16INK4A, p18INK4C and p19INK4D (Malumbres and Barbacid, 2005). The INK4 proteins specifically 
bind to and inhibit the monomeric CDK4 and CDK6 catalytic subunits, disrupting their catalytic 
sites and preventing association with D-type cyclins (Sherr and Roberts, 1999). Furthermore, 
in addition to transcriptional upregulation, it has been observed that TGFβ can also enhance 
the protein stability of p15INK4B (Sandhu et al., 1997). Along with p15INK4B, TGFβ has also been 
shown to transcriptionally induce a number of other CDK inhibitors, including p21CIP1 (Datto, 
Yu and Wang, 1995; Reynisdóttir et al., 1995), p27KIP1 (also known as cyclin-dependent kinase 
inhibitor 1B, CDKN1B) (Polyak, Kato, et al., 1994a; Polyak, Lee, et al., 1994) and p57KIP2 (also 
known as cyclin-dependent kinase inhibitor 1C, CDKN1C) (Lee, Reynisdóttir and Massagué, 
1995; Matsuoka et al., 1995). Collectively, these three CDK inhibitors constitute the CDK 
interacting protein/kinase inhibitory protein (CIP/KIP) family, which along with the 
aforementioned INK4 proteins, comprise the two families of mammalian CDK inhibitors 
involved in regulating the cell cycle. In contrast to the INK4 family members, which specifically 
interact with and inhibit the cyclin-D-dependent CDKs (CDK4 and CDK6), CIP/KIP family 
members can interact and inhibit many different cyclin-CDK complexes. However, CIP/KIP 
proteins display higher affinity for G1 and S phase CDKs and therefore, along with the INK4 
proteins, primarily function to regulate the G1/S phases of the cell cycle. Subsequent research 
demonstrated that the TGFβ-mediated transcriptional induction of p15INK4B and p21CIP1 
expression is dependent on both SMAD and members of the forkhead box O (FOXO) family of 
transcription factors (FOXO1, FOXO3 and FOXO4) (Seoane et al., 2004; Gomis et al., 2006). 
Interestingly, increased levels of p15INK4B in response to TGFβ stimulation also 
functions to regulate the action of p27KIP1. In proliferating cells, p27KIP1 is predominantly found 
in a complex with cyclin-D-CDK4/CDK6 that remains catalytically active and thus functions as 
a reservoir of p27KIP1 (Blain, Montalvo and Massagué, 1997). However, upon increased 
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expression of p15INK4B in response to TGFβ stimulation, p15INK4B can prevent p27KIP1 from 
binding to cyclin-D-dependent CDK4/CDK6 complexes. This promotes p27KIP1 to interact with 
cyclin-CDK2 complexes, thereby inhibiting the kinase activity of CDK2 (Reynisdóttir and 
Massagué, 1997). In this way, TGFβ can induce cytostasis at the G1/S phase by targeting two 
distinct cyclin-CDK complexes for inhibition through the upregulation of p15INK4B and 
redistribution of p27KIP1. The inhibition of these G1 phase cyclin-CDK complexes prevents the 
hyperphosphorylation of pRb (p105), RBL1 (p107), RBL2 (p130) and other substrates, 
therefore preventing the transactivation of genes required for S phase progression (Siegel 
and Massagué, 2003). 
In addition to the transcriptional induction of CDK inhibitors, the transcriptional 
repression of growth-promoting transcription factors is another important mechanism by 
which TGFβ can induce cell-cycle arrest. Principal among these are the proto-oncogenic 
transcription factor c-MYC and the DNA-binding protein inhibitors (also knowns as inhibitors 
of differentiation) ID-1, ID-2 and ID3 (Kang, Chen and Massagué, 2003).  
TGFβ stimulation has been shown to rapidly down-regulate both the RNA and protein 
levels of c-MYC in various different cell lines (Alexandrow and Moses, 1995). The importance 
of this is highlighted by the observation that TGFβ-mediated cell-cycle arrest is prevented in 
cells in which c-MYC is overexpressed or in which there is a failure to down-regulate c-MYC 
expression (Alexandrow et al., 1995; Chen, Kang and Massagué, 2001). Research from a 
number of independent groups identified the components of a transcriptional repressor 
complex and the molecular mechanism by which it facilitates the down-regulation of c-MYC 
in response to TGFβ (Chen et al., 2002; Yagi et al., 2002; Frederick et al., 2004). This complex 
consists of SMAD3, SMAD4, the transcription factor E2F4 and the transcriptional repressor 
RBL1. The SMAD3-SMAD4-E2F4 transcriptional repressor complex binds to adjacent SMAD 
and E2F binding sites, referred to as a TGFβ inhibitory element (TIE) within the promoter 
region of the c-MYC gene (Chen et al., 2002). As previously mentioned, RBL1 (alternatively 
referred to as p107), along with pRb (p105) and RBL2 (p130), which collectively comprise the 
pocket protein family of cell-cycle regulators (Cobrinik, 2005), are subject to CDK-dependent 
phosphorylation and inhibition that occurs in the nucleus. However, the fraction of RBL1 that 
participates in the SMAD3-SMAD4-E2F4 transcriptional repressor complex resides in the 
cytoplasm and is therefore not subjected to CDK-mediated inhibitory phosphorylation (Siegel 
and Massagué, 2003). Intriguingly, in addition to preventing its growth-promoting functions, 
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the repression of c-MYC expression also contributes to the transcriptional activation of the 
CDK inhibitors p15INK4B and p21CIP1 that occurs in response to the same TGFβ signals (discussed 
previously). Therefore, c-MYC down-regulation serves two functions and represents a critical 
node at the centre of the TGFβ cytostatic response (Siegel and Massagué, 2003). 
The transcriptional repression of c-MYC constitutes a hallmark of the cytostatic 
programme mediated by TGFβ, however the repression of other growth-promoting 
transcription factors also contributes to this process. TGFβ-induced cell-cycle arrest in 
epithelial cells involves the suppression of the ID-1, ID-2 and ID-3 proteins (Kang, Chen and 
Massagué, 2003), which along with ID-4, comprise the inhibitors of DNA 
binding/differentiation (ID) family of transcription factors. The ID proteins contain a helix-
loop-helix (HLH) domain however they lack a DNA-binding domain and they therefore they 
operate to antagonise the function of basic HLH (bHLH) transcription factors (Ruzinova and 
Benezra, 2003). TGFβ family members, including BMP isoforms, have been shown to both 
positively and negatively regulate ID members depending on cell type and context. ID proteins 
have been reported to promote cell proliferation through a number of different mechanisms. 
For example, overexpression of ID-1 in cultured cells results in reduced expression of p16INK4A 
(also known as cyclin-dependent kinase inhibitor 2A, CDKN2A), a member of the INK4 family 
of CDK inhibitors. p16INK4A can arrest cells in the G1 phase by inhibiting CDK4 and CDK6 and 
has been implicated in mediating cellular senescence (i.e. irreversible G0 phase) (Ohtani et al., 
2001). Overexpression of ID-1 and the resulting suppression of p16INK4A has also been 
reported to contribute to increased proliferation of prostate cancer cells (Ouyang et al., 
2002). The ability of TGFβ to repress the expression of ID-1 occurs via a ‘self-enabling 
response’ and is dependent on the induction of the transcriptional repressor activating 
transcription factor 3 (ATF3; otherwise referred to as cyclic AMP-dependent transcription 
factor) (Kang, Chen and Massagué, 2003). In epithelial cells, TGFβ rapidly induces the 
expression of ATF3 in a SMAD3-dependent manner (the primary gene response). ATF3 
subsequently interacts with SMAD3 to form a transcriptional repressor complex, along with 
SMAD4. The SMAD3-SMAD4-ATF3 complex binds to the ID1 gene promoter, thereby 
mediating the repression of ID-1 (the secondary gene response). 
Furthermore, in certain osteosarcoma and glioblastoma cell lines, ID-2 (but not ID-1 
or ID-3) has been shown to directly interact with pRb, RBL1 and RBL2 and inhibit the growth-
suppressing activities of these proteins, thereby promoting cell proliferation (Lasorella, 
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Iavarone and Israel, 1996). Subsequent research highlighted the importance of TGFβ-
mediated c-MYC repression in the regulation of ID-2 by demonstrating that ID-2 is a direct 
transcriptional target of MYC transcription factors. The binding of c-MYC or N-MYC to 
enhancer (E)-box elements within the ID2 promoter region induced up-regulation of ID-2 
expression (Lasorella et al., 2000). Thus, c-MYC downregulation in response to TGFβ signals 
may result in the concomitant suppression of ID-2 expression in certain cell types. However, 
although the initial repression of ID-2 during the TGFβ-mediated cytostatic response is 
dependent on suppression of c-MYC, sustained repression of ID-2 appears to involve a c-MYC-
independent mechanism, as c-MYC levels recover even though TGFβ stimulation is 
maintained. Research has indicated that the sustained repression of ID-2 expression requires 
upregulation of the transcriptional repressors MAX-interacting protein 1 (MXI-1) and MAX 
dimerisation protein 4 (MAD4), which compete with c-MYC for binding to the transcriptional 
regulator MYC-associated factor X (MAX) (Siegel, Shu and Massagué, 2003). Therefore, 
prolonged TGFβ stimulation results in a shift from c-MYC-MAX complexes to MXI-1/MAD4-
MAX heterodimeric complexes at the ID2 promoter, facilitating the sustained repression of 
ID-2 during TGFβ-induced cell-cycle arrest. 
The appropriate balance between cell proliferation and cell death is fundamental to 
correct tissue growth and physiological homeostasis. Consequently, perturbations of this 
balance can result in development of pathological conditions, most notably tumorigenesis, 
and the participation of TGFβ signalling will be discussed in subsequent chapters. 
 
 
1.3.4 Epithelial-mesenchymal transition (EMT) 
Epithelial-mesenchymal transition (EMT) is the cellular process by which a polarised epithelial 
cell undergoes profound biochemical and morphological alterations that enable it to acquire 
a mesenchymal cell phenotype (Kalluri and Weinberg, 2009). EMT is a fundamental 
developmental process which occurs multiple times throughout embryogenesis and also 
participates in the wound healing response. However, it has become apparent that EMT 
contributes to disease pathogenesis, most notably tissue fibrosis (Kim, Sheppard and 
Chapman, 2018) and tumour invasion and metastasis (Hanahan and Weinberg, 2011). 
 Epithelial cells typically form layers, tubes or vesicles in which the cells exhibit apical-
basal polarity and intimately associate with adjacent cells through specialised lateral cell-cell 
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contacts including tight junctions, adherens junctions and desmosomes. Upon initiation of 
EMT, one of the earliest events to occur is the dissolution of tight junctions (also knowns as 
occluding junctions) at the apical-lateral surfaces, characterised by decreased expression of 
claudin and occludin transmembrane proteins and delocalisation of the cytoplasmic protein 
zonula occludens-1 (ZO-1; also referred to as tight junction protein-1, TJP1) (Lamouille, Xu 
and Derynck, 2014). This is followed by disassembly of the more basolateral adherens 
junctions and desmosome complexes, with concomitant reorganisation of the actin 
cytoskeleton. Consequently, epithelial cells lose their apical-basolateral cell polarity and 
develop a fibroblastoid (i.e. spindle-like) morphology with ‘front-rear’ polarity. In addition, 
cells undergoing EMT increase secretion of extracellular proteases and alter expression of 
extracellular matrix (ECM) proteins. This enables the cells to become migratory and, in the 
context of tumorigenesis, facilitates invasion and metastasis. Throughout the process of EMT 
there is a reprogramming of the transcriptional profile of the cell, in which epithelial gene 
expression is lost and there is enhanced or de novo expression of mesenchymal genes such 
as N-cadherin, vimentin and fibronectin (Zavadil et al., 2001; Valcourt et al., 2005). 
 TGFβ has been identified as a potent inducer of EMT in both transformed and non-
transformed epithelial cell types in culture (Miettinen et al., 1994; Caulin et al., 1995; Piek et 
al., 1999; Valdés et al., 2002) and numerous studies have demonstrated the importance of 
TGFβ-activated SMAD-dependent signalling in this process (Xu, Lamouille and Derynck, 2009). 
One of the principal mechanisms by which TGFβ can induce EMT is by regulating the 
expression of critical transcription factors that mediate the transcriptional reprogramming 
that occurs during the process. This transcriptional reprogramming involves three distinct 
families of transcription factors: Snail, two zinc finger E-box-binding homeobox (ZEB1 and 
ZEB2) proteins and members of the basic helix-loop-helix (bHLH) family. The Snail superfamily 
are zinc-finger transcription factors of which there are five encoded in the human genome: 
SNAI1 and SNAI2 (more commonly referred to as Snail and Slug respectively), SNAI3, 
SCRATCH1 and SCRATCH (Nieto, 2002). In epithelial cells, both Snail and Slug have been 
shown to mediate the transcriptional repression of the adhesion protein E-cadherin through 
interaction with E-box elements within the CDH1 gene promoter (Batlle et al., 2000; Cano et 
al., 2000; Bolós et al., 2003). The delocalisation and down-regulation of E-cadherin expression 
is considered to be a hallmark event of EMT that directly facilitates the dissolution of 
adherens junctions in addition to contributing to transcriptional reprogramming via the 
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release of soluble β-catenin (Lamouille, Xu and Derynck, 2014). TGFβ can induce Snail 
expression in epithelial cells, however this appears dependent on activation of the MAPK 
pathway, requiring the activity of the MAPKKs MEK1 and MEK2, but independent of SMAD4 
(Peinado, Quintanilla and Cano, 2003). Furthermore, TGFβ-mediated induction of Snail has 
also been reported to upregulate the expression of matrix metalloproteinase 2 and 9 (MMP2 
and MMP9) (Jordà et al., 2005; Taki et al., 2006). In epithelial cells, the upregulation of MMP2 
and MMP9 in response to TGFβ may involve activation of p38 MAPK signalling but not 
ERK1/ERK2 (Kim, Kim and Moon, 2004) and contributes to the invasive behaviour of 
carcinoma cells. 
 In addition to regulating the transcriptional programme, TGFβ can also induce EMT by 
promoting the disassembly of cell junctions and concomitant loss of apical-basal cell polarity 
(Lamouille, Xu and Derynck, 2014). TGFβ has been shown to directly regulate the polarity 
protein partitioning defective 6 homolog alpha (PAR6) (Ozdamar et al., 2005). PAR6 is a 
component of the PAR complex, along with PAR3, atypical protein kinase C (aPKC) and the 
Rho family small GTPase cell division control protein 42 homolog (CDC42) (Joberty et al., 2000; 
Lin et al., 2000). The PAR complex is believed to be required for the assembly and 
maintenance of tight junctions (but not adherens junctions), thereby facilitating cell-cell 
contact and sustaining epithelial cell polarity (Gao 2002). In epithelial cells, the TGFβ type I 
receptor (TGFβR1) colocalises with PAR6 and ZO-1 at tight junctions, whereas the TGFβ type 
II receptor (TGFβR2) was found to be uniformly distributed in discrete puncta at the apical 
surface. However, upon TGFβ stimulation, TGFβR2 redistributed to tight junctions and 
colocalised with both TGFβR1 and ZO-1. Moreover, TGFβR1 was found to constitutively 
interact with PAR6 and occludin, a structural component of tight junctions at the endogenous 
level, and interaction of PAR6 with TGFβR1 facilitated its phosphorylation at Ser345 by the 
constitutively active TGFβR2 kinase. Mutation of the serine residue to alanine prevented 
TGFβ-induced dissolution of tight junctions (Ozdamar et al., 2005). TGFβR2-mediated 
phosphorylation of PAR6 enables recruitment of the E3 ubiquitin-ligase SMURF1 to the PAR 
complex, where it can regulate cell polarity by mediating the ubiquitylation and subsequent 
proteasomal degradation of RAS homolog gene family member A (RhoA )(Wang et al., 2003; 
Tian et al., 2011). RhoA is the prototypical member of the Rho family of small GTPases and 
has important functions in modulating the formation and stability of cell-cell junctions (Fukata 
and Kaibuchi, 2001; Sahai and Marshall, 2002; Perez-Moreno, Jamora and Fuchs, 2003). 
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Therefore, the localised SMURF1-mediated degradation of RhoA promotes TGFβ-dependent 
dissolution of tight junctions during EMT (Ozdamar et al., 2005). 
 
 
1.3.5 Apoptosis 
Apoptosis is an evolutionary conserved form of regulated cell death that occurs in both 
physiological and pathophysiological situations in multicellular organisms. The term apoptosis 
was first used in 1972 to describe a form of programmed cell death that exhibited 
morphological features distinct from those observed in cells undergoing pathological, 
necrotic cell death (Hengartner, 2000). 
TGFβ can regulate apoptosis in a variety of different cell types and physiological 
contexts. TGFβ-mediated apoptosis has been shown to play an important role in 
organogenesis and limb formation during embryonic development or during normal adult 
tissue remodelling (Dünker, Schmitt and Krieglstein, 2002; Schuster, Dünker and Krieglstein, 
2002; Beier et al., 2006). Furthermore, the ability of TGFβ to induce apoptosis is one of the 
principal contributions to the tumour suppressive function of TGFβ cytokines (Ikushima and 
Miyazono, 2010a). TGFβ can either promote or suppress apoptosis, although in the majority 
of cases the pro-apoptotic ability of TGFβ has been reported. Consequently, a coherent 
molecular understanding of how TGFβ regulates apoptosis has yet to be elucidated, and as 
with many aspects of TGFβ signalling, it appears to be highly dependent on cell type and 
context. Furthermore, apoptosis is regulated by many other signals and therefore integration 
of multiple signalling pathways is likely to be required before a cell decides upon the 
important decision between survival and programmed cell death (Zhang, Alexander and 
Wang, 2017). 
A number of studies have highlighted the importance of SMAD proteins as mediators 
of TGFβ-induced apoptosis in multiple different cell types. In human pulmonary epithelial 
cells, constitutive overexpression of SMAD3 in the presence of TGFβ stimulation strongly 
induced apoptosis. Although overexpression of SMAD2 could also potentiate TGFβ-induced 
apoptosis, this occurred to a much lesser degree (Yanagisawa et al., 1998). Furthermore, 
overexpression of a dominant negative form of SMAD3, in which the three serine residues 
within the carboxy-terminal SSXS motif were mutated to alanine, or the inhibitory SMAD7 
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impaired TGFβ-induced apoptosis in human hepatocellular carcinoma cells (Yamamura et al., 
2000). 
Activated SMAD transcriptional complexes have been shown to regulate the 
expression of several apoptotic genes. The TGFβ-inducible early-response gene (TIEG1; also 
known as Krueppel-like factor 10, KLF10) was one of the first TGFβ-responsive genes 
identified that contributes to TGFβ-induced apoptosis. TIEG1 is a zinc-finger transcription 
factor that is transcriptionally induced by TGFβ in various pancreatic epithelial cells 
(Tachibana et al., 1997) and pulmonary epithelial cells (Chalaux et al., 1999). Overexpression 
of TIEG1 inhibits cell proliferation and simultaneously induces apoptosis in TGFβ-responsive 
pancreatic epithelial cells (Tachibana et al., 1997). Furthermore, the pro-apoptotic function 
of TIEG1 may be due in part to its ability to supress the expression of the apoptosis regulator 
B-cell lymphoma 2 (BCL-2) protein. BCL-2 is the prototypical member of the evolutionarily 
conserved BCL-2 protein family which regulates apoptosis through their ability to regulate 
mitochondrial cytochrome c release (i.e. the intrinsic apoptotic pathway) (Czabotar et al., 
2014). The BCL-2 family comprises three subfamilies; the anti-apoptotic (pro-survival) 
subfamily, the pro-apoptotic subfamily and the BH3-only subfamily. All the family members 
share sequence and structural homology and contain between one and four BCL-2 homology 
(BH) domains (BH1-BH4). Additionally, most members also contain a transmembrane (TM) 
domain, which enables association with organelle membranes, most notably the outer 
mitochondrial membrane. In humans, there are six members of the anti-apoptotic subfamily, 
which is comprised of BCL-2 along with BCL-XL (also known as BCL-2-like protein 1, BCL2-L1), 
BCL-W (also known as BCL-2-like protein 2, BCL2-L2), induced myeloid leukaemia cell 
differentiation protein (MCL1; also known as BCL-2-like protein 3, BCL2-L3), BCL2-A1 (BCL-2-
like protein 5, BCL2-L5) and BCL-B (also known as BCL-2-like protein 10). The members of this 
subfamily contain four BH domains and a TM domain, with the exception of BCL2-A1 which 
lacks a TM domain. The pro-apoptotic subfamily consists of three members, BAX (also known 
as BCL-2-like protein 4, BCL2-L4), BCL-2 homologous antagonist/killer (BAK; also known as 
BCL-2-like protein 7, BCL2-L7) and BCL-2-related ovarian killer protein (BOK; also known as 
BCL-2-like protein 9, BCL2-L9). As with the anti-apoptotic subfamily members, the pro-
apoptotic members also contain four BH domains and a TM domain and adopt similar globular 
structures. They promote apoptosis by undergoing oligomerisation to form pores in the outer 
mitochondrial membrane, resulting in efflux of cytochrome c into the cytosol and ultimately 
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activation of the executioner caspase proteases caspase-3 and caspase-7 (Tait and Green, 
2010). The third subfamily of BCL-2 proteins are the BH3-only proteins, of which there are 
eight mammalian members consisting of BH3-interacting domain death agonist (BID), BCL2-
associated agonist of cell death (BAD; also knowns as BCL2-L8), BCL2-interacting mediator of 
cell death (BIM; also known as BCL2-L11), BCL2-interacting killer (BIK), BCL2-modifying factor 
(BMF), activator of apoptosis harakiri (HRK; also known as BH3-interacting domain-containing 
protein 3, BID3), NOXA (also known as phorbol-12-myristate-13-acetate-induced protein 1, 
PMAIP1) and p53 upregulated modulator of apoptosis (PUMA; also known as BCL2-binding 
component 3, BBC3). Unlike the other two BCL-2 protein subfamilies, the BH3-only members 
display little sequence homology and (as their name implies) only contain a BH3 domain. 
Overexpression of any of the BH3-only proteins is sufficient to promote apoptosis, however 
the members are differentially regulated (Taylor, Cullen and Martin, 2008). 
TGFβ has been shown to induce apoptosis by regulating the expression of a number 
of different BCL-2 protein family members in various different cell types. For example, in both 
liver and mammary gland epithelial cells, TGFβ stimulation results in apoptosis and the 
upregulation of the BH3-only proteins BIM and BMF in a SMAD4-dependent manner. RNAi-
mediated depletion of either BIM or BMF protected cells from TGFβ-induced cell death and 
this protection was further enhanced when BIM and BMF protein levels were depleted 
simultaneously (Ramjaun et al., 2007). Similarly, in a gastric epithelial cell line which is 
amenable to TGFβ-mediated apoptosis, BIM and BMF expression was upregulated in 
response to TGFβ stimulation. However, in this cell context, only RNAi-mediated depletion of 
BIM expression was able to render the cells resistant to TGFβ-induced apoptosis (Ohgushi et 
al., 2005). Furthermore, TGFβ can induce apoptosis in human Burkitt lymphoma (BL) cell lines 
by mediating the differential transcriptional regulation of BCL-2 family members. Stimulation 
of BL cells with TGFβ promoted apoptosis by enhancing the transcription of the pro-apoptotic 
BH3-only subfamily member BIK, while simultaneously repressing the expression of the anti-
apoptotic subfamily member BCL-XL (Spender et al., 2009). The transcriptional repression of 
BIK involves the TGFβ-dependent recruitment of SMAD3 and SMAD4 to the endogenous BIK 
promoter. 
In certain hepatocellular carcinoma cell lines, the expression of death-associated 
protein kinase 1 (DAPK1) is increased during TGFβ-induced apoptosis (Jang et al., 2002). 
DAPK1 is a calcium/calmodulin (Ca2+/CaM)-dependent serine-threonine protein kinase that 
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has been reported to mediate apoptosis in response to numerous different stimuli. One of 
the proposed mechanisms by which DAPK1 is thought to mediate apoptosis is through 
activation of the tumour suppressor cellular tumour antigen p53 (TP53) in a p19ARF-
dependent manner (Raveh et al., 2001). The regulation of DAPK1 transcription by TGFβ is 
dependent on SMAD2 and SMAD3, and expression of a kinase-inactive mutant form of DAPK1 
or downregulation of DAPK1 expression using RNAi inhibited TGFβ-induced apoptosis (Jang 
et al., 2002). 
In addition to transcriptional regulation, a number of studies have identified proteins 
whose expression, although not regulated by TGFβ, is required for TGFβ-induced apoptosis. 
For example, the adaptor protein DAXX (also knowns as death domain-associated protein 6, 
DAP6) has been reported to directly interact with the TGFβ type II receptor and mediate 
TGFβ-induced apoptosis in murine hepatocytes. DAXX has previously been shown to interact 
with the death domain of the transmembrane cell death receptor tumour necrosis factor 
(TNF) receptor superfamily member 6 (also known as Fas) to activate the c-Jun amino-
terminal kinase (JNK) signalling pathway and potentiate Fas-induced apoptosis (Yang et al., 
1997). In addition, DAXX has also been reported to interact with the cytoplasmic domain of 
the TGFβ type II receptor kinase and in doing so functions as an adaptor protein to facilitate 
TGFβ-induced activation of the JNK pathway and therefore mediate TGFβ-induced apoptosis 
(Perlman et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 73 
1.4 TGFβ SIGNALLING IN HUMAN PATHOLOGIES 
 
1.4.1 TGFβ signalling in cancer 
TGFβ cytokines regulate cytostasis and apoptosis, which are fundamental cellular processes. 
These processes, along with regulation of cell adhesion and the cellular microenvironment, 
contribute to the tumour suppressive effects exerted by TGFβ in normal, premalignant cells. 
However, perturbations in the signalling pathway, either via inactivation of core components 
or defective downstream responses (i.e. loss of tumour suppressive functions), can enable 
cancer cells to evade the tumour suppressive influence of TGFβ. Furthermore, TGFβ signalling 
can be co-opted by cancer cells to facilitate cancer progression and metastasis via the ability 
of TGFβ to promote epithelial-mesenchymal transition, autocrine mitogen production, 
immunosuppression and migration. Therefore, paradoxically, TGFβ can function as either a 
tumour suppressor or tumour promoter depending on cellular context and understanding of 
the molecular basis of this switch is crucial to deciphering the therapeutic potential of the 
pathway (Massagué, 2008b; Ikushima and Miyazono, 2010b; Inman, 2011a; Wakefield and 
Hill, 2013; Colak and Ten Dijke, 2017). 
 Inactivation of core components of the TGFβ signalling pathway, either by mutation 
or allelic loss of heterozygosity (LOH), can enable cancer cells to evade the tumour 
suppressive effects of TGFβ. Thus far, the most frequently mutated components of the 
pathway are the TGFβ type I and type II receptors and the common mediator SMAD4, all of 
which have been associated with the pathogenesis of multiple different human cancers (Levy 
and Hill, 2006). SMAD4 (originally termed deletion target in pancreatic carcinoma, locus 4; 
DPC4) was initially identified as a candidate tumour suppressor gene in human pancreatic 
carcinomas (Hahn et al., 1996). Allelic loss at human chromosome 18q occurs in 
approximately 90 percent of human pancreatic carcinomas and over 60 percent of colorectal 
carcinomas (Padua and Massagué, 2009). The SMAD4/DPC4 gene, along with another 
candidate tumour suppressor gene DCC, was found to be within the minimally lost region on 
chromosome 18q21 (Thiagalingam et al., 1996) and homozygous deletions of the 
SMAD4/DPC4 gene were observed in approximately 30 percent of pancreatic carcinomas 
analysed (Hahn et al., 1996). 
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Furthermore, mutations in SMAD4 that result in protein instability have been 
identified that are associated with the pathogenesis of acute myelogenous leukaemia and 
pancreatic adenocarcinoma (Wan et al., 2005; L. Yang et al., 2006). A missense mutation in 
the SMAD4 MH1 domain (c.305C>T, Pro102Leu) and a frameshift mutation that results in 
premature termination within the MH2 domain (D483-552) undergo rapid proteasomal 
degradation via Skp1, Cullin, F-box containing complex (SCF)-β-TrCP E3 ubiquitin protein 
ligase-mediated polyubiquitylation (L. Yang et al., 2006). 
 Evasion of TGFβ-mediated tumour suppression can also occur as a result of defects in 
downstream signalling responses. As alluded to previously, TGFβ-induced cytostasis is one of 
the critical tumour suppressive responses, however epigenetic silencing of the TGFβ target 
genes p15INK4B and p21CIP1 by aberrant DNA methylation and histone modifications have been 
implicated in the pathogenesis of acute myelogenous leukaemia (Geyer, 2010). In addition, 
homozygous deletion of the p15INK4B gene has been reported in human glioblastoma 
multiforme (GBM) (Jen et al., 1994) and the tumour suppressive function of p15INK4B has also 
been demonstrated in murine models (Krimpenfort et al., 2007). The p15INK4B gene (CDKN2B) 
is located on human chromosome 9p21, within the same locus as two other cyclin-dependent 
kinases inhibitors (CDKIs) p16INK4A (CDKN2A) and p14ARF (encoded by an alternative reading 
frame of CDKN2A). Homozygous deletion of both CDKN2B and CDKN2A conferred a higher 
tumour predisposition and the development of a wider range of tumours compared with 
CDKN2A deficient mice, with the loss of p15INK4B specifically promoting the development of 
skin squamous and basal cell carcinomas and various soft tissue sarcomas (Krimpenfort et al., 
2007). Thus, defective cytostatic gene responses resulting from either epigenetic inactivation 
or allelic deletion can result in the abrogation of TGFβ tumour suppression (Massagué, 
2008a). 
 Cancer cells which successfully evade the tumour suppressive effects of TGFβ 
signalling can subsequently co-opt the pathway and switch TGFβ signalling to a tumour 
promoting state. One of the mechanisms by which this occurs is through the production of 
autocrine mitogenic factors which can promote cellular proliferation (Massagué, 2008b). In 
vitro studies have demonstrated that hyper-diploid GBM cells proliferate in response to TGFβ 
stimulation, which is mediated via the induction of platelet-derived growth factor subunit B 
(PDGFB, also referred to as PDGF-2) (Jennings and Pietenpol, 1998). However, the ability of 
TGFβ to induce the expression of PDGFB in glioblastoma cells is dependent on the methylation 
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state of the PDGFB gene promoter (Bruna et al., 2007). Therefore, epigenetic regulation of 
specific target genes can determine whether TGFβ exerts tumour suppressive or tumour 
promoting functions depending on cancer cell context (Kesari, Jackson-Grusby and Stiles, 
2007). 
 The ability to induce and sustain angiogenesis (i.e. the growth of nascent blood 
vessels) is considered to be a fundamental acquired capability of developing tumours and is 
thus referred to a ‘hallmark of cancer.’ The importance of angiogenesis in the context of 
tumorigenesis can be exemplified by the observation that tumours developing in transgenic 
mice are susceptible to angiogenic inhibitors (Hanahan and Weinberg, 2000). TGFβ has been 
to shown to stimulate angiogenesis through the induction of the angiogenic factors vascular 
endothelial growth factor (VEGF) and connective tissue growth factor (CTGF), and the TGFβ-
mediated induction of CTGF expression has been reported to contribute to breast cancer 
metastasis (Sánchez-Elsner et al., 2001; Kang et al., 2003). 
 
 
1.4.2 TGFβ-induced fibrosis 
Fibrosis is a pathophysiological condition predominantly characterised by the excessive and 
aberrant deposition of extracellular matrix (ECM) components including collagen, fibronectin, 
laminin and vitronectin as a consequence of chronic myofibroblast activation (Krieg, Abraham 
and Lafyatis, 2007; Gordon and Blobe, 2008). Under physiological conditions, synthesis and 
deposition of ECM components occurs as part of the normal wound healing response, 
however tissue fibrosis is generally considered to be a failure of this response to terminate 
(Leask and Abraham, 2004). The pathological accumulation of ECM components can occur in 
multiple different tissues where it can interfere with normal organ function and unabated can 
result in organ failure (Gordon and Blobe, 2008). 
 Research has demonstrated that TGFβ is a critical regulator of ECM production and it 
is therefore unsurprising that aberrant TGFβ signalling has been implicated in the 
pathogenesis of tissue fibrosis. TGFβ has been shown to directly upregulate the transcription 
of both collagen and fibronectin, principal components of the ECM (Ignotz and Massagué, 
1986). Moreover, the TGFβ-mediated transactivation of the COL1A2 gene (collagen alpha-2(I) 
chain, also referred to as type I collagen) has been shown to be dependent on SMAD3 in 
human dermal fibroblasts (Chen et al., 1999; Verrecchia, Chu and Mauviel, 2001). 
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Furthermore, the importance of SMAD3 in mediating TGFβ-induced fibrosis is exemplified by 
a number of observations including that SMAD3 deficient mice exposed to ionising radiation 
exhibit decreased radiation-induced fibrosis, with reduced myofibroblast recruitment, 
compared with wild type mice (Flanders et al., 2002). Additionally, SMAD3 deficient mice 
appear to be resistant to both bleomycin (Zhao et al., 2002) and TGFβ-induced pulmonary 
fibrosis (Bonniaud et al., 2004). In the bleomycin-induced pulmonary fibrosis model, SMAD3 
deficient mice exhibited fewer fibrotic lesions and reduced hydroxyproline content in the 
lungs following bleomycin treatment. Furthermore, SMAD3 deficiency also resulted in 
reduced mRNA expression of the major ECM components type I pro-collagen and fibronectin 
in response to bleomycin. Although bleomycin treatment increased the mRNA expression of 
TGFβ1, there was no observable difference between wild type and SMAD3 deficient mice 
(Zhao et al., 2002; Flanders, 2004). 
 In addition to directly regulating aspects of the wound healing response and hence 
the pathogenesis of tissue fibrosis, TGFβ can also indirectly promote these processes via the 
induction of profibrotic cytokines that can stimulate fibroblast proliferation. For example, 
connective tissue growth factor (CTGF) is a profibrotic cytokine, which following TGFβ-
mediated transcriptional upregulation, can function in either an autocrine or paracrine 
manner to induce fibroblast proliferation (Kim, Sheppard and Chapman, 2018). One of the 
proposed mechanisms by which CTGF exerts is profibrotic effects is by enhancing the ability 
of TGFβ to bind to its cognate cell surface receptor kinases at low TGFβ concentrations (Abreu 
et al., 2002; Leask and Abraham, 2004). 
 Furthermore, plasminogen activator inhibitor-1 (PAI-1, also referred to as serpin E1) 
is a well-defined transcriptional target of SMAD-dependent TGFβ signalling (Dennler et al., 
1998). PAI-1 is a member of the serine protease inhibitor (Serpin) superfamily and functions 
as the principal physiological inhibitor of the serine proteases tissue-type plasminogen 
activator (t-PA) and urokinase-type plasminogen activator (u-PA). Inhibition of t-PA and u-PA 
prevents the proteolytic cleavage of the zymogen plasminogen into its catalytically active 
form plasmin, itself a serine protease (Yasar Yildiz et al., 2014). Plasmin is a critical mediator 
of fibrinolysis (i.e. the degradation of fibrin), a physiological process that prevents the 
development of thrombosis. However, plasmin, along with plasmin-dependent matrix 
metalloproteinases (MMPs), have important functions in the degradation of ECM protein 
components. Under pathological conditions, high levels of PAI-1 ultimately results in the 
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inactivation of plasmin and plasmin-dependent MMPs, contributing to the excessive 
accumulation of collagen and other ECM proteins that are characteristic of tissue fibrosis. 
Consequently, excessive levels of PAI-1 have been implicated in the pathogenesis of tissue 
fibrosis in multiple different organ types including hepatic, pulmonary, cardiac and renal 
(Ghosh and Vaughan, 2012). 
 In addition to upregulation of ECM components and profibrotic cytokines, TGFβ has 
also been proposed to mediate tissue fibrosis pathogenesis via the transcriptional repression 
of proteins involved in ECM degradation (Verrecchia and Mauviel, 2007). For example, TGFβ-
activated SMAD3-SMAD4 complexes have been reported to abrogate the cytokine-induced 
expression of matrix metalloproteinase-1 (MMP-1) in dermal fibroblast cells (Yuan and Varga, 
2001). MMP-1, alternatively referred to as interstitial collagenase, is involved in regulating 
ECM and has been reported to proteolytically cleave type I, II and III collagen (Matrisian, 
1990). Thus, SMAD-mediated repression of MMP-1 gene transcription may be important for 
preventing excessive ECM degradation induced by inflammatory cytokines. However, 
aberrant TGFβ signalling may consequently promote the development of tissue fibrosis by 
downregulating enzymes required for ECM degradation. 
 
 
1.4.3 Pharmacological intervention of TGFβ-associated human pathologies 
Aberrant TGFβ signalling has been implicated in the pathogenesis of numerous human 
disorders including cancer, tissue fibrosis and heredity disorders (discussed in the preceding 
sections of this chapter) and as such has generated significant interest for drug development 
by pharmaceutical and biotechnology companies. However, as discussed previously, TGFβ 
signalling regulates a diverse array of cellular responses and therefore, the highly pleiotropic 
and context-dependent nature of pathway has provided a considerable challenge for 
pharmacological intervention (Connolly, Freimuth and Akhurst, 2012). Despite this, a number 
of potential therapeutics have been developed using a variety of different drug design 
strategies and have proceeded through preclinical assessment to clinical trials. These include 
anti-ligand antisense oligonucleotides, ligand-competitive peptides, monoclonal antibodies 
against ligands or receptors and small-molecule inhibitors (SMIs) targeting the serine-
threonine kinase activity of the TGFβ receptors (Akhurst and Hata, 2012). 
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 Antisense oligonucleotides (also referred to as antisense RNA; asRNA) have been 
under clinical development for a number of TGFβ-associated human pathologies. One 
example, Trabedersen (AP 12009), is an antisense oligodeoxynucleotide specific for human 
TGFβ2 mRNA that has progressed to clinical trials (Schlingensiepen et al., 2006, 2011). 
Overexpression of TGFβ2 has been reported in numerous malignant tumours including 
glioblastoma, pancreatic carcinoma and melanoma. Therefore, targeting mRNA translation 
using antisense oligonucleotides to mediate downregulation of TGFβ2 protein synthesis is a 
potential therapeutic approach. However, although trabedersen exhibited efficacy and safety 
in phase II clinical trials for treatment of high-grade glioblastoma (Bogdahn et al., 2011), there 
remains difficulties with systemic drug delivery of antisense oligonucleotides (Akhurst, 2017). 
 Along with antisense oligonucleotides, TGFβ ligands have also been targeted for 
clinical intervention using monoclonal antibodies. In therapeutic applications, monoclonal 
antibodies are advantageous due to their target specificity and extracellular mechanism of 
action, a discernible benefit when attempting to neutralise extracellular ligands. Although 
monoclonal antibodies are less convenient to administer intravenously, their inherent 
pharmacokinetic stability enables infrequent drug administration (Akhurst and Hata, 2012). 
A number of monoclonal antibodies have been developed that have proceeded through 
various stages of pre-clinical development however fresolimumab, a high-affinity fully 
humanised monoclonal antibody that neutralises the active forms of all three TGFβ isoforms, 
has progressed furthest in clinical development (Lonning, Mannick and McPherson, 2011; 
Rice et al., 2015). In a phase I clinical study, fresolimumab was determined to be well tolerated 
in a cohort of patients with advanced malignant melanoma or renal cell carcinoma, with no 
dose-limiting toxicity observed (Morris et al., 2014). Although this phase I study 
demonstrated preliminary evidence of anti-tumour efficacy that deserves further 
investigation, a subset of patients developed a variety of skin lesions including hyperkeratosis 
and reversible non-malignant keratoacanthomas (KA), with one patient also developing 
cutaneous squamous cell carcinoma (SCC) at the highest drug dosing level. Furthermore, a 
clinical study in patients with recurrent high-grade glioma demonstrated that fresolimumab 
was efficiently delivered to the tumour following intravenous administration (den Hollander 
et al., 2015). Although no clinical benefits were observed in this study, it was nonetheless 
important as it was the first demonstration of blood-brain barrier (BBB) penetration and 
tumour uptake of a radiolabelled therapeutic monoclonal antibody in glioma patients. 
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 A multitude of small-molecule inhibitors (SMIs) have been developed that specifically 
target the TGFβ type I receptor kinase and inhibit the phosphorylation and activation of 
SMAD2 and SMAD3. In general, these SMIs are ATP mimetics that competitively bind to the 
hydrophobic ATP-binding pocket within the kinase domain of the receptor (Yingling, 
Blanchard and Sawyer, 2004; Akhurst and Hata, 2012). A number of these type I receptor SMIs 
have been extensively utilised in TGFβ signalling research, including SB-505124, an inhibitor 
of the type I receptors ACVR1B (ALK4), TGFβR1 (ALK5) and ACVR1C (ALK7) (DaCosta Byfield et 
al., 2004) that has been employed throughout this thesis. 
Over the previous two decades, protein kinases have emerged as one of the most 
predominant drug targets in the field of oncology, with around 20 SMIs targeting protein 
kinases approved for clinical use (Cohen and Alessi, 2013). However, despite the prominent 
association between aberrant TGFβ signalling and cancer development and metastasis, only 
one SMI specifically targeting the TGFβ type I receptor, LY2157299 (developed by Eli Lilly and 
commercially referred to as galunisertib) has progressed to clinical trials to date. Although a 
number of trials have indicated a clinical benefit of galunisertib monotherapy in various 
different cancers (Akhurst, 2017), research has identified serious adverse effects associated 
with continuous administration of type I receptor SMIs. For example, pharmacological 
inhibition of TGFβ signalling using SB-525334, a pharmacological inhibitor of TGFβ type 
receptor, significantly decreased the incidence rate and tumour size of uterine leiomyomas 
(a tumour of mesenchymal origin) in Eker rats. However, in contrast, inhibition of TGFβ 
signalling by SB-525334 promoted the development of renal neoplastic lesions including 
adenomas and carcinomas in the same rat model (Laping et al., 2007). Furthermore, it was 
observed in preclinical toxicity studies that administration of two different pharmacological 
inhibitors of the TGFβ type I receptor resulted in serious cardiac toxicity through the induction 
of heart valve lesions (Anderton et al., 2011). Therefore, although pharmacological inhibition 
of TGFβ signalling appears to exhibit clinical benefit towards certain tumour types, it may also 
result in serious adverse effects and even promote the pathogenesis of other tumour types, 
which is perhaps unsurprising given the pleiotropic nature of TGFβ signalling and its ability to 
function as a tumour suppressor. 
Although numerous human pathologies have been associated with aberrant TGFβ 
signalling, targeting the pathway for therapeutic intervention presents significant challenges. 
Due to the diverse array of physiological functions regulated by TGFβ signalling, complete 
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inhibition of the pathway using pharmacological approaches such as antisense 
oligonucleotides or monoclonal antibodies that target TGFβ ligands or small-molecule 
inhibitors of TGFβ receptor kinase activity may result in severe adverse effects in patients. For 
example, as discussed in section 1.5.1, TGFβ functions as a tumour suppressor in normal, 
premalignant cells and therefore any perturbation of this protective function may result in 
considerable detrimental outcomes in patients. Therefore, a comprehensive understanding 
of TGFβ signalling pathway regulation in different cellular contexts will be invaluable to the 
development of more safe and effective therapeutic strategies. Moreover, identification of 
novel regulatory components of the TGFβ pathway may reveal potential pharmacological 
targets that would enable the development of therapeutic interventions that specifically 
target discrete aspects of the pathway and reduce the likelihood of adverse side effects 
occurring. 
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1.5 AIMS OF THE PHD THESIS 
The TGFβ signalling pathways perform critical functions during embryonic development and 
adult tissue homeostasis (section 1.4), and consequently malfunction of pathway 
components contributes the development of various human pathologies (section 1.5). The 
context-dependent nature of TGFβ signalling necessitates extensive pathway regulation and 
deciphering these ancillary regulatory components and contextual determinants may 
facilitate more targeted pharmacological approaches to treating TGFβ-related pathologies. 
 One of the most prevalent molecular mechanisms of regulating signal transduction 
pathways is through post-translational modification of signalling components. Extensive 
research has delineated multiple regulatory protein phosphorylation and ubiquitylation 
mechanisms throughout the TGFβ signalling pathway. Therefore, the inceptive broad aim of 
this doctoral project was to perform a pharmacological screen in an endogenous TGFβ-
dependent transcriptional luciferase reporter cell line, in order to identify potential novel 
regulators of the TGFβ signalling pathway (section 3.1). 
 The data obtained from the pharmacological screen identified a number of small-
molecule inhibitors which mediated a significant reduction in TGFβ-induced luciferase 
reporter activity. Due to time limitations and the available expertise and research tools within 
the MRC Protein Phosphorylation and Ubiquitylation Unit, I decided to focus on the most 
prominent hit that resulted from the screen, a small-molecule inhibitor of salt-inducible 
kinases (SIKs). Therefore, a subsequent aim of the project was to analyse the effect of multiple 
small-molecule kinase inhibitors that target SIKs on the TGFβ pathway and TGFβ-dependent 
transcriptional responses (sections 3.2 and 3.3 respectively). 
 In addition to employing the use of small-molecule kinase inhibitors, another aim of 
the project was to use alternative experimental methods by which to interrogate SIK function 
in order to further validate the initial observations (section 3.4). Manipulation of the 
upstream activating kinase of SIK isoforms, LKB1, or depletion of SIK protein levels provided 
further evidence for the role of SIKs in modulating TGFβ-dependent transcriptional responses. 
Moreover, genetic inactivation of SIK2 and SIK3 recapitulated the effect of SIK inhibition on 
TGFβ-mediated transcriptional induction of the target gene PAI-1, providing robust evidence 
for the role of SIKs in TGFβ signalling. 
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 Finally, the fourth aim of the thesis project was to investigate the effect of SIK catalytic 
inhibition in the context of the TGFβ-regulated physiological processes such as cellular 
proliferation and apoptosis (section 3.6) 
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2 MATERIALS AND METHODS 
 
2.1 MATERIALS 
 
2.1.1 Antibodies 
For Western immunoblotting analysis, all primary IgG antibodies were used at 1:1000 dilution 
unless otherwise stated. Anti-Phospho-SMAD3 (S423/S425) Rabbit polyclonal IgG (600-401-
919) was purchased from Rockland Inc. Anti-GFP Mouse monoclonal IgG (11814460001) was 
purchased from Roche. Anti-Phospho-SMAD2 (S465/S467) Rabbit polyclonal IgG (3101), anti-
SMAD2/3 Rabbit monoclonal IgG (8685), anti-c-Myc Rabbit monoclonal IgG (5605), anti-
p27KIP1 Rabbit monoclonal IgG (3688), anti-p21WAF1/CIP1 Rabbit monoclonal IgG (2947), anti-
GAPDH Rabbit monoclonal IgG (used at 1:5000 dilution) (2118), anti-SIK2 Rabbit IgG (6919) 
were all purchased from Cell Signalling Technology (CST). Anti-PAI-1 Rabbit polyclonal IgG 
(ab66705), anti-CTGF Rabbit polyclonal IgG (ab6992) and anti-CRTC3 Rabbit monoclonal IgG 
(ab91654) were purchased from Abcam. Anti-Phospho-CRTC3 (S370) Sheep polyclonal IgG 
(S253D, 3rd bleed) and anti-SIK3 Sheep polyclonal IgG (S373D, 3rd bleed) were generated by 
MRC PPU Reagents and Services. Species-specific horseradish peroxidase (HRP)-conjugated 
secondary antibodies were used at 1:2500-5000 dilution. Rabbit anti-Sheep polyclonal IgG 
(H+L) Secondary Antibody, HRP (31480) and Goat anti-Mouse polyclonal IgG (H+L) Secondary 
Antibody, HRP (31430) were purchased from Thermo Fisher Scientific. Goat anti-Rabbit 
polyclonal IgG (H+L), HRP-conjugated Secondary Antibody (7074) was purchased from CST. 
 
 
2.1.2 Cytokines 
Purified recombinant human TGFb1 was acquired from either R&D Systems or PeproTech and 
reconstituted in sterile 4 mM HCl containing 1 mg mL-1 bovine serum albumin (BSA) (Sigma-
Aldrich). Purified recombinant human BMP-2 was obtained from R&D Systems and 
reconstituted in sterile 4 mM HCl containing 0.1% (w/v) BSA. Aliquots of both cytokines were 
prepared at 1000-fold the required concentration and stored at -20°C. 
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2.1.3 Small-molecule pharmacological inhibitors 
The small-molecule inhibitors used in this thesis are detailed in the table below. All the 
inhibitors were reconstituted at 10 mM in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and 
aliquots stored at -20°C. The inhibitors were used at the concentrations and durations 
indicated in the respective figure legends. For all experiments involving the use of inhibitors, 
an equivalent volume of DMSO was used as a control. 
 
Small-molecule inhibitor Company Product number 
Bosutinib Cayman Chemical 12030 
Dasatinib Cayman Chemical 11498 
HG-9-91-01 MRC-PPU Reagents and Services - 
LDN193189 MRC-PPU Reagents and Services - 
MRT199665 MRC-PPU Reagents and Services - 
MRT67307 Sigma-Aldrich SML0702 
SB-505124 Sigma-Aldrich S4696 
 
Table 1. Details of the small-molecule inhibitors employed in this thesis including the 
respective company and product number information 
 
 
2.1.4 RT-qPCR primers 
All the oligonucleotide PCR primers utilised in this thesis were purchased from Invitrogen and 
resuspended at 100 mM in Nuclease-free H2O and subsequently stored at -20°C. The primer 
sequences were either designed using the National Centre for Biotechnology Information 
(NCBI) Primer-BLAST online software tool (Ye et al., 2012) or obtained from peer-reviewed 
published literature. 
 
Target gene Oligonucleotide sequence (5’ – 3’) 
CTGF (forward) GGA GAT TTT GGG AGT ACG G 
CTGF (reverse) TAC CAA TGA CAA CGC CTC CT 
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GAPDH (forward) TGC ACC ACC AAC TGC TTA GC 
GAPDH (reverse) GGC ATG GAC TGT GGT CAT GAG 
PAI-1 (forward) AGC TCC TTG TAC AGA TGC CG 
PAI-1 (reverse) ACA ACA GGA GGA GAA ACC CA 
ID-1 (forward) AGG CTG GAT GCA GTT AAG GG 
ID-1 (reverse) GAC GAT CGC ATC TTG TGT CG 
SMAD7 (forward) CTG TGC AAA GTG TTC AGG TG 
SMAD7 (reverse) TTG AGA AAA TCC ATC GGG TA 
murine 18S rRNA (forward) GTA ACC CGT TGA ACC CCA TT 
murine 18S rRNA (reverse) CCA TCC AAT CGG TAG TAG CG 
 
Table 2. Details of the oligonucleotide primers and their associated sequence used for RT-
qPCR experiments in this thesis project 
 
 
2.1.5 Small interfering RNA (siRNA) oligonucleotides 
All the siRNA oligonucleotides employed in this thesis were purchased from Dharmacon and 
are detailed along with their sequences in the table below. All siRNA oligonucleotides were 
resuspended at 20 µM in RNase-free 1x siRNA Buffer (Dharmacon) according to the 
manufacturer’s protocol and subsequently stored at -20°C. 
 
siRNA Oligonucleotide sequence Product number 
ON-TARGETplus SMARTpool Human SIK1 ACGAUUAGAUUCAAGCAAU J-003959-14 
ON-TARGETplus SMARTpool Human SIK1 GGAGUACUGUCACGACCAU J-003959-15 
ON-TARGETplus SMARTpool Human SIK1 GAAAAUCUAUCGUGAGGUU J-003959-16 
ON-TARGETplus SMARTpool Human SIK1 GCUCGGACCUCAGUGGUUU J-003959-17 
ON-TARGETplus SMARTpool Human SIK2 GAAAAUCUACCGAGAAGUA J-004778-11 
ON-TARGETplus SMARTpool Human SIK2 AAUCAUGGCCGGUUAAAUG J-004778-12 
ON-TARGETplus SMARTpool Human SIK2 CAACAGGUCUCCAGUGAGC J-004778-13 
ON-TARGETplus SMARTpool Human SIK2 GAAAGCGUCUCCACUCUCC J-004778-14 
ON-TARGETplus SMARTpool Human SIK3 GAACAGCGACGAUGCUUAU J-004779-08 
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ON-TARGETplus SMARTpool Human SIK3 AUAGGGAACUGCAUGGAUA J-004779-09 
ON-TARGETplus SMARTpool Human SIK3 GACAGUAAGAGUUCAAGUA J-004779-10 
ON-TARGETplus SMARTpool Human SIK3 CCACGCACCUCGUCACCAA J-004779-11 
ON-TARGETplus Control siRNA UGGUUUACAUGUCGACUAAUU - 
 
Table 3. Details of the siRNA oligonucleotides and the associated sequence information 
used during this thesis project 
 
 
2.1.6 Recombinant proteins 
Recombinant proteins with either N-terminal GST or N-terminal maltose-binding protein 
(MBP) affinity tags were expressed and affinity purified by the protein production team within 
MRC PPU Reagents and Services at the University of Dundee. All the recombinant proteins 
used in this thesis are detailed in section 2.2.21 and are commercially available to researchers 
via the website (https://mrcppureagents.dundee.ac.uk). 
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2.2 METHODS 
 
2.2.1 Mammalian cell culture 
A-172 human glioblastoma, A549 human pulmonary adenocarcinoma, U2OS human 
osteosarcoma, HACAT human immortalised keratinocyte, HEK-293 human embryonic kidney 
and HeLa human cervical adenocarcinoma cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone), 2 
mM L-glutamine (Gibco), 100 units mL-1 Penicillin (Gibco) and 100 µg mL-1 Streptomycin 
(Gibco) (hereafter referred to as D10F media). NMuMG murine mammary epithelial cells 
were cultured in D10F media supplemented with 10 µg mL-1 insulin (from bovine pancreas) 
(Sigma-Aldrich). Primary and immortalised mouse embryonic fibroblast (MEF) cells were 
cultured in DMEM supplemented with 20% (v/v) FBS, 2 mM L-glutamine, 100 units mL-1 
Penicillin (Gibco), 100 µg mL-1 Streptomycin (Gibco), 1x Minimum Essential Medium (MEM) 
Non-Essential Amino Acids (NEAA) (Gibco) and 1 mM Sodium Pyruvate (Gibco). All cell lines 
were maintained at 37°C in a humidified atmosphere with 5% (v/v) CO2 levels. 
 For subculture of cell lines, cells were washed once with sterile 1x Dulbecco’s 
Phosphate-Buffered Saline (DPBS) (Gibco) and then incubated at 37°C with approximately 2 
mL 1x 0.05% (w/v) Trypsin-EDTA (Gibco) to facilitate cell dissociation (duration dependent on 
the adherence of the cell line). Once dissociated, cells were subsequently resuspended in the 
appropriate culture media (detailed previously) to a final volume of 10 mL per 10 cm cell 
culture plate. Immediately prior to use, culture media and trypsin solution were pre-
incubated to 37°C. All cell culture procedures were conducted in a laminar flow cabinet using 
aseptic technique and adhering to biological safety (category 2) regulations. 
 
 
2.2.2 Cryopreservation of mammalian cell lines 
Sub-confluent cells were washed once with 1x DPBS, dissociated from the culture plate using 
1x 0.05% (w/v) Trypsin-EDTA (Gibco) and subsequently resuspended in culture media. The 
cell concentration and viability of the suspension was determined prior to centrifugation at 
300 x g for 2 minutes. The culture media was subsequently aspirated, and the cell pellet 
resuspended in cryopreservation media (50% (v/v) culture media, 40% (v/v) FBS and 10% (v/v) 
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DMSO) at a concentration of approximately 1.0-2.0 x 106 cells mL-1 and equal volumes 
dispensed into 2.0 mL cryogenic vials. Cryogenic vials were then stored at -80°C for 24 hours 
in a cell-freezing container (Mr. Frosty Freezing Container; Thermo Fisher Scientific) to 
provide a controlled rate of freezing. The cryogenic vials were subsequently transferred to 
liquid nitrogen for long-term storage. 
In order to thaw cells, cryogenic vials were incubated in a water bath at 37°C for 
approximately 2 minutes and cell suspension transferred into 10 mL of appropriate culture 
media. The cell suspension was centrifuged at 300 x g for 2 minutes and the resulting cell 
pellet resuspended in 10 mL culture media and subsequently transferred into a 10 cm cell 
culture plate. 
 
 
2.2.3 Transformation of primary MEFs 
Primary MEFs were transformed via retroviral-mediated transduction of the oncoprotein 
Simian virus 40 (SV-40) large T antigen. In order to produce the retroviral transduction media, 
HEK-293 FT cells were transfected with the following cDNA plasmids (amount/volume 
specified per 10 cm cell culture plate): SV-40 large T antigen (6.0 µg), Gag/Pol (3.8 µg) and 
vesicular stomatitis virus glycoprotein G (VSV-G) (2.2 µg) using Lipofectamine 2000 
Transfection Reagent (Invitrogen) (36 µL). Transfection solution was prepared in 10 mL Opti-
MEM Reduced Serum Media (Gibco) and incubated on cells for 6 hours at 37°C. Transfection 
media was subsequently aspirated and replaced with D10F media and incubated overnight 
(approximately 16 hours). Culture media was subsequently replaced with new D10F media 
and incubated for a further 24 hours. Viral transduction media was collected, filtered through 
0.45 µm cellulose acetate membrane syringe filter and either used immediately or 
cryopreserved in liquid nitrogen prior to storage at -80°C. Polybrene (hexadimethrine 
bromide) (10 µg mL-1) was added to the transduction media in order to enhance the retroviral 
transduction efficiency (Davis, Morgan and Yarmush, 2002) prior to incubation on the 
required cell line for 24 hours. Following transduction, cells were subjected to antibiotic 
selection using the appropriate culture media (detailed in section 2.2.1) supplemented with 
200 µg mL-1 Hygromycin B Gold (InvivoGen). 
 
 89 
 
2.2.4 Pharmacological screen 
U2OS 2G transcriptional reporter cells (Rojas-Fernandez et al., 2015) were seeded in 96-well 
cell culture plates (5.0 x 103 cells per well). Cells were subsequently incubated with a panel of 
88 small-molecule inhibitors, in the presence or absence of TGFβ1 stimulation (5 ng mL-1) for 
24 hours prior to lysis for subsequent luciferase assay (as detailed in section 2.2.14). The 
inhibitor screen was performed in triplicate and for each 96-well culture plate, the 
luminescence values were normalised to internal DMSO treated plate controls. Luminescence 
values from cells incubated with the inhibitors in the presence of TGFβ1 were then normalised 
to the values obtained from cells incubated with the inhibitors alone to generate mean 
relative luciferase values for each condition. All the inhibitors in the panel were used at 1 µM 
concentration. 
 
 
2.2.5 Treatment of cells with cytokines and small-molecule inhibitors 
Prior to simulation with cytokines, cells were cultured in serum-free culture media for 
approximately 16 hours at 37°C in order to reduce basal cell signalling. In the case of NMuMG 
cells, cells were cultured in low-serum (1% (v/v) FBS) culture media (detailed in section 2.2.1) 
prior to cytokine stimulation. Cells were stimulated with 5 ng mL-1 TGFβ1 or 6.25 ng mL-1 BMP-
2 (unless otherwise stated) for the durations indicated in the respective figure legends. For 
all experiments involving cytokine stimulations, non-stimulated cells were included as 
negative controls. 
 The small-molecule inhibitors utilised in this thesis are detailed in section 2.1.4 and 
used at the concentrations and durations indicated in the respective figure legends. For all 
experiments involving the use of inhibitors, cells were treated with an equivalent volume of 
DMSO as a negative control. 
 
 
2.2.6 Transfection of cells with siRNA 
The siRNA oligonucleotides employed in this thesis are detailed in section 2.1.6. For all RNAi 
experiments, cells were seeded in 6-well cell culture plates (1.0 x 105 cells per well) unless 
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otherwise stated. Cells were transfected with 20 nM of siRNA oligonucleotide targeting the 
protein of interest or 20 nM non-targeting siRNA oligonucleotide as a negative control. 
Transfection solutions were prepared using 1 mL Opti-MEM Reduced Serum Media (Gibco) 
containing TransFectin Lipid Reagent (Bio-Rad) or Lipofectamine RNAiMAX Transfection 
Reagent (Invitrogen) (4 µL per well) and the required volume of siRNA oligonucleotide. The 
transfection solution was subsequently vortexed for approximately 10 seconds and then 
incubated at ambient temperature for 15-20 minutes. For the purpose of siRNA transfections, 
the culture media on cells was exchanged for Opti-MEM Reduced Serum Media and 200 µL 
of the relevant transfection solution was added drop-wise per well. Approximately 6-8 hours 
following transfection, the transfection media was exchanged for the appropriate normal 
culture media and cells were stimulated with the required cytokines for the durations 
indicated in figure legends. Cells were lysed 72 hours post-transfection unless otherwise 
stated in the respective experiment figure legend. 
 
 
2.2.7 Mammalian cell lysis 
Unless otherwise stated, the lysis of mammalian cell cultures for protein extraction occurred 
as follows. The culture media was aspirated and cells were washed twice with cold 1x DPBS 
and incubated with lysis buffer (50 mM Tris/HCl pH 7.5, 270 mM sucrose, 150 mM sodium 
chloride, 1 mM EDTA pH 8.0, 1 mM EGTA pH 8.0, 1 mM sodium orthovanadate, 10 mM sodium 
b-glycerophosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1% (v/v) Nonidet 
P-40 (NP-40)) supplemented with Complete, EDTA-free Protease Inhibitors (Roche) (one 
tablet per 25 mL) for approximately 5 minutes on ice. The volume of lysis buffer used was 
dependent on the cell line, cell confluency and the size of the cell culture plate. Cell lysates 
were transferred to 1.5 mL microcentrifuge tubes and centrifuged at 16,000 x g for 10 minutes 
at 4°C and either processed immediately or cryopreserved in liquid nitrogen prior to storage 
at -80°C. The protein concentrations of the cell lysate samples were determined using Pierce 
Coomassie (Bradford) Protein Assay Kit (Thermo Fisher Scientific) (further detailed in 
subsequent section 2.2.9). In order to denature and reduce the protein, cell lysate samples 
were subsequently diluted using 4x NuPAGE LDS (lithium dodecyl sulfate) sample buffer 
(Invitrogen) supplemented with 8% (v/v) 2-Mercaptoethanol (2-ME) (Sigma-Aldrich) and the 
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sample concentrations were equalised. Lysate samples were stored at either -20°C or -80°C 
and incubated at 95°C for 5 minutes immediately prior to SDS-PAGE analysis (section 2.2.12). 
 For experiments analysing apoptosis, the cell lysis protocol was amended to ensure 
that both adherent and non-adherent (i.e. apoptotic) cells were collected and occurred as 
follows. The culture media and PBS wash (both containing detached cells) were collected 
along with the trypsinised cells into 50 mL conical centrifuge tubes and centrifuged at 300 x g 
for 2 minutes. The supernatant was aspirated, and cell pellet resuspended in cold 1x DPBS 
followed by another centrifugation step as before. The cell pellet was subsequently lysed 
using an appropriate volume of lysis buffer and the samples prepared as described previously. 
 
 
2.2.8 Protein concentration measurement 
The protein concentration of cell lysate samples was determined using the Bradford assay 
method (Bradford, 1976) using the Pierce Coomassie (Bradford) Protein Assay Kit (Thermo 
Fisher Scientific). The Bradford assay is a colorimetric protein assay that involves the binding 
of Coomassie Brilliant Blue G-250 dye to proteins under acidic conditions, which induces a 
shift in the absorbance maximum of the dye from 465 nm to 595 nm. In order to quantify the 
protein concentration of lysate samples, a standard curve was prepared using a dilution-series 
of bovine serum albumin (BSA) protein standard, with a concentration range from 0.0625 mg 
mL-1 to 1.0 mg mL-1. To ensure the absorbance values of the lysate samples were within the 
range of the protein standard curve, the lysate samples were diluted in ultrapure H2O (usually 
10-fold dilution, however dependent on cell type and confluency) prior to performing the 
assay. The protein standards and diluted lysate samples were added to a 96-well microplate 
in triplicate (5 µL per well) along with the Bradford reagent (200 µL per well, equilibrated to 
ambient temperature prior to use) and incubated for approximately 5 minutes at ambient 
temperature. The absorbance values of all the sample were measured at 595 nm using a 
VersaMax microplate spectrophotometer and SoftMax Pro (version 4.8) software (Molecular 
Devices) and the protein concentrations of the lysate samples determined by reference to the 
protein standard curve. Baseline absorbance values were obtained using a blank solution (5 
µL ultrapure H2O, 200 µL Bradford reagent per well). 
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2.2.9 Endogenous CRTC3 immunoprecipitation (IP) 
Cells were lysed for protein extraction and the protein concentration of lysate samples 
determined as detailed previously (section 2.2.7 and 2.2.8 respectively). 2 µg anti-CRTC3 
polyclonal Sheep IgG (MRC PPU Reagents and Services, S277D, 2nd bleed) was added to 750 
µg cell lysate and incubated for 1 hour at 4°C on a bench-top rotating platform. Lysate 
samples were subsequently added to 20 µL Protein G Agarose resin suspension (pre-washed 
three times with lysis buffer) and incubated for 1 hour at 4°C on a bench-top rotating 
platform. Lysate samples were subsequently centrifuged at 800 x g for 1 minute at 4°C and 
the resin washed three times with lysis buffer to remove unbound proteins. The agarose resin 
was subsequently resuspended in 60 µL 1x NuPAGE LDS sample buffer containing 2% (v/v) 2-
mercaptoethanol and incubated at 95°C for 5 minutes to elute the immunoprecipitated 
proteins. Samples were then transferred to Corning Costar Spin-X centrifuge tube filters (0.22 
µm cellulose acetate membrane) (Sigma-Aldrich) and centrifuged at 16,000 x g for 2 minutes 
to remove the agarose resin. The IP samples, along with total cell lysate and flow-through 
samples if required, were subsequently stored at -20°C prior to SDS-PAGE and Western 
immunoblot analysis (section 2.2.12 and 2.2.13 respectively). 
 
 
2.2.10 Covalent conjugation of antibodies to protein G agarose 
Protein G agarose resin and the required antibody (2 µg Ab per 10 µL agarose resin 
suspension) were incubated for 2 hours at 4°C with continuous rotation. The antibody-resin 
conjugate was subsequently washed three times with 100 mM sodium borate (pH 9.3). The 
antibody-resin was then resuspended in 100 mM sodium borate (pH 9.3) supplemented with 
20 mM dimethyl pimelimidate (DMP) (5.2 mg mL-1) and incubated for 30 minutes at room 
temperature on a bench-top rotating platform (this incubation step was performed twice). 
Following the second incubation with DMP, the antibody-resin was washed four times with 
50 mM glycine (pH 2.5) in order to remove any non-covalently conjugated antibody. The 
antibody-resin was subsequently washed twice with 200 mM Tris/HCl (pH 8.0) and then 
incubated in 200 mM Tris/HCl (pH 8.0) overnight at 4°C on a bench-top rotating platform. 
Following this, the covalently conjugated antibody-resin was resuspended in phosphate-
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buffered saline (PBS) containing 0.01% (v/v) sodium azide (NaN3) and subsequently stored at 
4°C. 
 
 
2.2.11 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Two different SDS-PAGE systems were employed in this thesis; self-cast SDS polyacrylamide 
gels using the ATTO Dual Mini Slab gel electrophoresis system (ATTO Corporation) or NuPAGE 
4-12% Bis-Tris precast polyacrylamide gels (Invitrogen) using either XCell SureLock Mini-Cell 
or XCell SureLock Midi-Cell systems (Invitrogen). The protein concentrations of the cell lysate 
samples were equalised using 1x NuPAGE LDS sample buffer containing 2% (v/v) 2-ME, 
incubated at 95°C for 5 minutes and briefly centrifuged prior to sample loading. Self-cast SDS 
polyacrylamide gels were prepared with an acrylamide concentration of either 10% or 12% 
and contained the following constituents; 375 mM Tris-HCl (pH 8.6), required volume of 
acrylamide/bis-acrylamide (29:1 molar ratio) solution (Sigma-Aldrich) and 0.1% (w/v) SDS. 
The polymerisation of acrylamide was catalysed via the addition of 0.075% (w/v) ammonium 
persulfate (APS) and 0.1% (v/v) tetramethylethylenediamine (TEMED). A small volume 
(approximately 600-800 µL) of 100% propan-2-ol was added to eliminate air bubbles and 
ensure the resolving gel formed a level surface. The resolving gel was incubated for at least 
20 minutes at RT to ensure sufficient polymerisation and the propan-2-ol removed prior to 
the addition of the stacking gel. The stacking gel was prepared containing 125 mM Tris-HCl 
(pH 6.8), 0.1% (w/v) SDS, 4% (w/v) acrylamide, 0.075% (w/v) APS and 0.1% (v/v) TEMED and 
was added directly onto the polymerised resolving gel. A polypropylene sample comb (1 mm, 
12-well) was immediately inserted and the gel allowed to polymerise for approximately 30 
minutes at RT. Following polymerisation of the stacking gel, the sample comb was removed, 
and the sample wells rinsed with ultrapure H2O. The SDS polyacrylamide gels were inserted 
into the ATTO Dual Mini Slab electrophoresis chamber, which was subsequently filled with 1x 
SDS-PAGE electrophoresis running buffer containing 25 mM Tris-HCl (pH 8.3), 192 mM glycine 
and 0.1% (v/v) SDS. For NuPAGE 4-12% Bis-Tris precast polyacrylamide gels, 1x MOPS (3-
Morpholinopropane-1-sulfonic acid) SDS running buffer (Formedium) (final concentration 50 
mM MOPS, 50 mM Tris Base, 3.47 mM SDS and 1 mM EDTA) was used. Reduced cell lysate 
samples (10-20 µg total protein unless stated otherwise in the respective figure legends) were 
 94 
then loaded into the sample wells using sterile gel-loading micropipette tips. Precision Plus 
Protein All Blue Prestained Protein Standards (Bio-Rad), with molecular weights of 250, 150, 
100, 75, 50, 37, 25, 20, 15 and 10 kDa, were combined with 1x NuPAGE LDS sample buffer 
containing 2% (v/v) 2-ME and used for molecular weight estimation. For the ATTO SDS-PAGE 
system, electrophoresis was conducted at constant voltage of 160 V for approximately 90 
minutes. For the NuPAGE Bis-Tris SDS-PAGE system, electrophoresis was conducted at 
constant voltage of 180 V for approximately 60 minutes. 
 
 
2.2.12 Western immunoblotting 
Immediately following SDS-PAGE of cell lysate and IP samples, the resolved proteins were 
electrophoretically transferred onto Amersham Protran 0.45 µm nitrocellulose Western 
blotting membranes (GE Healthcare Life Sciences). Protein transfer was performed using 
either Mini Trans-Blot Cell (Bio-Rad) or Trans-Blot Cell (Bio-Rad) electroblotting system at 80 
V (constant voltage) for 80 minutes at 4°C using 1x transfer buffer containing 25 mM Tris-HCl 
(pH 8.3), 192 mM glycine and 20% (v/v) methanol. The efficiency of protein transfer was 
assessed by reversible staining of the nitrocellulose membranes with Ponceau S (0.1% (w/v) 
in 5% acetic acid) solution (Sigma-Aldrich). In order to remove the Ponceau S staining prior to 
blocking, membranes were washed with Tris-buffered saline (TBS) (50 mM Tris-HCl pH 7.5, 
150 mM NaCl) containing 0.1% (v/v) TWEEN 20 (Sigma-Aldrich), hereafter referred to as TBS-
T (0.1%). Membranes were blocked using 5% (w/v) non-fat milk in TBS-T (0.1%) for 1 hour at 
RT on a bench-top platform rocker. The membranes were subsequently incubated with the 
appropriate primary antibodies (detailed in section 2.1.1) diluted in either 5% (w/v) milk-TBS-
T (0.1%) or 4% (w/v) bovine serum albumin (BSA)-TBS-T (0.1%) overnight (approximately 16 
hours) at 4°C with continuous agitation. Following this, membranes were washed three times 
for 5 minutes using TBS-T (0.1%) prior to incubation with the relevant species-specific 
horseradish peroxidase (HRP)-conjugated secondary antibodies. Membranes were incubated 
with the HRP-conjugated secondary antibodies (detailed in section 2.1.1) diluted 1:2500-5000 
in 5% (w/v) milk-TBS-T (0.1%) for 1 hour at RT on a bench-top platform rocker. The 
membranes were subsequently washed three times for 5 minutes using TBS-T (0.1%) prior to 
enhanced chemiluminescence detection. Membranes were incubated with Amersham 
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Enhanced Chemiluminescent (ECL) Western Blotting Detection Reagents (GE Healthcare Life 
Sciences) for approximately 2-4 minutes according to the manufacturer’s instructions and 
subsequently exposed onto Medical X-Ray Film (Konica Minolta) or Amersham Hyperfilm ECL 
(GE Healthcare Life Sciences) under safelight conditions. The films were developed using an 
SRX-101A automated medical film processor (Konica Minolta). 
 
 
2.2.13 Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
The oligonucleotide PCR primers employed in this thesis are detailed in section 2.1.5. For all 
RT-qPCR experiments, cells were seeded in 6-well cell culture plates (1.0 x 105 cells per well) 
and cultured in serum-free or low-serum culture media prior to incubation with the required 
cytokines and/or inhibitors for the durations indicated in the respective figure legends. Total 
RNA was isolated from the cells using the RNeasy Micro Kit (Qiagen) according to the 
manufacturer’s protocol and the RNA concentration and quality subsequently determined 
using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). Complementary DNA 
(cDNA) was synthesised from 0.5-1.0 µg of isolated RNA using iScript cDNA Synthesis Kit (Bio-
Rad) according to the manufacturer’s protocol. All RT-qPCR reactions were conducted in 
triplicate and included 50% (v/v) SsoFast EvaGreen Supermix (Bio-Rad), 0.5 µM forward 
primer, 0.5 µM reverse primer and the required volume of cDNA. RT-qPCR experiments were 
performed using CFX96 or CFX384 Real-Time PCR Detection Systems (Bio-Rad). The Ct (cycle 
threshold) values for each gene of interest were normalised to the arithmetic mean Ct value 
of the reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal 
RNA (rRNA) using Microsoft Excel software. The 2-DDCt relative quantification method was then 
used to analyse the relative changes in gene expression between control and treatment 
conditions (Livak and Schmittgen, 2001). GraphPad Prism software (version 8.0) was used to 
generate graphs and perform statistical analysis. 
 
 
2.2.14 Luciferase transcriptional reporter assay 
U2OS 2G transcriptional reporter cells (Rojas-Fernandez et al., 2015) were seeded in 6-well 
cell culture plates (1.0 x 105 cells per well) and incubated with the required small-molecule 
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inhibitors/cytokines at the indicated concentrations and duration. Cells were subsequently 
washed twice with 1x DPBS at ambient temperature and lysed using 1x Cell Culture Lysis 
Reagent (CCLR; Promega) (280 µL per well, equilibrated to ambient temperature prior to use). 
Cell culture plates were incubated for approximately 5 minutes on bench-top platform rocker 
to ensure efficient cell lysis. Cell lysates were transferred to 1.5 mL microcentrifuge tubes and 
kept on ice. Lysate samples were vortexed for approximately 10 seconds, centrifuged at 
12,000 x g for 2 minutes at 4°C and 200 µL of supernatant transferred to new 1.5 mL 
microcentrifuge tubes. Lysate samples were subsequently transferred to 96-well white flat-
bottom cell culture microplate (Greiner Bio-One) (20 µL per well in triplicate). An equivalent 
volume of 2x Luciferase Assay Buffer (50 mM Tris/Phosphate pH 7.8, 16 mM MgCl2, 2 mM 
dithiothreitol (DTT), 1 mM adenosine triphosphate (ATP), 30% (w/v) glycerol, 1% (w/v) bovine 
serum albumin (BSA), 250 µM D-Luciferin, 8 µM sodium pyrophosphate) was subsequently 
added to each well and the microplate incubated for approximately 1 minute on a bench-top 
vibrating platform. Luminescence values were obtained using an EnVision 2104 Multimode 
Microplate Reader (PerkinElmer). The protein concentrations of each lysate sample were 
determined using Pierce Coomassie (Bradford) Protein Assay Kit (Thermo Fisher Scientific) as 
detailed in section 2.2.9 and used to normalise luminescence values. 
 
 
2.2.15 Cellular fractionation (cytoplasmic/nuclear) 
Extraction of separate cytoplasmic and nuclear protein fractions from cultured mammalian 
cells was performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. The supplied lysis buffers (CER I 
and NER) were supplemented with 1x Complete, EDTA-free Protease Inhibitors (Roche) 
immediately prior to use. Subcellular fractions were reduced using NuPAGE 4x LDS sample 
buffer containing 8% (v/v) 2-mercaptoethanol and incubated at 95°C for 5 minutes prior to 
SDS-PAGE. Fractions were resolved by SDS-PAGE and analysed via Western immunoblotting 
as detailed previously (sections 2.2.12 and 2.2.13 respectively). 
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2.2.16 Annexin V staining assay 
NMuMG murine mammary epithelial cells were incubated with SB-505124 (1 µM), 
MRT199665 (1 µM) or an equivalent volume of DMSO, in the presence or absence of 
recombinant human TGFβ1 (5 ng mL-1) for 12 hours. Following the cytokine/inhibitor 
treatment, both adherent and non-adherent (i.e. apoptotic) cells were collected into 50 mL 
conical centrifuge tubes, pelleted by centrifugation (300 x g, 2 minutes) and washed once 
using cold 1x DPBS. Cells were subsequently centrifuged (300 x g, 2 minutes), the cell pellets 
were resuspended in Annexin Binding Buffer, ABB (10 mM HEPES, 140 mM NaCl, 2.5 mM 
CaCl2, pH 7.4) and transferred to 1.5 mL microcentrifuge tubes. The required cell suspension 
samples were then incubated with Annexin V, Alexa Fluor 488 conjugate (Invitrogen; A13201) 
for 15 minutes at RT and protected from light. The appropriate samples were subsequently 
incubated with 5 µg mL-1 DAPI (4’,6-diamidino-2-phenylindole) (Invitrogen). Samples were 
immediately analysed using a BD LSRFortessa Cell Analyser (BD Biosciences) and BD FACSDiva 
acquisition software (BD Biosciences). Annexin V Alexa Fluor 488 fluorescence was detected 
by excitation at 488 nm and emission at 530 ± 30 nm, and DAPI fluorescence was detected by 
excitation at 355 nm and emission at 450 ± 50 nm. Single cells were identified on the basis of 
forward light scatter (FSC) and side light scatter (SSC), and subsequently evaluated for 
Annexin V Alexa Fluor 488 and DAPI fluorescence. Data analysis was performed using FlowJo 
Single Cell Analysis Software (BD Biosciences). Generation of graphs and statistical analysis 
was performed using GraphPad Prism (version 8.0) software. 
 
 
2.2.17 Crystal violet cellular viability assay 
Protocol adapted from (Feoktistova, Geserick and Leverkus, 2016). NMuMG murine 
mammary epithelial cells were seeded in 96-well cell culture plates (1.0 x 104 cells per well) 
and incubated for 24 hours at 37°C to enable adherence of cells to culture plates. The 
inclusion of wells containing culture medium without cells were used as negative control 
wells. Following initial 24-hour incubation, culture media was aspirated and replaced with 
reduced serum (1% v/v FBS) DMEM (200 µL per well) supplemented with 10 µg mL-1 bovine 
insulin (Sigma-Aldrich) containing the required inhibitors or equivalent volume DMSO, with 
or without recombinant human TGFβ1 (5 ng mL-1) and incubated for a further 24 hours. Cells 
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were subsequently fixed using 10% (v/v) methanol/10% (v/v) acetic acid (100 µL per well) for 
5 minutes at ambient temperature and subsequently washed with 1x PBS. Fixed cells were 
stained using 0.5% (w/v) crystal violet staining solution (0.5 g crystal violet powder (Sigma-
Aldrich), 80 mL distilled H2O and 20 mL methanol) (50 µL per well) for 20 minutes at ambient 
temperature on a bench-top platform rocker. Plates were subsequently washed carefully 
using tap water, inverted on filter paper to remove residual liquid and allowed to air-dry 
overnight. Following this, 200 µL methanol was added per well and incubated for 20 minutes 
at ambient temperature on a bench-top platform rocker. The absorbance value of each well 
was measured at 570 nm (OD570) using a 96-well microplate spectrophotometer. The mean 
OD570 value of negative control wells (i.e. wells not containing cells) was subtracted from the 
values obtained from each well on the culture plate and the percentage of viable (i.e. 
attached) cells for each condition determined relative to the mean average OD570 value of 
non-stimulated (DMSO control) cells. 
 
 
2.2.18 Cellular proliferation assay 
The CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit (Promega) was used to 
determine the relative number of viable HaCaT human immortalised keratinocyte cells in 
culture under certain conditions. HaCaT cells were seeded in 96-well cell culture plates (1.0 x 
103 cells per well). Culture media (100 µL per well, refer to section 2.2.1), with or without 
recombinant human TGFβ1 (5 ng mL-1), was exchanged every 24 hours for a duration of 7 days. 
Every 24 hours, one set of replicate wells were incubated with the CellTiter 96 AQueous One 
Solution Reagent (20 µL per well) for 2 hours at 37°C. The amount of soluble formazan 
product formed via the cellular reduction of the MTS tetrazolium compound is directly 
proportional to the number of metabolically active (i.e. viable) cells in culture. The absorbance 
of each well was measured at 490 nm (OD490) using a 96-well microplate spectrophotometer 
and the absorbance values for each well were normalised to the OD490 values from wells 
containing culture media but without cells. 
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2.2.19 Removal of GST affinity tag from purified recombinant proteins 
The glutathione S-transferase (GST) affinity tag of purified recombinant proteins was 
removed via proteolytic cleavage using PreScission Protease. PreScission Protease is a fusion 
protein of human rhinovirus (HRV) 3C protease and GST (Walker et al., 1994) which 
specifically cleaves between the Gln and Gly residues of the amino acid recognition sequence 
Leu-Glu-Val-Leu-Phe-Gln/Gly-Pro (LEVLFQ/GP) (Cordingley et al., 1990). The PreScission 
Protease was added to the GST-tagged recombinant protein at a ratio of 1:100 by weight and 
incubated overnight (approximately 16 hours) at 4°C with continuous rotation. Efficient 
cleavage of the GST tag from the recombinant protein was analysed via SDS-PAGE and 
subsequent Coomassie protein staining. 
 
 
2.2.20 In vitro protein kinase assay 
21 µL reaction solutions were prepared containing 200 ng of protein kinase and 2 µg of 
substrate protein in 1x kinase assay buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 10 mM 
magnesium acetate, 0.1% (v/v) 2-mercaptoethanol and 0.1 mM [g32P]-ATP). Reactions were 
conducted at 30°C for 30 minutes at 1050 rpm and terminated via the addition of 7 µL 
NuPAGE 4x LDS sample buffer containing 8% (v/v) 2-mercaptoethanol. For in vitro kinase 
assays involving the use of small-molecule inhibitors, reaction solutions containing all the 
required components were incubated at 30°C for 10 minutes at 1050 rpm prior to the 
addition of 0.1 mM [g32P]-ATP. Reactions were then performed as detailed previously. 
Samples were incubated at 95°C for 5 minutes and subsequently centrifuged at 5.0 x 103 x g 
for 1 minute. Samples were loaded (20 µL per well) into NuPAGE 4-12% Bis-Tris precast 
polyacrylamide gel and resolved via SDS-PAGE (section 2.2.12). The polyacrylamide gel was 
subsequently stained with InstantBlue Coomassie Protein Stain (Expedeon) to visualise the 
resolved recombinant proteins and imaged using the ChemiDoc Imaging System (Bio-Rad). 
32P radioactivity was analysed via autoradiography using Amersham Hyperfilm (GE Healthcare 
Life Sciences). 
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DU number Protein Residues Affinity tag Expression 
33547 TGFbRIT204D 200-501 N-terminal GST Baculovirus 
19395 SMAD2 1-467 N-terminal GST Escherichia coli 
33974 SMAD3 1-425 N-terminal GST Escherichia coli 
19398 SMAD4 1-502 N-terminal GST Escherichia coli 
40321 SIK1 2-783 N-terminal MBP Baculovirus 
16624 SIK2 2-926 N-terminal GST Baculovirus 
16623 SIK3 2-1369 N-terminal GST Baculovirus 
 
Table 4. Details of the recombinant proteins used for in vitro protein kinase assays in this 
thesis 
 
 
2.2.21 Statistical analysis 
All experiments have a minimum of three biological replicates unless otherwise stated in the 
respective figure legend. In addition, all luciferase, RT-qPCR, cellular proliferation, annexin V 
staining and crystal violet staining experiments have at least three technical repeats for each 
biological replicate. The data are presented as the arithmetic mean with error bars denoting 
the standard error of the mean (SEM). The statistical significance of differences between 
experimental conditions were assessed using either Student’s t-test or analysis of variance 
(ANOVA) with Bonferroni correction using GraphPad Prism (version 8.0) analysis software. 
Differences in the mean of experimental conditions was considered significant if the 
probability value (p-value) was <0.05. All immunoblotting figures are representative. 
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3 RESULTS 
 
3.1 SMALL-MOLECULE INHIBITOR SCREEN IN ENDOGENOUS TGFb-
RESPONSIVE TRANSCRIPTIONAL REPORTER CELL LINE 
 
3.1.1 Introduction 
In order to identify novel regulatory components of the TGFb signalling pathway, I employed 
a pharmacological approach using an endogenous transcriptional reporter cell line for the 
TGFb pathway (Rojas-Fernandez et al., 2015), previously generated through a collaboration 
between the Sapkota lab and the research group of Prof. Ron Hay (Centre for Gene Regulation 
and Expression, School of Life Sciences, University of Dundee). 
The cell line was generated using the CRISPR (clustered regularly interspaced short 
palindromic repeats)-Cas9 (CRISPR-associated protein 9) genome editing system to insert a 
polycistronic transcriptional reporter cassette immediately downstream and in-frame of the 
endogenous promoter region for the TGFb-responsive target gene plasminogen activator 
inhibitor 1 (PAI-1). The transcription of PAI-1 is potently induced in response to TGFb 
stimulation in multiple different cell lines in a SMAD-dependent manner (Keeton et al., 1991; 
Dennler et al., 1998). Furthermore, the promoter region of the PAI-1 gene has been 
frequently utilised in order to generate conventional luciferase-based bioassay reporter 
systems for the study of TGFb-dependent transcriptional regulation (Abe et al., 1994). 
Therefore, the PAI-1 promoter region represented an appropriate target for CRISPR-Cas9-
mediated insertion of the transcriptional reporter cassette. 
The CRISPR-Cas genome editing system involves the introduction of a DNA double-
stranded break (DSB) at a targeted genomic locus mediated by the RNA-guided DNA 
endonuclease Cas9 (Jiang and Doudna, 2017). The specificity of the Cas9 nuclease is 
determined via a 20-nucleotide (nt) sequence within its associated single-guide RNA (sgRNA) 
which binds to the targeted genomic DNA sequence through Watson-Crick base pairing (Ran 
et al., 2013). A U2OS human osteosarcoma cell line stably expressing the Cas9 nuclease was 
co-transfected with a vector encoding the sgRNA targeting the start codon region of the 
endogenous PAI-1 gene together with a donor vector containing a dual-reporter cassette 
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flanked by two sequences (consisting of approximately 500 nucleotides) homologous to the 
PAI-1 gene that facilitates homologous recombination (HR). Following HR, the reporter 
cassette was incorporated in-frame with the ATG start codon of the endogenous PAI-1 gene 
(figure 3.1-A). The transcriptional reporter cassette contained cDNA encoding the firefly 
luciferase enzyme, immediately followed by an internal ribosome entry site (IRES), green 
fluorescent protein (GFP) and the 2A self-cleaving peptide. The IRES element facilitates 5’ cap-
independent protein translation (Pelletier and Sonenberg, 1988), thereby enabling the 
separate expression of the luciferase enzyme and GFP. The 2A self-cleaving peptide ensures 
the separation of the GFP from the endogenous PAI-1 protein. 
 
 
 
 
 
 
 
 
Figure 3.1A. Schematic representation of the endogenous TGFb-responsive transcriptional 
reporter system 
The dual-reporter cassette containing cDNA encoding both the firefly luciferase enzyme and 
GFP was inserted in-frame with the ATG start codon of the endogenous PAI-1 gene in U2OS 
human osteosarcoma cells. The IRES element facilitates the separate expression of the 
luciferase enzyme and GFP, whilst the 2A self-cleaving peptide ensures the separation of the 
GFP protein from the endogenous PAI-1 protein. 
 
 
The development of this endogenous transcriptional reporter system was termed second-
generation (2G) TGFb transcriptional reporter and therefore the cell line is hereafter referred 
to as U2OS 2G transcriptional reporter. This system presents a number of advantages over 
existing transcriptional reporter systems that are based upon the overexpression of 
exogenous cDNA expression vectors containing a promoter fragment or repeats of specific 
nucleotide sequences. Most significantly, our endogenous transcriptional reporter system 
takes into consideration the native chromatin context and gene regulatory components. 
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3.1.2 Characterisation of endogenous TGFb transcriptional reporter cell line 
For the purpose of this thesis, it was necessary to characterise the U2OS 2G TGFb 
transcriptional reporter cell line prior to performing the small-molecule inhibitor screen. A 
time-course stimulation of wild type U2OS and U2OS 2G reporter cells with recombinant 
human TGFb1 over a period of 24 hours resulted in comparable levels of SMAD3 
phosphorylation at serine 423 and serine 425 (the conserved carboxy-terminal residues 
subject to phosphorylation by the TGFb type I receptor kinase), attaining maximal 
phosphorylation level at approximately 3 hours (figure 3.1B). As expected, expression levels 
of SMAD2 and SMAD3 proteins were comparable between wild type and 2G reporter cells 
and remained consistent over the stimulation time course (figure 3.1B). In the wild type U2OS 
cells, TGFb1 stimulation resulted in a concomitant increase in the protein expression of PAI-
1, with the highest expression occurring at approximately 6 hours before decreasing back to 
basal levels. In contrast, PAI-1 protein expression is completely absent in the U2OS 2G 
reporter cells (figure 3.1B). In the initial study describing the development of the 2G 
transcriptional reporter cell line, sequence analysis of the PAI-1 locus revealed that genomic 
integration of the dual-reporter cassette occurred in a heterozygous manner. Moreover, it 
was also revealed that the non-integrated PAI-1 allele was disrupted via the insertion of a 
single nucleotide, resulting in a non-functional allele and consequently the absence of PAI-1 
protein expression (Rojas-Fernandez et al., 2015). However, TGFb1 stimulation of the U2OS 
2G reporter cells induced a time-dependent increase in the expression of GFP, with the 
maximal expression observed at 24 hours (figure 3.1B). The differences in the protein 
expression dynamics of PAI-1 and GFP observed in the wild type and 2G reporter cells 
respectively may be explained by a number of factors. The decrease in PAI-1 protein 
expression observed after 6 hours of TGFb stimulation may be partially explained by its 
physiological function as a major regulator of fibrinolysis (i.e. the enzymatic degradation of 
fibrin-containing blood clots). In order to perform this function, PAI-1 is secreted into the 
blood plasma by a number of different mammalian cells types including endothelial cells 
(Loskutoff et al., 1983; Sawdey, Podor and Loskutoff, 1989), where it can subsequently bind 
and inhibit its principal substrates, tissue-type plasminogen activator (t-PA) and urokinase-
type plasminogen activator (u-PA) (Chmielewska, Rånby and Wiman, 1983; Kruithof et al., 
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1984). Consequently, the detection of PAI-1 protein expression via immunoblotting is likely 
to be influenced by its secretion into the culture media when culturing cells in vitro. 
Therefore, in all subsequent experiments involving either wild type U2OS or U2OS 2G 
transcriptional reporter cells, TGFb stimulation was performed for 6 hours and 24 hours 
respectively (unless otherwise stated in figure legends). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1B. Comparison of U2OS osteosarcoma wild-type and 2G transcriptional reporter 
cell lines. 
U2OS wild type and 2G transcriptional reporter cells were stimulated with recombinant 
human TGFb1 (5 ng mL-1) and lysed at the indicated time points. Cell lysates (12 µg total 
protein) were resolved via SDS-PAGE and transferred to nitrocellulose membranes. The 
membranes were subsequently subjected to immunoblotting with the indicated antibodies. 
The immunoblot is representative of two independent experiments. 
 
 
In order to further demonstrate that the 2G transcriptional reporter cells are 
responsive to TGFb stimulation, experiments were performed involving the compound SB-
505124, a small-molecule inhibitor of the TGFb type I receptor kinases ACVR1B (ALK4), 
TGFβR1 (ALK5) and ACVR1C (ALK7) (DaCosta Byfield et al., 2004). Stimulation of U2OS 2G 
transcriptional reporter cells with TGFb resulted in a statistically significant 2.5-fold increase 
in luciferase activity compared with unstimulated control cells. However, this TGFb-induced 
increase in luciferase activity was completely inhibited when cells were co-incubated with SB-
505124 (figure 3.1C-A). Furthermore, using the same experimental conditions, it was 
 105 
observed that SB-505124 inhibits TGFb-mediated phosphorylation of SMAD3 and therefore 
completely inhibited the concomitant TGFb-induced increase in GFP protein expression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1C. The TGFb type I receptor kinase inhibitor SB-505124 abrogates TGFb-induced 
luciferase activity and GFP expression in 2G transcriptional reporter cells. 
(A) U2OS 2G transcriptional reporter cells were stimulated with recombinant human TGFb1 
(5 ng mL-1) in the presence of SB-505124 (1 µM) or equivalent volume of DMSO, for 24 hours 
prior to cell lysis and luciferase assay. The experiment was performed five times and all 
luminescence values were normalised to the total protein concentration of the respective cell 
lysate sample. (B) U2OS 2G transcriptional reporter cells were stimulated with recombinant 
human TGFb1 (5 ng mL-1) in the presence of SB-505124 (1 µM) or equivalent volume of DMSO, 
for 24 hours prior to cell lysis. Cell lysates (12 µg total protein) were resolved via SDS-PAGE 
and transferred to nitrocellulose membranes. The membranes were subsequently subjected 
to immunoblotting with the indicated antibodies. Immunoblots are representative of two 
independent experiments. 
 
 
Therefore, collectively these experiments demonstrate that the U2OS 2G transcriptional 
reporter cell line is responsive to TGFb stimulation and that the increase in luciferase activity 
or GFP expression is specifically dependent on TGFb-mediated phosphorylation of SMAD3. 
Although slight differences were observed in protein expression dynamics between 
endogenous PAI-1 and GFP, the system effectively mimics the TGFb-dependent 
transcriptional regulation of PAI-1 expression. I was therefore confident that this 
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transcriptional reporter cell line was a good system to employ in order to identify novel 
regulators of the SMAD-dependent signalling pathway. 
 
 
3.1.3 Identification of putative hits obtained from the pharmacological screen 
Once it had been confirmed that the U2OS 2G transcriptional reporter cells were a robust 
system for studying SMAD-dependent TGFb-mediated transcriptional regulation, we 
employed them in a 96-well plate format pharmacological screen in order to identify potential 
novel regulators of the pathway. The panel used was composed of 88 small-molecule 
inhibitors predominantly targeting protein kinases but also a small number targeting enzymes 
of the ubiquitin system. The compounds were selected in order to ensure a broad coverage 
of the different kinase families within the human kinome. Furthermore, two compounds that 
are selective inhibitors of TGFb type I receptor kinases were also included as positive controls; 
SB-505124 (DaCosta Byfield et al., 2004) and A 83-01 (Tojo et al., 2005). In addition, a number 
of internal DMSO plate controls were included for subsequent data normalisation. 
 The U2OS 2G transcriptional reporter cells were seeded in 96-well cell culture plates 
and incubated with the inhibitor panel either in the presence or absence of TGFb1 stimulation 
(5 ng mL-1) for a period of 24 hours (figure 3.1-D). All the inhibitors were used at 1 µM 
concentration. The cells were subsequently lysed, and the transcriptional reporter activity 
analysed using luciferase assays. As expected, the two selective and potent inhibitors of the 
type I receptor kinases that were employed as positive controls (SB-505124 and A 83-01) both 
resulted in statistically significant inhibition of TGFb-induced luciferase activity compared 
with DMSO control treated cells (figure 3.1-E). Additionally, the compound D4476 also 
produced a statistically significant inhibition of TGFb-induced luciferase activity. D4476 is a 
member of a compound series that was initially identified as inhibitors of TGFbRI (ALK5) 
(Callahan et al., 2002). However, subsequent profiling of the compound against a panel of 
protein kinases revealed that it also inhibited the constitutively active serine-threonine 
protein kinase casein kinase 1 (CK1) with greater potency. D4476 was demonstrated to be an 
ATP-competitive inhibitor of CK1 with an IC50 value of 300 nM whereas it inhibited TGFbRI 
(ALK5) with an IC50 value of 500 nM (Rena et al., 2004). D4476 is relatively specific for CK1 and 
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TGFbRI (ALK5) (MRC PPU Kinase Profiling Inhibitor Database; http://www.kinase-
screen.mrc.ac.uk/kinase-inhibitors) and is therefore commonly used as a CK1 inhibitor.  
 
 
 
 
Figure 3.1D. Schematic representation of the experimental workflow for the small-molecule 
inhibitor screen in TGFb-responsive 2G transcriptional reporter cells. 
U2OS 2G transcriptional reporter cells were seeded in 96-well cell culture plates and then 
incubated with a panel of selective small-molecules inhibitors, in the presence or absence of 
TGFb1 stimulation (5 ng mL-1) for 24 hours. Cells were subsequently lysed and luciferase assays 
performed for each plate. The screen was performed in triplicate and the luminescence values 
for each plate were normalised to internal DMSO plate controls. The luminescence values for 
cells incubated with the inhibitor panel and TGFb were then normalised to the values 
obtained for cells incubated with the inhibitors alone. 
 
 
Plate 
number 
Inhibitor Molecular target IC50 (nM) Reference 
1 A-83-01 ALK5 12 Tojo M. et al (2005) 
2 MSC 2032964A ASK1 93 Guo X. et al (2010) 
3 KU-55933 ATM 13 Hickson I. et al (2004) 
4 ETP-46464 ATR 25 Toledo L.I. et al (2011) 
5 SU6668 (Orantinib) Aurora B, Aurora C 
PDGFR, VEGFR, 
FGFR 
35, 210 Sun L. et al (1999), Laird A.D. et al 
(2000), Godl K. et al (2005) 
6 PLX-4720 B-RAFV600E 13 Tsai J. et al (2008) 
7 Imatinib Abl 38 Buchdunger E. et al (1996) 
8 Dasatinib Abl, Src, Lck 0.5, 0.05, 0.4 Lombardo L.J. et al (2004) 
9 LDN193189 ALK2, ALK3 5, 30 Yu P.B. et al (2008), Cuny G.D. et al 
(2008) 
10 PCI-32765 (Ibrutinib) BTK 0.5 Honigberg L.A. et al (2010) 
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11 PD-0332991 
(Palbociclib) 
CDK4, CDK6 11, 16 Toogood P.L., et al (2005) 
12 CKI-7 dihydrochloride CK1 6000 Chijiwa T. et al (1989) 
13 D4476 CK1, ALK5 200, 500 Callahan J.F. et al (2002), Rena G. et al 
(2004) 
14 GSK626616 DYRK3 0.7 Erickson-Miller C.L. et al (2007) 
15 SB-505124 ALK4, ALK5 129, 47 DaCosta Byfield S. et al (2004) 
16 AG-490 EGFR, JAK 2000, - Gazit A. et al (1989), Gazit A. et al 
(1991), Meydan N. et al (1996), Wang 
L.H. et al (1999) 
17 (Z)-4-hydroxytamoxifen Estrogen receptor 
(ER) 
- Jordan V.C. et al (1977), Crewe H.K. et 
al (2002), Desta Z., et al (2004) 
18 Zearalenone Estrogen receptor 
(ER) 
  
19 CHIR 99021 GSK3  Ring D.B. (2003) 
20 BI-605906 IKKb 380 Clark K. (2011) 
21 IRAK-4 kinase inhibitor A IRAK4  Wang Z. (2006) 
22 CP-690550 
(Tofacitinib) 
JAK1, JAK2, JAK3 112, 20, 1 Changelian P.S. (2003), Flanagan M.E. 
(2010) 
23 INCB018424 
(Ruxolitinib) 
JAK1, JAK2 3.3, 2.8 Quintas-Cardama A. (2010) 
24 JNK-IN-8 JNK1, JNK2, JNK3 5, 19, 1 Zhang T. (2012) 
25 GSK2578215A LRRK2 10 Reith A.D. et al (2012) 
26 MAPKAP-K2 inhibitor A MAPKAP-K2  Anderson D.R. et al (2007) 
27 PF-3644022 MK2 5.2 Mourey R.J. et al (2010) 
28 MRT199665 MARKs, SIKs  Clark K. et al (2012) 
29 PD 0325901 MEK1, MEK2 0.3 Bain J. et al (2007), Barrett S.D. et al 
(2008) 
30 ML-9 hydrochloride MLCK - Nagatsu T. et al (1987) 
31 CGP-57380 MNK1 2200 Knauf U. et al (2001) 
32 CGP-57380 analog 
(SHN-093) 
MNK - Buxade M. et al (2005) 
33 AZD8055 mTORC1, mTORC2 0.8 Chresta C.M. et al (2010) 
34 Amgen-NIK-28 NIK - Li K. et al (2013) 
35 BIRB 796 
(Doramapimod) 
p38 MAPK 
a/b/g/d 
38, 65, 200, 520 Pargellis C. et al (2002), Regan J. et al 
(2002), Kuma Y. et al (2005) 
36 GSK2334470 PDK1 10 Najafov A. et al (2011) 
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37 GSK2606414 PERK 0.4 Axten J.M. et al (2012) 
38 GDC-0941 
(Pictilisib) 
PI3K 3 Folkes A.J. et al (2008) 
39 H-89 dihydrochloride PKA 135  Davies S.P. et al (2000) 
40 MK-2206 AKT1, AKT2, AKT3 5, 12, 65 Hirai H. et al (2010) 
41 AX20017 PknG 390 Walburger A. et al (2004) 
42 BI-2536 PLK1 0.8 Steegmaier M. et al (2007) 
43 GSK461364 PLK1 2.2 Gilmartin A.G. et al (2009) 
44 Necrostatin-1 RIP1  Degterev A. et al (2008) 
45 Necrostatin-1 (inactive 
analog) 
RIP1 - Degterev A. et al (2008) 
46 GSK429286 ROCK1 14 Goodman K.B. et al (2007) 
47 BI-D1870 RSK1-4 31, 24, 18, 15 Sapkota G.P. et al (2007) 
48 DMSO control - - - 
49 HG-9-91-01 SIK1, SIK2, SIK3 0.92, 6.6, 9.6 Clark K. et al (2012) 
50 BML-258 SphK1 - Paugh S.W. et al (2008) 
51 SKI II SphK1 500 French K.J. et al (2003) 
52 VPS34-IN1 VPS34 25 Bago R. et al (2014) 
53 STOCK1S-50699 WNK 37000 Mori T. et al (2013) 
54 TC-S 7006 MAP3K8 50 Gavrin L.K. et al (2005) 
55 Compound 401 DNA-PK 0.3 Griffin R.J. et al (2005) 
56 DMSO control - - - 
57 MRT67307 IKKe, TBK1 160, 19 Clark K. et al (2011), Clark K. et al 
(2012) 
58 HTH-01-015 NUAK1 100 Banerjee S. et al (2014) 
59 IPA-3 PAK1 2500 Deacon S.W. et al (2008) 
60 Rigel TRAF6 Inhibitor TRAF6 - - 
61 Princeton’s TrkA 
Inhibitor (compound 
20h) 
TrkA 0.6 Kim S.H. et al (2008) 
62 AZ-23 TrkA, TrkB 2, 8 Thress K. et al (2009) 
63 CGP-57380 analog 
(SHN-095) 
MNK - Buxade M. et al (2005) 
64 Mitoxantrone USP11 3150 Burkhart R.A. et al (2013) 
65 DMSO control - - - 
66 SJB3-019A USP1 78 Mistry H. et al (2013) 
67 DMSO control - - - 
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68 Resveratrol COX-1 - - 
69 MLN4924 NAE1 4.7 Soucy T.A. et al (2009) 
70 BAY 11-7082 NF-kB - Pierce J.W. et al (1997) 
71 - - - - 
72 - - - - 
73 ML240 p97 ATPase 100 Chou T.F. et al (2013) 
74 ML241 p97 ATPase 100 Chou T.F. et al (2013) 
75 Novartis compound 12a PKD1 - Meredith E.L. et al (2010) 
76 MLN9708 20S proteasome 3.4 Kupperman E. et al (2010) 
77 SRT 1720 SIRT1  Milne J.C. et al (2007) 
78 Smac mimic (compound 
3) 
Smac - Li L. et al (2004) 
79 DMSO control - - - 
80 VCP Inhibitor III VCP ATPase 20 Magnaghi P. et al (2013), Polucci P. et 
al (2013) 
81 Febuxostat XO 1.2 Osada Y. et al (1993) 
82 - - - - 
83 Blebbistatin Myosin II ATPase - Limouze J. et al (2004) 
84 Ischemin p53 CBP - Borah J.C. et al (2011) 
85 DBeQ p97 ATPase  Chou T.F. et al (2011) 
86 CCT007093 PPM1D 8400 Rayter S. et al (2008) 
87 Harmaline - - - 
88 DMSO control - - - 
89 DMSO control - - - 
90 DMSO control - - - 
91 DMSO control - - - 
92 DMSO control - - - 
93 DMSO control - - - 
94 DMSO control - - - 
95 DMSO control - - - 
96 DMSO control - - - 
 
Table 5. The small-molecule inhibitors comprising the library used for pharmacological 
screening in TGFb-responsive 2G transcriptional reporter cells 
The above table provides information regarding the small-molecule inhibitor compounds 
used for the pharmacological screening conducted as part of this thesis project, and includes 
the intended molecular target, the in vitro IC50 (nM) if known and the relevant published 
research. The information was obtained from the online inhibitor database provided by the 
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MRC PPU International Centre for Kinase Profiling (http://www.kinase-
screen.mrc.ac.uk/kinase-inhibitors) and various commercial supplier websites. 
 
 
Therefore, the inhibition of TGFb-induced luciferase reporter activity observed with SB-
505124, A 83-01 and D4476 provided a degree of confidence that the inhibitor screen was 
performed successfully, and that the data obtained was robust. 
Furthermore, it was also observed that LDN193189, a selective inhibitor of the BMP 
type I receptor kinases ALK2, ALK3 and ALK6 (Cuny et al., 2008), also resulted in the potent 
inhibition of TGFb-induced luciferase activity. This most likely occurred because the 
concentration of LDN193189 used in the screen (1 µM) is 10-fold higher than typically used 
to inhibit the BMP type I receptors and therefore at a sufficiently high concentration to also 
inhibit the TGFb type I receptors (Vogt, Traynor and Sapkota, 2011), although this observation 
was not subsequently verified experimentally in cells. 
Unsurprisingly, the majority of the inhibitor compounds did not significantly impact 
TGFb-induced transcriptional reporter activity. However, under these conditions it was 
discovered that HG-9-91-01, a potent inhibitor of salt-inducible kinase (SIK) isoforms, also 
significantly attenuated TGFb-induced luciferase activity, suggesting that SIKs may be novel 
regulators of TGFb-induced gene transcription. Therefore, I decided to focus the research on 
determining whether this initial observation was valid and the precise nature of any potential 
regulation of the TGFb signalling pathway by SIK isoforms. 
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Figure 3.1E. Data obtained from the pharmacological screen using the TGFb-responsive 2G 
transcriptional reporter cell line. 
(A) Data obtained from the small-molecule inhibitor screen indicating the top 5 compounds 
which significantly suppressed the TGFb-induced luciferase reporter activity compared to the 
DMSO control. The screen was performed in triplicate and the error bars represent the 
standard error of the mean (SEM). (B) Table indicating the mean relative luciferase activity 
values and the SEM values, in addition to the principal target protein kinases, of the top 5 
compounds which suppressed TGFb-induced luciferase reporter activity. 
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Figure 3.1F. Relative luciferase activity data from the pharmacological screen in TGFb-
responsive 2G transcriptional reporter cells 
The luciferase reporter values for each small-molecule inhibitor compounds were normalised 
to internal DMSO plate controls to generate relative values in order to ascertain which 
compounds may inhibit or potentiate the TGFb-dependent induction of the luciferase 
reporter enzyme. The values are the arithmetic mean obtained from three independent 
experiments and the error bars indicate the standard error of the mean (SEM). The red line 
denotes the overall average relative luciferase value obtained from the screen. Statistical 
analysis was performed using GraphPad Prism (version 8.0) software. 
 
 
3.1.4 Discussion 
The initial pharmacological screens performed as part of this doctoral project provided proof 
of concept that the endogenous 2G transcriptional reporter cells are a suitable system for 
conducting high-throughput screens. Although the experiments yielded a number of potential 
hits regarding novel regulators of the TGFb, a number of difficulties and considerations arose 
that could be improved for any subsequent high-throughput screening (HTS) experiments. 
Firstly, the seeding of cells and subsequent addition of inhibitor compounds to the cells in a 
96-well format was performed manually using multi-channel pipettes and therefore may be 
prone to pipetting errors. Therefore, the accuracy of these steps could be substantially 
improved by employing automated liquid dispensing equipment. Moreover, using automated 
liquid dispensing equipment would also enable larger screens (e.g. 384-well or 1536-well 
format) to be performed accurately and rapidly. Furthermore, automation of the screening 
procedure would have enabled the incorporation of multiple different concentrations of each 
compound instead of using a single concentration of 1 µM that was tested in our initial 
screens. This would have enabled us to obtain dose-response data for each inhibitor and 
therefore enhanced the robustness of the assay. 
Although the transcriptional reporter system employed in this project is specific to 
TGFb, in principal it would be possible to employ CRISPR-Cas genome editing technology to 
generate endogenous transcriptional reporter systems for any target gene of interest. This 
would provide a more relevant system for investigating the transcriptional regulation of 
specific genes or signalling pathways than systems which employ overexpression of 
exogenous cDNA reporter plasmids. 
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3.2 CHARACTERISATION OF SIK INHIBITORS IN THE CONTEXT OF TGFb 
SIGNALLING 
 
3.2.1 Introduction 
Salt-inducible kinases (SIKs) are serine-threonine specific protein kinases that belong to the 
AMP-activated protein kinase (AMPK)-related subfamily. The AMPK-related subfamily 
consists of 12 members that are all closely related by sequence homology to the catalytic 
domain of AMPK and includes brain-specific serine-threonine protein kinase 1 and 2 (BRSK1 
and BRSK2), microtubule affinity-regulating kinases 1-4 (MARKs1-4), maternal embryonic 
leucine-zipper kinase (MELK), NUAK1 and NUAK2 and three SIK isoforms (SIK1-3) (Bright, 
Thornton and Carling, 2009). 
 The catalytic subunits of AMPK (AMPKa1 and AMPKa2) were found to be direct 
substrates of the serine-threonine protein kinase LKB1 (also referred to as STK11) by three 
independent research groups (Hawley et al., 2003; Hong et al., 2003; Woods et al., 2003; 
Shaw et al., 2004). Activation of AMPK requires phosphorylation of a threonine residue (T172) 
within the activation loop of the catalytic subunit by LKB1 (Hawley et al., 2003). Furthermore, 
interaction of LKB1 with its regulatory subunits, the pseudokinase STRADa/b (STE20-related 
kinase adaptor protein) (Baas et al., 2003) and the scaffolding protein MO25a/b (also referred 
to as calcium-binding protein 39, CAB39) (Boudeau et al., 2003), is required for complete 
activation of AMPK (Hawley et al., 2003; Shackelford and Shaw, 2009). 
LKB1 was initially identified as the tumour suppressor gene responsible for the 
development of the autosomal dominant inherited condition Peutz-Jeghers syndrome (PJS) 
which is primarily characterised by the presence of benign gastrointestinal polyps (Hemminki 
et al., 1998). In addition, multiple epidemiological studies have reported an increased risk of 
developing gastrointestinal and non-gastrointestinal carcinomas including breast, ovarian 
and pulmonary in patients with PJS (Giardiello et al., 1987; Boardman et al., 1998; van Lier et 
al., 2011; Riegert-Johnson, Westra and Roberts, 2012). Subsequent genetic analysis revealed 
that the LKB1 gene is frequently mutated in sporadic pulmonary adenocarcinomas, 
particularly non-small cell lung carcinomas (NSCLC) (Sanchez-Cespedes et al., 2002; Ji et al., 
2007), and somatically mutated in at least 20 percent of cervical carcinomas (Wingo et al., 
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2009), thereby demonstrating that LKB1 is an important tumour suppressor in multiple 
different cell types. 
Following on from the identification of LKB1 as the upstream protein kinase involved 
in the activation of AMPK, LKB1 was also shown to phosphorylate and activate all the 
members of the AMPK-related subfamily (Lizcano et al., 2004). As with the AMPK catalytic 
subunits, the LKB1-STRADa/b-MO25a/b complex catalyses the phosphorylation of a 
conserved threonine residue within the activation loop of the AMPK-related kinases, which 
enhances their catalytic activity more than 50-fold. An exception to this is MELK, whose 
catalytic activity was independent of LKB1 and is thus proposed to catalyse 
autophosphorylation of its own activation (T)-loop threonine residue.  
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Figure 3.2A. LKB1 is a master protein kinase that phosphorylates and activates AMPK and 
AMPK-related subfamily members. 
(A) The tumour suppressor serine-threonine protein kinase LKB1, in complex with its 
regulatory subunits STRADa/b and MO25a/b, phosphorylates and activates the two AMPK 
catalytic subunits (AMPKa1 and AMPKa2) as well 12 other members of the AMPK-related 
family of serine-threonine protein kinases (N.B. the one exception is MELK, which is reported 
to undergo autophosphorylation in order to become catalytically active). (B) Sequence 
alignment of the activation segment of the AMPKa catalytic subunits and the 13 members of 
the AMPK-related family protein kinases. The activation segment is defined as the region 
between and including two conserved tripeptide motifs, the amino-terminal Asp-Phe-Gly 
(DFG) motif and the carboxy-terminal Ala-Pro-Glu (APE) motif. The DFG motif is situated 
within the magnesium-binding loop and participates in the coordination of an Mg2+ ion 
required for the catalytic activity. By contrast, although highly conserved in the activation 
segment of protein kinases, the function of the APE motif remains uncertain. LKB1 regulates 
the catalytic activity of AMPK and the majority of AMPK-related family members by 
phosphorylating a conserved threonine (Thr, T) residue within the activation (T)-loop 
(indicated by an asterisk), enhancing their activity over 50-fold. Multiple protein sequence 
alignment was performed in Jalview (version 2.10.5) software (Waterhouse et al., 2009) using 
the Clustal Omega sequence alignment programme. Highly conserved amino acid residues 
are indicated by dark blue shading. (C) Phylogenetic tree derived from the protein sequence 
alignment of the catalytic protein kinase domain of AMPKa catalytic subunits and all the 13 
members of the AMPK-related family. The phylogenetic tree was calculated using the 
neighbour-joining (NJ) method (Saitou and Nei, 1987) in Jalview (version 2.10.5). 
Abbreviations: AMPK, 5’-AMP-activated protein kinase; BRSK, Brain-specific 
serine/threonine-kinase; MARK, MAP/microtubule affinity-regulating kinase; MELK, Maternal 
embryonic leucine zipper kinase; NUAK, NUAK family SNF1-like kinase; SIK, Salt-inducible 
kinase; SNRK, Sucrose non-fermenting related kinase. 
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Figure 3.2B. Comparison of the protein expression of SIK2 and SIK3 isoforms across a panel 
of human and murine cell lines. 
Cell lysate samples (12 µg total protein) obtained from multiple human and murine cell lines 
routinely used for in vitro cell culturing were resolved via SDS-PAGE and membranes 
subjected to immunoblotting with the indicated antibodies. Cell lines: A-172 (human 
glioblastoma), A549 (human pulmonary adenocarcinoma), NMuMG (murine mammary 
epithelial), SK-OV-3 (human ovarian adenocarcinoma), K-562 (human bone marrow-derived 
chronic myelogenous leukaemia (CML)), MDA-MB-468 (human mammary adenocarcinoma), 
U2OS (human osteosarcoma), PC-3 (human prostate adenocarcinoma), ARPE-19 (human 
retinal pigmented epithelium), SH-SY5Y (human bone marrow-derived neuroblastoma), HuH-
7 (human hepatocellular carcinoma), THP-1 (human peripheral blood-derived acute 
monocytic leukaemia (AML-M5)), HACAT (human spontaneously transformed keratinocytes), 
MCF-7 (human mammary adenocarcinoma). 
 
 
3.2.2 Two structurally distinct SIK inhibitors suppress TGFb-induced luciferase 
transcriptional reporter activity 
The pharmacological screen detailed previously identified SIK isoforms as potential novel 
regulators of TGFb-induced gene transcription. Therefore, I sought to further validate this 
observation. In addition to HG-9-91-01, the compound MRT199665, a structurally distinct 
small-molecule inhibitor that is also known to inhibit SIK isoforms (Clark et al., 2012) was also 
employed. Although both of these compounds are ATP-competitive kinase inhibitors, they 
exhibit contrasting specificities. MRT199665 is a potent inhibitor of most of the AMPK-related 
kinases with the exception of BRSK1 and BRSK2, and also inhibits the AMPK catalytic subunits 
(figure 3.2C). By contrast, HG-9-91-01 is a potent inhibitor of the three SIK isoforms however 
it does not inhibit AMPK or any of the other AMPK-related kinases (figure 3.2C). Therefore, it 
was examined whether both of these compounds could suppress TGFb-dependent gene 
transcription. Indeed, both HG-9-91-01 and MRT199665 significantly attenuated TGFb-
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induced luciferase activity in the U2OS 2G transcriptional reporter cell line. This evidence 
provided greater confidence that the effect of these small-molecule inhibitors on TGFb-
mediated gene transcription was reproducible and not an experimental artefact 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2C. The chemical structures and IC50 values of the pharmacological inhibitors HG-
9-91-01 and MRT199665. 
(A) The chemical structures of HG-9-91-01 and MRT199665, structurally unrelated small-
molecule kinase inhibitors of SIK isoforms. The molecular structures were created using 
ChemDraw Professional software (version 17.0) (PerkinElmer). (B) IC50 (nanomolar) values for 
inhibition of LKB1, AMPK and the AMPK-related subfamily of protein kinases by HG-9-91-01 
and MRT199665 in vitro. The information regarding chemical structures and IC50 values was 
obtained from (Clark et al., 2012). 
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Figure 3.2D. The structurally distinct SIK inhibitors HG-9-91-01 and MRT199665 both 
attenuate TGFb-induced luciferase reporter activity. 
U2OS 2G transcriptional reporter cells were incubated with SB-505124 (1 µM), HG-9-91-01 
(0.5 µM), MRT199665 (1 µM) or equivalent volume of DMSO in the presence or absence of 
TGFb1 stimulation (5 ng mL-1) for 24 hours prior to lysis and luciferase assay. Luminescence 
values were normalised to the total protein concentration of the respective cell lysate sample 
and luciferase activity determined relative to unstimulated DMSO treated cells. The 
experiment was performed in triplicate and error bars represent standard error of the mean 
(SEM). 
 
 
3.2.3 SIK inhibitors attenuate phosphorylation of CRTC3 in U2OS osteosarcoma cells 
When employing the use of small-molecule inhibitors in research it is critical to ensure that 
the compounds are effectively inhibiting the intended molecular target at the concentration 
used and in the different cell types studied. In the context of pharmacological inhibitors of 
protein kinases, it is important to analyse the phosphorylation of known substrates of the 
target kinase. The SIK isoforms, along with MARKs and AMPK itself are known to catalyse the 
phosphorylation of cAMP-responsive element-binding protein (CREB)-regulated 
transcriptional co-activator (CRTC) isoforms (Altarejos and Montminy, 2011; Mair et al., 2011; 
Sonntag et al., 2017). In particular, research has demonstrated that SIK isoforms have an 
important function in the regulation of macrophage polarisation through phosphorylation of 
CRTC3. In macrophages, SIK isoforms have been shown to phosphorylate CRTC3 at serine 62, 
serine 162, serine 329 and serine 370, resulting in the interaction of CRTC3 with 14-3-3 
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binding proteins. The phosphorylation-dependent interaction between CRTC3 and 14-3-3 
proteins inhibits the function of CRTC3 by preventing its translocation to the nucleus and thus 
supresses the transcriptional activity of CREB. Consequently, pharmacological inhibition of SIK 
isoforms promotes the dephosphorylation of CRTC3, thereby facilitating the translocation of 
CRTC3 to the nucleus where it can enhance CREB-dependent gene transcription, including IL-
10 transcription, in response to Toll-like receptor (TLR) stimulation of macrophages (Clark et 
al., 2012; MacKenzie et al., 2013). Therefore, recent research has demonstrated that genetic 
or pharmacological inhibition of SIK isoforms can enhance the production of anti-
inflammatory cytokines and thereby promote macrophages to adopt a regulatory phenotype 
(Sundberg et al., 2014; Lombardi et al., 2016a; Darling et al., 2017). As a result, SIKs have been 
proposed as potential therapeutic targets for the development of novel anti-inflammatory 
drugs. 
 
 
 
 
 
 
 
 
Figure 3.2E. The small-molecule inhibitors HG-9-91-01 and MRT199665 attenuate the 
phosphorylation of CRTC3 in U2OS osteosarcoma cells. 
Wild type U2OS osteosarcoma cells were incubated with HG-9-91-01 (0.5 µM), MRT199665 
(1 µM) or an equivalent volume of DMSO for 1 hour prior to cell lysis. Lysate samples (1 mg 
total protein) were subjected to immunoprecipitation of endogenous CRTC3 using anti-CRTC3 
polyclonal sheep IgG conjugated to Protein G Agarose resin. Following elution from the 
antibody-resin, total cell lysate (20 µg protein) and IP samples were resolved via SDS-PAGE 
and subsequently transferred to nitrocellulose membranes. The membranes were subjected 
to immunoblotting using the indicated antibodies. 
 
 
Therefore, it was important to examine the efficacy of both HG-9-91-01 and MRT199665 in 
U2OS human osteosarcoma cells. However, it proved difficult to adequately detect CRTC3 
phosphorylation directly in total cell lysates via SDS-PAGE and Western immunoblotting and 
as a result it was necessary to immunoprecipitate CRTC3 from total cell lysates prior to 
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performing SDS-PAGE in order to do so. Incubation of wild type U2OS osteosarcoma cells with 
either HG-9-91-01 (0.5 µM) or MRT199665 (1 µM) resulted in a substantial reduction in 
phosphorylation of CRTC3 at serine 370 compared with DMSO control treated cells, indicating 
that both compounds were effectively inhibiting SIKs at the respective concentrations used 
(figure 3.2E). 
 
 
3.2.4 Analysis of SIK inhibitors on receptor-mediated SMAD3 phosphorylation 
The development of cell-permeable small-molecule inhibitors targeting protein kinases has 
helped to delineate the physiological substrates and hence the cellular functions of these 
enzymes in the study of cell signalling. However, the degree of target selectivity of an inhibitor 
represents one of the principal caveats of using small-molecule inhibitors as research tools. A 
number of studies have performed in vitro profiling of some commonly used inhibitors against 
panels of protein kinases in order to investigate the specificities of these compounds (Davies 
et al., 2000; Bain et al., 2003). This research revealed that certain compounds that were 
reported to inhibit particular protein kinases also inhibited multiple other kinases and, in 
some cases, more potently than their intended target. Thus, it is critically important to 
consider the specificities of small-molecule inhibitors to avoid drawing erroneous 
conclusions. 
 Therefore, it was important to test whether the inhibition of the TGFb-induced 
luciferase reporter activity that was observed upon treatment with the inhibitors HG-9-91-01 
and MRT199665 (figure 3.2D) was a result of the off-target inhibition of the TGFb receptor 
kinases upstream of SMAD2/SMAD3 phosphorylation. Wild type U2OS osteosarcoma cells 
were incubated with SB-505124, HG-9-91-01, MRT199665 or DMSO and stimulated with 
recombinant human TGFb1 (5 ng mL-1) for 1 hour. As expected, incubation of cells with the 
TGFb type I receptor inhibitor SB-505124 completely abolished the receptor-mediated 
phosphorylation of SMAD3. However, the HG-9-91-01 compound also resulted in partial 
attenuation of receptor-mediated SMAD3 phosphorylation, whereas cells treated with 
MRT199665 exhibited SMAD3 phosphorylation levels comparable to that observed in DMSO 
control treated cells (figure 3.2-D). This suggested that HG-9-91-01 could potentially inhibit 
either the TGFb type I or type II receptor kinase and therefore the ability of HG-9-91-01 and 
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MRT199665 to inhibit the TGFb type I receptor TGFbRI (ALK5) was subsequently tested in 
vitro. At the three inhibitor concentrations analysed (0.1, 1.0 and 10 µM), HG-9-91-01 
potently inhibited the catalytic activity of TGFbRI (figure 3.2F). However, in contrast, 
MRT199665 had no inhibitory effect on TGFbRI activity (figure 3.2F). Collectively, these results 
indicate that the inhibition of TGFb-induced luciferase reporter activity by HG-9-91-01 
observed in the pharmacological screen and subsequent validation experiments occurred 
due, in part, to the off-target inhibition of the TGFb type I receptor kinases. Interestingly, 
MRT199665 displayed no inhibition of the TGFb type I receptor in vitro and did not affect 
receptor-mediated phosphorylation of SMAD3, however it consistently blocked TGFb-
induced luciferase transcriptional reporter activity. This resulted in the hypothesis that the 
inhibitory effect of MRT199665 on TGFb-dependent gene transcription occurred downstream 
of the receptor-mediated phosphorylation and activation of SMAD2 and SMAD3. For these 
reasons, the HG-9-91-01 compound was not used in any subsequent experiments and the 
attention was focused upon validating the effect of MRT199665 on TGFb signalling. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2F. HG-9-91-01 inhibits the TGFb receptor-mediated phosphorylation of SMAD3 
(A) Wild-type U2OS osteosarcoma cells were incubated with SB-505124, HG-9-91-01 and 
MRT199665 at the concentrations indicated or equivalent volume of DMSO and stimulated 
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with recombinant human TGFb1 (5 ng mL-1) for 1 hour prior to cell lysis. Cell lysates (12 µg 
total protein) were resolved via SDS-PAGE and transferred to nitrocellulose membranes. The 
membranes were subsequently subjected to immunoblotting with the indicated antibodies. 
Immunoblots are representative of three independent experiments. (B) In vitro kinase assay 
analysis of recombinant constitutively active TGFbRI (ALK5) in the presence of either HG-9-
91-01 or MRT199665 at three different concentrations (0.1, 1.0 and 10.0 µM). Results indicate 
mean percentage activity remaining and standard deviation (SD) resulting from three 
independent experiments. The in vitro kinase assay experiments were performed by the MRC 
PPU International Centre for Kinase Profiling at the University of Dundee (http://www.kinase-
screen.mrc.ac.uk). 
 
 
3.2.5 In vitro protein kinase analysis of SIK isoforms against SMAD2 and SMAD3 
Following on from the identification of SIKs as potential regulators of TGFb-induced luciferase 
reporter activity, we wanted to investigate whether SMAD2 or SMAD3 were potential 
substrates for any of the SIK isoforms. Therefore, we performed in vitro protein kinase assays 
using baculovirus-expressed recombinant MBP-SIK1 (2-783), GST-SIK2 (2-926) and GST-SIK3 
(2-1369) protein kinases and bacterially expressed (Escherichia coli) GST-SMAD2 (1-467) or 
GST-SMAD3 (1-425). As a positive control for SMAD phosphorylation, the baculovirus-
expressed recombinant cytoplasmic protein kinase domain (residues 200-501) of the type I 
TGFb receptor (TGFbRI, alternatively known as ALK5) with a single point mutation (T204D) 
was included. The threonine (Thr, T) 204 residue is located at the carboxyl-terminal end of 
the GS domain adjacent to the canonical start of the kinase domain. Phosphorylation of 
multiple serine and threonine residues within the GS domain of TGFbRI by the type II receptor 
kinase (TGFbRII) is required for TGFbRI activation and subsequent downstream signalling. 
Therefore, substitution of Thr204 with an acidic aspartic acid residue (Asp, D) simulates 
negatively charged phosphate groups and results in a constitutively activated receptor. 
Consequently, TGFbRIT204D displays enhanced kinase activity in vitro and signals independent 
of both TGFb ligand and TGFbRII (Wieser, Wrana and Massagué, 1995). 
 Phosphorylation of SMAD2 was observed in the presence of TGFbRIT204D, GST-SIK2 and 
to a lesser extent GST-SIK3. However, the level of SMAD2 phosphorylation was substantially 
less than the autophosphorylation observed for both GST-SIK2 and GST-SIK3. Unfortunately, 
the purified recombinant MBP-SIK1 protein displays negligible in vitro kinase activity, as 
observed by very weak autophosphorylation and also confirmed by further analysis 
conducted by the MRC PPU International Centre for Kinase Profiling at the University of 
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Dundee. Therefore, it proved challenging to ascertain whether the SIK1 isoform could 
phosphorylate either SMAD2 or SMAD3 in vitro.  
 Surprisingly, when in vitro kinase assays were performed using GST-SMAD3 as the 
substrate, SMAD3 phosphorylation was not observed in the presence of TGFbRIT204D under 
the experimental conditions employed (figure 3.2G). Subsequent repeat experiments using 
different preparations of TGFbRIT204D yielded the same observation. It is possible that the 
purified recombinant GST-SMAD3 does not fold correctly, or that the GST tag somehow 
interferes with the ability of the purified recombinant TGFbRIT204D to phosphorylate the 
SMAD3 carboxy-terminal SSXS motif. Interestingly however, robust phosphorylation of GST-
SMAD3 in the presence of GST-SIK2, and to a lesser extent in the presence of GST-SIK3 was 
observed (figure 3.2G-B). Furthermore, the level of SMAD3 phosphorylation was substantially 
higher than the level of autophosphorylation observed for both GST-SIK2 and GST-SIK3 (figure 
3.2G-B). Additionally, the inclusion of the small-molecule SIK inhibitor HG-9-91-01 at 1 µM 
completely inhibited the ability of both GST-SIK2 and GST-SIK3 to phosphorylate SMAD3 
(figure 3.2G-C). This raised the possibility that SMAD3 (and perhaps SMAD2, to a lesser 
degree) are substrates of SIKs and in particular the SIK2 isoform. However, these in vitro 
kinase assays were conducted using recombinant SMAD2 and SMAD3, both of which 
contained an amino-terminal GST-tag. Glutathione S-transferase (GST) is composed of 222 
amino acid residues (with an approximate molecular weight of 26 kDa) and is thus considered 
to be a relatively large affinity tag. It is therefore conceivable that the phosphorylation that 
was observed in these assays was a result of phosphorylation of the GST tag and not the SMAD 
protein itself. Both the recombinant GST-SMAD2 and GST-SMAD3 contained a PreScission 
Protease cleavage sequence to enable the removal of the GST tag. The PreScission Protease 
specifically cleaves between the Gln and Gly residues of the amino acid recognition sequence 
Leu-Glu-Val-Leu-Phe-Gln/Gly-Pro (LEVLFQ/GP) (Cordingley et al., 1990). When subsequent in 
vitro protein kinase assays were conducted using proteolytically cleaved full-length 
recombinant SMAD3 protein, SIK2 and SIK3 recombinant kinase were still able to robustly 
phosphorylate SMAD3, indicating that they were indeed phosphorylating SMAD3, and not the 
GST affinity tag, in vitro. Moreover, as observed in previous experiments, the inclusion of the 
potent SIK small-molecule inhibitor HG-9-91-01 completely abolished the ability of SIK2 and 
SIK3 to phosphorylate SMAD3, providing evidence that the SMAD3 phosphorylation is 
occurring due to SIKs and not a contaminating protein kinase. Identifying the residues of 
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SMAD3 that are subject to SIK-mediated phosphorylation and discerning the functional 
consequences is the principal focus of my current research. 
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Figure 3.2G. In vitro kinase assay analysis of SIK isoforms against GST-SMAD2 and GST-
SMAD3 
(A) In vitro kinase assay using recombinant human TGFbRIT204D (residues 200-501), MBP-SIK1 
(residues 2-783), GST-SIK2 (residues 2-926) and GST-SIK3 (residues 2-1369) protein kinases 
(200 ng kinase per reaction) and GST-SMAD2 (residues 1-467) (2 µg substrate per reaction). 
Kinase assay reactions were performed using 1x kinase assay buffer containing 0.1 mM 
[g32P]-ATP (500 cpm pmol-1) for 30 minutes at 30°C. Reactions were terminated via the 
addition of NuPAGE 4x LDS sample buffer containing 8% (v/v) 2-ME and incubation at 95°C 
for 5 minutes. Samples were resolved via SDS-PAGE and polyacrylamide gel subsequently 
stained with Coomassie protein stain before radioactivity was analysed by autoradiography. 
(B) In vitro kinase assay using recombinant human TGFbRIT204D (residues 200-501), MBP-SIK1 
(residues 2-783), GST-SIK2 (residues 2-926) and GST-SIK3 (residues 2-1369) protein kinases 
(200 ng kinase per reaction) and GST-SMAD3 (residues 1-425). Kinase reactions were 
conducted using the same experimental procedure as described above. (C) In vitro kinase 
assay using recombinant human TGFbRIT204D (residues 200-501), GST-SIK2 (residues 2-926) 
and GST-SIK3 (residues 2-1369) protein kinases (200 ng kinase per reaction) and GST-SMAD3 
(residues 1-425). In addition, either SB-505124 or HG-9-91-01 small-molecule kinase 
inhibitors (both at 1 µM concentration) were included as positive controls. Kinase reactions 
were conducted using the same experimental procedure as described previously. 
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Figure 3.2H. In vitro kinase assay analysis of recombinant SIK2 and SIK3 against SMAD3 
(A) The GST affinity tag was removed from recombinant GST-SMAD3 using PreScission 
Protease. Reaction was performed using 1:100 (weight) ratio of protease to substrate and 
incubated overnight at 4°C with continuous rotation. (B) In vitro kinase assay using 
recombinant human TGFbRIT204D (residues 200-501), GST-SIK2 (residues 2-926) and GST-SIK3 
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(residues 2-1369) protein kinases (200 ng kinase per reaction) and cleaved recombinant 
SMAD3 (residues 1-425). In addition, either SB-505124 or HG-9-91-01 small-molecule kinase 
inhibitors (both at 1 µM concentration) were included as positive controls. Kinase reactions 
were conducted using the same experimental procedure as described previously. 
 
 
3.2.6 MRT199665 does not affect the TGFb-dependent nuclear accumulation of SMAD2 or 
SMAD3 
The regulation of gene transcription mediated by TGFb is critically dependent on the nuclear 
accumulation of activated SMAD transcriptional complexes. The steady-state 
nucleocytoplasmic distribution of R-SMADs was initially considered to be static, with R-
SMADs residing exclusively in the cytoplasm in the absence of a signal and subsequently 
translocating into the nucleus upon detection of a TGFb signal. In contrast to this, SMAD4 is 
distributed equally between the cytoplasm and nucleus, undergoing rapid and constant 
nucleocytoplasmic shuttling even in the absence of a TGFb signal (Pierreux, Nicolás and Hill, 
2000). However, upon further investigation, evidence also suggested that R-SMADs are 
undergoing continuous nucleocytoplasmic shuttling and require sustained receptor activation 
in order to maintain them in nucleus and facilitate TGFb-dependent transcriptional regulation 
(Inman, Nicolás and Hill, 2002; Reguly and Wrana, 2003; Hill, 2009). As a result, the 
concentration of activated SMAD complexes present in the nucleus is dictated by the levels 
of activated receptor complexes in the cytoplasm (Inman, Nicolás and Hill, 2002). 
 Therefore, it was necessary to determine whether the MRT199665 compound was 
affecting SMAD nuclear translocation following TGFb stimulation, as this may account for the 
inhibition of TGFb-induced luciferase reporter activity observed in the previous experiments. 
Wild type U2OS osteosarcoma cells were incubated with either the TGFb type I receptor 
inhibitor SB-505124, the SIK inhibitor MRT199665 or an equivalent volume of DMSO and 
stimulated with recombinant human TGFb1 for 1 hour and subsequently fractionated into 
cytoplasmic and nuclear fractions. In DMSO control cells, phosphorylated SMAD2 and SMAD3 
were exclusively present in the nuclear fractions, with enhanced levels observed following 
TGFb stimulation (figure 3.2I). As expected, treatment of cells with SB-505124 dramatically 
reduced the levels of phosphorylated SMAD2 and SMAD3 in the nucleus following TGFb 
stimulation (figure 3.2I). Consistent with previous experiments, MRT199665 did not affect the 
level of receptor-mediated SMAD2 or SMAD3 phosphorylation. Furthermore, the nuclear 
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translocation of SMAD2 and SMAD3 in response to TGFb signals remained unaffected by 
treatment with MRT199665 (figure 3.2I). This data implied that the inhibitory effect of 
MRT199665 on TGFb-induced luciferase reporter activity occurred following nuclear 
accumulation, at the level of gene transcription. 
 
 
 
 
 
 
 
 
 
Figure 3.2I. MRT199665 does not affect the TGFb-induced nuclear translocation of SMAD2 
or SMAD3 
Wild type U2OS osteosarcoma cells were incubated with SB-505124 (1 µM), MRT199665 (1 
µM) or an equivalent volume of DMSO in the presence or absence of stimulation with 
recombinant human TGFb1 (5 ng mL-1) for 1 hour prior to cell lysis. Cell lysates were separated 
into cytoplasmic and nuclear fractions, resolved via SDS-PAGE and transferred to 
nitrocellulose membranes. Membranes were subsequently subjected to immunoblotting 
with the indicated antibodies. Alpha tubulin and lamin A/C were used as markers for 
cytoplasmic and nuclear fractions respectively. Immunoblots are representative of two 
independent experiments. 
 
 
3.2.7 Discussion 
In the previous section 3.1, I reported that the small-molecule inhibitor screen performed in 
the endogenous TGFb-dependent transcriptional reporter cell line resulted in the 
identification of HG-9-91-01, an ATP-competitive inhibitor of SIK isoforms, as a potential 
regulator of TGFb signalling. Therefore, in this section, the further characterisation of SIK 
inhibition in the context of TGFb signalling has been presented. 
 In addition to HG-9-91-01, MRT199665, another ATP-competitive small-molecule 
inhibitor that has been used to inhibit the catalytic activity of SIK isoforms was also utilised. 
Although HG-9-91-01 and MRT199665 are structurally unrelated inhibitors, they are capable 
of potently inhibiting SIKs in vitro (<100 nM IC50 values). Therefore, the effect of both of these 
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inhibitors on the endogenous TGFb transcriptional reporter cell line was subsequently 
analysed. Treatment of U2OS 2G transcriptional reporter cells with either HG-9-91-01 or 
MRT199665 resulted in the statistically significant attenuation of TGFb-dependent luciferase 
reporter activity. Subsequently, it was important to demonstrate that both HG-9-91-01 and 
MRT199665 were effectively inhibiting SIK isoforms in U2OS osteosarcoma cells at the 
concentrations that were employed. In order to do this, the phosphorylation status of the 
validated physiological SIK substrate CRTC3, a transcriptional co-activator involved in CREB-
dependent gene transcription, was therefore analysed. The incubation of U2OS cells with 
either HG-9-91-01 or MRT199665 promoted the dephosphorylation of CRTC3 at the SIK-
dependent phosphorylation site serine 370. Collectively, this data indicated that two 
structurally unrelated kinase inhibitors of SIKs were both capable of mediating the 
attenuation of the endogenous TGFb-dependent transcriptional reporter at concentrations 
that were effective at inhibiting SIK isoforms in cultured cells. However, one of the principal 
caveats of using small-molecule inhibitors in experimental research is that they are associated 
with the ‘off-target’ inhibition of protein kinases other than those for which they are intended 
to inhibit. As a consequence, it is vital to conduct experiments with the appropriate controls 
in order to avoid the erroneous interpretation of experimental data. Although in this section 
it has been demonstrated that two structurally unrelated kinase inhibitors exert the same 
effect on TGFb transcriptional reporter, the data is not sufficient to ascertain whether this is 
through inhibition of SIK isoforms. For example, although HG-9-91-01 is selective for SIK 
isoforms amongst the AMPK-related family of kinases, it is also capable of mediating the 
inhibition of other protein kinase such as discoidin domain-containing receptor 2 (DDR2), 
ephrin type A and type B receptors, fibroblast growth factor receptor 1 (FGFR1), receptor 
interacting serine/threonine-protein kinase 2 (RIPK2), protein-tyrosine kinase 6 (PTK6, 
otherwise referred to as breast tumour kinase; BRK) and tyrosine-protein kinase Yes (YES1). 
Moreover, in addition to mediating the inhibition of SIK isoforms, MRT199665 is also capable 
of potently inhibiting the AMPK catalytic subunits, the four MARK isoforms and NUAK1 in 
vitro. Consequently, the observation that HG-9-91-01 and MRT199665 can attenuate the 
TGFb-dependent induction of luciferase activity in the endogenous transcriptional reporter 
cell line may be a consequence of the ‘off-target’ inhibition of either the TGFb type I or type 
II serine-threonine receptor kinases. The data obtained from subsequent experiments 
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demonstrated that HG-9-91-01 is capable of completely abrogating the receptor-mediated 
phosphorylation of SMAD3 and is a potent inhibitor of the TGFb type I receptor ALK5 in vitro. 
Therefore, unfortunately, it was not possible to deploy HG-9-91-01 in any subsequent 
experiments involving TGFb signalling performed as part of this doctoral project. 
 Although MRT199665 did not inhibit the TGFb type I receptor nor affect SMAD2 and 
SMAD3 phosphorylation, another possible explanation for the consistent observation that 
MRT199665 attenuates TGFb-dependent luciferase reporter activity is that it may prevent the 
nuclear translocation of the TGFb-activated SMAD transcription factors SMAD2 and SMAD3. 
However, from the experiments presented in this section, it has been demonstrated that 
MRT199665 does not impede the ability of either SMAD2 or SMAD3 to translocate into the 
nucleus in response to TGFb stimulation. Therefore, the effect of MRT199665 appears to 
occur further downstream the signalling pathway, potentially at the level of transcriptional 
regulation. This may occur by either preventing the association of activated SMAD 
transcriptional complexes with regulatory DNA sequences or by interfering with the 
interaction of SMAD complexes with obligate transcriptional co-regulators. In future research, 
I aim to investigate whether incubation of cells with MRT199665 influences the ability of 
activated SMAD transcriptional complexes to associate with regulatory DNA sequences by 
conducting chromatin immunoprecipitation (ChIP) experiments. The ChIP assay would involve 
the immunoprecipitation of SMAD2 and SMAD3 from cell lysates following stimulation with 
recombinant TGFb and determining their ability to bind to regulatory sequences within the 
PAI-1 promoter region. 
 From the experiments presented thus far, it is important to state that the effect of 
MRT199665 on TGFb-induced transcriptional responses may well be the result of inhibition 
of protein kinases other than SIKs. The further validation of SIKs in the modulation of TGFb-
mediated transcriptional induction will be addressed in subsequent sections. 
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3.3 VALIDATION OF SIK INHIBITION AS A REGULATOR OF TGFb-INDUCED 
GENE TRANSCRIPTION 
 
3.3.1 Introduction 
The data presented in the preceding section demonstrated that the small-molecule kinase 
inhibitor MRT199665 is capable of attenuating the induction of the endogenous TGFb-
dependent luciferase reporter activity and moreover, this attenuation occurred without 
affecting receptor-mediated R-SMAD phosphorylation or the nuclear translocation of 
activated SMAD complexes. This therefore results in the hypothesis that the effect of the 
MRT199665 kinase inhibitor is transpiring further downstream the pathway at the level of 
transcriptional regulation, however as mentioned in the previous discussion section, future 
experiments are aimed to test this hypothesis. In this section, evidence is presented that 
demonstrates that the effect of MRT199665 is not restricted to the endogenous TGFb-
dependent transcriptional reporter cell line and that the inhibitor mediates the attenuation 
of TGFb-induced transcriptional upregulation of the physiological target gene PAI-1 in two 
different human cancer cell lines. Furthermore, the following data also indicates that 
MRT199665 attenuates the transcriptional induction of additional TGFb target genes, 
indicating that it is not a gene-dependent observation and may be prevalent in other TGFb-
mediated transcriptional responses. 
 
 
3.3.2 The small-molecule inhibitor MRT199665 suppresses TGFb-induced target gene 
expression 
The small-molecule inhibitor screen and subsequent validation experiments that were 
performed demonstrated that MRT199665 could efficiently attenuate the activity of an 
endogenous TGFb-dependent transcriptional reporter. Furthermore, this attenuation 
occurred in the absence of receptor kinase inhibition, diminished receptor-mediated 
phosphorylation of the intracellular mediators SMAD2 and SMAD3 or perturbation of SMAD 
nuclear translocation. The small-molecule inhibitor screen and initial validation experiments 
conducted employed an endpoint luciferase assay as the detection method. Bioluminescence 
is a frequently used detection technique in high-throughput screening (HTS) assays for 
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chemical biology and drug discovery applications (Thorne, Inglese and Auld, 2010). One of the 
principal advantages for the utilisation of luminescence-based assays is that, unlike 
fluorescence-based detection systems, they do not require excitation light energy. Therefore, 
they provide a sensitive assay detection technique with a high signal-to-background ratio. 
However, the main limitation of luminescence-based reporter assays in HTS is the potential 
for compounds to modulate the enzymatic activity of luciferase, resulting in experimental 
artefacts that can interfere with the interpretation of assay results (Thorne, Inglese and Auld, 
2010). In cell-based assays, the enzymatic activity of luciferase can be confounded by 
compounds that inhibit the luciferase enzyme, although the mode of action that results in 
enzyme inhibition can vary. For example, the compound resveratrol has been investigated for 
its apparent therapeutic potential as a cardioprotective, neuroprotective and 
chemopreventive agent, in addition to the observation that it can extend the lifespan of a 
number of model organisms (Baur and Sinclair, 2006). Despite this, the molecular mechanism 
and signalling networks by which resveratrol may mediate these potential therapeutic effects 
remain uncertain. Research employing luciferase-based reporter gene assays to identify 
molecular pathways regulated by resveratrol may be undermined by the reported 
observation that resveratrol can potently inhibit the enzymatic activity of firefly luciferase 
(Bakhtiarova et al., 2006). Furthermore, research has also demonstrated that firefly luciferase 
is susceptible to the phenomenon of ligand-induced protein stabilisation. Compounds that 
function as effective competitive inhibitors of firefly luciferase can reduce the rate of protein 
degradation in vivo, thereby resulting in an accumulation of the reporter enzyme and 
increased luminescence signal upon detection (Thompson, Hayes and Lloyd, 1991). 
Therefore, considering the potential for compounds to modulate the enzymatic activity of 
luciferase, one possible explanation for the attenuation of luciferase signal observed 
following treatment with MRT199665, is that the compound may be inhibiting the luciferase 
enzyme. As previously discussed, the endogenous TGFb-dependent transcriptional reporter 
cell line developed in the lab contained a dual-reporter cassette containing both firefly 
luciferase enzyme and GFP. Therefore, using this cell line, we tested whether the MRT199665 
compound also attenuated the protein expression of GFP following TGFb stimulation. U2OS 
2G transcriptional reporter cells were incubated with either DMSO, SB-505124 or MRT199665 
and stimulated with recombinant human TGFb1 (5 ng mL-1) for 6 hours. In DMSO control 
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treated cells, TGFb induced receptor-mediated phosphorylation of both SMAD2 and SMAD3, 
resulting in a concomitant induction of GFP protein expression (figure 3.3A-A). This induction 
was dependent on TGFb, as treatment with the TGFb type I receptor kinase inhibitor SB-
505124 abrogated both SMAD phosphorylation and GFP expression (figure 3.3A-A). 
Consistent with previous experiments, treatment of cells with MRT199665 did not affect the 
level of receptor-mediated SMAD2/SMAD3 phosphorylation in response to TGFb, however in 
these cells, the TGFb-mediated induction of GFP expression was completely prevented (figure 
3.3A-A). In addition, we investigated the effect of MRT199665 on the TGFb-induced 
expression of endogenous PAI-1 in wild type U2OS osteosarcoma cells. TGFb induces a 2-fold 
induction in the relative expression of PAI-1 mRNA and this induction is prevented when cells 
are treated with SB-505124 (figure 3.3A-B). Treatment of U2OS cells with MRT199665 
significantly attenuated both PAI-1 mRNA and protein expression in response to TGFb (figure 
3.3A-B). Importantly, this datum indicates that the effect of the MRT199665 small-molecule 
inhibitor on the endogenous TGFb-responsive luciferase reporter is not a consequence of the 
compound modulating the activity of the luciferase enzyme. Furthermore, it also provides 
further evidence to suggest that MRT199665 exerts it effect at the level of target gene 
transcription. 
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Figure 3.3A. MRT199665 attenuates the expression of TGFb-dependent target genes in 
multiple human cancer cell lines 
(A) U2OS 2G transcriptional reporter cells were incubated with SB-505124 or MRT199665 at 
the concentrations indicated, or an equivalent volume of DMSO and stimulated with 
recombinant human TGFb1 (5 ng mL-1) for 6 hours prior to cell lysis. Cell lysates (12 µg total 
protein) were resolved via SDS-PAGE and transferred to nitrocellulose membranes. The 
membranes were subsequently subjected to immunoblotting with the indicated antibodies. 
Immunoblot is representative of two independent experiments. (B) Wild-type U2OS human 
osteosarcoma cells were incubated with SB-505124 or MRT199665 (both inhibitors used at 1 
µM concentration), or an equivalent volume of DMSO and stimulated with recombinant 
human TGFb1 (5 ng mL-1) for 6 hours prior to lysis and RNA isolation. Complementary DNA 
(cDNA) was synthesised from the isolated RNA and RT-qPCR analysis performed for the 
indicated TGFb target gene. The statistical analysis was performed on data from three 
independent experiments. (C) Wild-type A-172 human glioblastoma cells were incubated with 
SB-505124 or MRT199665 (both inhibitors used at 1 µM concentration), or an equivalent 
volume of DMSO and stimulated with recombinant human TGFb1 (5 ng mL-1) for 6 hours prior 
to lysis and RNA isolation. Complementary DNA (cDNA) was synthesised from the isolated 
RNA and RT-qPCR analysis performed for the indicated TGFb target genes. Statistical analysis 
was performed on data obtained from three biological replicates. The experiment was 
conducted by Dr. Polyxeni Bozatzi. 
 
 
Subsequently, experiments were performed to investigate whether MRT199665 could 
abrogate TGFb-induced expression of PAI-1 within a different cellular context. Therefore, the 
A-172 human glioblastoma cell line, which have previously been employed by other research 
groups to interrogate TGFb signalling (Seystahl et al., 2015; Jun et al., 2017; Kit Leng Lui et al., 
2017) was utilised. The upregulation of PAI-1 expression was robustly upregulated in 
response to TGFb stimulation. Similar to U2OS osteosarcoma cells, the mRNA expression of 
PAI-1 increases 2-fold following 6 hours of incubation with recombinant human TGFb1 (figure 
3.3A-C). Consistent with the effect observed on TGFb-induced PAI-1 expression in U2OS cells, 
co-treatment of A-172 cells with 1 µM MRT199665 and TGFb1 for 6 hours also robustly 
attenuated PAI-1 mRNA expression induced by TGFb stimulation (figure 3.3A-C). 
 Furthermore, it was also important to ascertain whether or not the effect of 
MRT199665 on TGFb-dependent gene transcription was restricted to PAI-1 or could 
MRT199665 treatment also modulate the expression of other known TGFb target genes. 
Therefore, using the TGFb-responsive A-172 human glioblastoma cell line, the effect of 
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MRT199665 on the transcription of two other well-characterised TGFb target genes, SMAD7 
and connective tissue growth factor (CTGF), was investigated. As discussed in section 1.2.3, 
SMAD7 functions as an inhibitory SMAD protein to antagonise TGFβ signalling via numerous 
different mechanisms including competing with R-SMADs for binding to the activated TGFβ 
type I receptor, recruiting E3 ubiquitin protein ligases to the activated receptor complex to 
mediate its proteasomal degradation and also facilitating the dephosphorylation of the 
activated TGFβ type I receptor through recruitment of protein phosphatase 1 (PP1) (Kavsak 
et al., 2000; Shi et al., 2004; Valdimarsdottir et al., 2006). SMAD7 is a direct transcriptional 
target of SMAD-dependent TGFβ signalling (Nakao et al., 1997; Afrakhte et al., 1998; 
Nagarajan et al., 1999; Denissova et al., 2000) and thus functions in a negative feedback 
mechanism. Stimulation of A-172 glioblastoma cells with TGFb1 for 6 hours induced an 
approximately 3-fold induction in the mRNA expression of SMAD7 that was efficiently 
attenuated when cells were co-incubated with SB-505124 (figure 3.3A-C). As observed with 
TGFβ-mediated induction of PAI-1 mRNA expression, co-incubation with MRT199665 
attenuated TGFβ-induced transcriptional upregulation of SMAD7 (figure 3.3A-C). However, 
the attenuation of SMAD7 mRNA expression by MRT199665 only occurs partially in this cell 
line, in contrast to the near-complete attenuation observed for PAI-1 mRNA expression. 
 
 
3.3.3 Discussion 
The data presented in this section has demonstrated that the small-molecule kinase inhibitor 
MRT199665 is able to attenuate TGFβ-dependent transcription of multiple different target 
genes in two different human cancer cell lines. Although the observed transcriptional 
attenuation mediated by MRT199665 is experimentally robust, experiments involving the 
expression of inhibitor-resistant mutant SIK isoforms are required in order to ascertain that 
the observed effects are occurring through inhibition of the SIKs and not through the 
inhibition of other protein kinases. Experiments analysing the effect of other structurally 
unrelated small-molecule inhibitors of SIK isoforms are presented in the subsequent section 
3.5. 
 The observation that MRT199665 attenuates the transcription of three different TGFβ 
target genes (PAI-1, SMAD7 and CTGF) indicates the mechanism by which the MRT199665 
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compound exerts its suppressive effect may be similar across numerous TGFβ-mediated 
transcriptional responses. One of the principal means by which to test this hypothesis would 
be to conduct RNA sequencing (RNA-Seq) in order to analyse the entire transcriptome, and 
specifically the TGFβ-dependent transcriptome, in a particular cellular context. This would 
hopefully provide an insight into whether the effects of MRT199665 treatment are specific to 
a subset of TGFβ target genes or whether it is universal to TGFβ-dependent gene 
transcription. 
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3.4 GENETIC EVIDENCE FOR THE INVOLVEMENT OF SIK ISOFORMS IN THE 
MODULATION OF TGFβ SIGNALLING 
 
3.4.1 Introduction 
The data presented thus far in this thesis project has demonstrated that the small-molecule 
kinase inhibitor MRT199665 is capable of modulating the TGFβ-mediated transcriptional 
regulation of specific target genes in multiple human cancer cell lines. Although small-
molecule kinase inhibitors are invaluable experimental tools which can aid in deciphering the 
cellular functions of protein kinases, their use is accompanied with substantial limitations 
(discussed in further detail in the relevant sections), the principal of which is the ‘off-target’ 
inhibition of kinases other than those for which they are intended to inhibit. Consequently, in 
order to obtain robust data, it is imperative to demonstrate that any observed effects can be 
corroborated with alternative experimental means of inactivating the protein kinases of 
interest. Therefore, in the following section, evidence will be presented demonstrating the 
effect of modulating the upstream activating kinase of SIKs, RNAi-mediated depletion of SIK 
protein levels and the genetic inactivation of SIK isoforms on specific TGFβ-dependent 
transcriptional responses. 
 
 
3.4.2 Overexpression of catalytically active LKB1 potentiates the TGFβ-mediated 
induction of PAI-1 expression 
In order to provide genetic evidence for the function of SIK isoforms in the TGFβ pathway 
regulation, I utilised the HeLa human cervical adenocarcinoma cell line which do not express 
endogenous LKB1. As previously discussed, the serine-threonine protein kinase LKB1, in 
complex with its regulatory subunits STRADa/β and MO25a/β, functions as a master 
upstream regulatory kinase by phosphorylating and activating AMPK along with 12 members 
of the AMPK-related family including all three SIK isoforms (Hawley et al., 2003; Hong et al., 
2003; Woods et al., 2003; Lizcano et al., 2004; Shaw et al., 2004; Shackelford and Shaw, 2009). 
Therefore, normal HeLa cells which lack endogenous LKB1 expression have been extensively 
used in order to investigate the cellular functions of LKB1 and the downstream protein kinases 
that LKB1 activates. It has been proposed that the undetectable levels of LKB1 mRNA 
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observed in HeLa cells is a result of epigenetic inactivation caused by hypermethylation of the 
LKB1 promoter region (Tiainen, Ylikorkala and Mäkelä, 1999). Subsequent research also 
reported the occurrence of large homozygous deletions within the LKB1 gene locus of HeLa 
cells, resulting in the complete loss of full-length LKB1 mRNA transcript and protein 
expression (Wingo et al., 2009; McCabe et al., 2010). The loss of LKB1 expression in HeLa cells 
may contribute to the highly proliferative phenotype of these cells as expression of 
exogenous LKB1 exerted a growth suppressive effect (Tiainen, Ylikorkala and Mäkelä, 1999). 
Importantly for the purposes of this thesis project, in normal LKB1-deficient HeLa cells 
or in HeLa cells expressing a catalytically inactive form of LKB1, the kinase activities of SIK1, 
SIK2 (alternatively referred to as QIK) and SIK3 (alternatively referred to as QSK) were found 
to be significantly reduced (20- to 40-fold) compared with HeLa cells expressing wild-type 
LKB1 (Lizcano et al., 2004). In order to generate a catalytically inactive form of LKB1, the 
aspartic acid residue of the DFG motif was mutated to an alanine residue (D194A). The DFG 
motif is situated within the protein kinase domain and is involved in the coordination of an 
Mg2+ ion required for catalytic activity. Thus, mutation of the invariant aspartic acid to alanine 
disrupts this function and consequently renders LKB1 inactive (Guldberg et al., 1999; Sapkota 
et al., 2001; Boudeau et al., 2003, 2004; Woods et al., 2003; Lizcano et al., 2004; Shaw et al., 
2004; Scott et al., 2007; Fogarty and Hardie, 2009). 
 When normal LKB1-deficient HeLa cells were stimulated with recombinant human 
TGFβ1 for 6 hours, the mRNA expression of the target gene PAI-1 increased approximately 
1.5-fold compared with unstimulated control cells. However, the stable overexpression of 
wild-type LKB1 (LKB1WT) significantly enhanced the TGFβ-induced transcriptional 
upregulation of PAI-1 more than 7-fold compared with normal control HeLa cells (figure 3.4A-
A). Moreover, even when comparing unstimulated normal LKB1-deficient and LKB1WT HeLa 
cells, PAI-1 mRNA expression was substantially elevated by the restoration of LKB1 protein 
expression (figure 3.4A-A). Crucially, the exogenous expression of a catalytically inactive LKB1 
mutant (LKB1D194A) failed to enhance either basal or TGFβ-induced PAI-1 transcript levels 
(figure 3.4A-A). Indeed, PAI-1 mRNA expression levels were virtually identical between 
normal LKB1-deficient HeLa cells and those expressing the kinase inactive LKB1D194A form 
(figure 3.4A-A). Furthermore, the observations at the transcript level were reiterated at the 
level of protein expression. PAI-1 protein expression was undetectable by immunoblotting in 
normal LKB1-deficient cells, even in the presence of TGFβ stimulation (figure 3.4A-B). By 
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contrast, basal levels of PAI-1 protein were weakly detected in LKB1WT HeLa cells and 
stimulation of these cells with TGFβ substantially enhanced PAI-1 protein expression. As 
observed with mRNA expression, the kinase inactive LKB1D194A mutant was incapable of 
enhancing either basal or TGFβ-induced PAI-1 expression (figure 3.4A-B). 
Thus, this data provides initial genetic evidence that the protein kinase activity of SIK 
isoforms are involved in the modulation of TGFβ-dependent transcriptional regulation of the 
target gene PAI-1. However, there remains a number of additional crucial experiments to be 
conducted using these cell lines. Firstly, it would be important to demonstrate that the 
enhanced mRNA and protein expression of PAI-1 observed in the LKB1WT HeLa cells could be 
attenuated by the incubation of these cells with the small-molecule kinase inhibitor of SIK 
isoforms MRT199665. Additionally, it would also be imperative to demonstrate that SIK 
catalytic activity is abrogated in the normal LKB1-deficient HeLa cells and the HeLa cells 
expressing the LKB1D194A kinase inactive mutant. One would predict that the phosphorylation 
of the physiological SIK substrate CRTC3 at serine 370 is substantially reduced, and that this 
phosphorylation is enhanced upon the stable overexpression of LKB1WT. Moreover, it would 
also be interesting to analyse other TGFβ target genes in this context and to investigate TGFβ-
dependent gene transcription in the context of LKB1-deficient MEF cell lines, which have 
previously been generated (Clark et al., 2012). 
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Figure 3.4A. The overexpression of wild type LKB1 potentiates the TGFβ-dependent 
transcriptional induction of PAI-1 
(A) Wild type HeLa human cervical adenocarcinoma cells and HeLa cells stably overexpressing 
either LKB1WT or catalytically inactive LKB1D194A were stimulated with recombinant human 
TGFb1 (5 ng mL-1) for 6 hours prior to lysis and RNA isolation. Complementary DNA (cDNA) 
was synthesised from the isolated RNA and RT-qPCR analysis performed for the indicated 
TGFb target gene (PAI-1). (B) Wild type HeLa human cervical adenocarcinoma cells and HeLa 
cells stably overexpressing either LKB1WT or catalytically inactive LKB1D194A were stimulated 
with recombinant human TGFb1 (5 ng mL-1) for 8 hours prior to cell lysis. Cell lysates (10 µg 
total protein) were resolved via SDS-PAGE and transferred to nitrocellulose blotting 
membranes. The membranes were subsequently subjected to immunoblotting with the 
indicated antibodies. Immunoblot is representative of two independent experiments. 
 
 
 
3.4.3 The RNAi-mediated depletion of SIK isoforms attenuates TGFβ-mediated 
upregulation of PAI-1 expression 
To determine whether the modulation of TGFβ-induced PAI-1 expression was occurring 
through the SIKs, the protein expression of SIK isoforms was suppressed both individually and 
in combination using short interfering RNA (siRNA)-mediated gene silencing technology 
(Meister and Tuschl, 2004; Carthew and Sontheimer, 2009). The siRNA-mediated depletion of 
either SIK1 or SIK2 protein expression resulted in a partial reduction of TGFβ-induced PAI-1 
protein expression compared to the expression levels observed in untransfected, transfection 
reagent control (RM; RNAiMAX) or non-targeting (NT) siRNA control cells (figure 3.4B-A). It is 
important to note that although the efficacy of SIK2 and SIK3 depletion could be analysed via 
immunodetection, due to the unavailability of an antibody that reliably detects endogenous 
human or murine SIK1, it was not possible to demonstrate the efficacy of SIK1 knockdown by 
immunoblotting. The depletion of the SIK3 isoform, either individually or in combination with 
SIK1 and SIK2, resulted in an even more pronounced suppression of TGFβ-mediated 
transcriptional upregulation of PAI-1 expression compared to control cell expression levels 
(figure 3.4B-A). This suggests that all three isoforms of SIKs may contribute to the 
transcriptional induction of PAI-1 expression in response to TGFβ stimulation. 
 Upon further investigation of SIK3 protein depletion, we observed that an almost 
complete silencing of SIK3 is required in order to observe the attenuation of TGFβ-
upregulated PAI-1 expression (figure 3.4B-B). In cells in which the siRNA-mediated depletion 
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was only partial, the residual amount of SIK3 protein still present appeared to be sufficient to 
enable the equivalent PAI-1 upregulation as observed in control cells. Due to the 
inconsistencies in the efficacy of siRNA-mediated gene silencing of SIK isoforms, it was 
decided to focus upon alternative and more robust experimental methods of disrupting SIK 
function via genetic inactivation of kinase activity discussed in the subsequent section 3.4.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4B. The effect of RNAi-mediated silencing of SIK isoforms on TGFβ-dependent 
induction of PAI-1 expression 
(A) U2OS human osteosarcoma cells were transiently transfected with either non-targeting 
(NT) siRNA oligonucleotide or siRNA oligonucleotide pools targeting the three SIK isoforms. 
Untransfected cells or cells transfection with only the lipid transfection reagent were included 
as experimental controls. Cells were incubated in the absence or presence of recombinant 
human TGFβ1 (5 ng mL-1) for 8 hours prior to cell lysis. Cell lysates (12 µg total protein) were 
resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. The membranes 
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were subsequently subjected to immunoblotting with the indicated antibodies. Immunoblot 
is representative of three independent experiments. (B) U2OS osteosarcoma cells were 
transiently transfected with either non-targeting (NT) siRNA oligonucleotide or siRNA 
oligonucleotide pools targeting the SIK3 isoform. Cells were subsequently incubated in the 
absence or presence of recombinant human TGFβ1 (5 ng mL-1) for 8 hours prior to cell lysis. 
Cell lysates (12 µg total protein) were resolved via SDS-PAGE and transferred to nitrocellulose 
blotting membranes. The membranes were subsequently subjected to immunoblotting with 
the indicated antibodies. Immunoblot is representative of two independent experiments. 
 
 
3.4.4 The genetic inactivation of SIK isoforms attenuates TGFβ-mediated transcriptional 
induction of PAI-1 
In order to further establish the potential role of SIK isoforms in TGFb signal transduction, the 
TGFb-mediated transcriptional induction of the target gene PAI-1 was analysed in mouse 
embryonic fibroblasts (MEFs) in which the wild type SIK2 and SIK3 proteins were replaced 
with catalytically inactive knock-in (KI) mutant forms. The development of the kinase inactive 
SIK KI mice was conducted by the research groups of Prof. Philip Cohen and Prof. Simon Arthur 
(respectively located in the MRC Protein Phosphorylation and Ubiquitylation Unit, and the 
Division of Cell Signalling and Immunology, both within the School of Life Sciences at the 
University of Dundee). The generation of primary MEF cell lines from the murine embryos 
was performed by Dr. Nicola J. Darling (P. Cohen research group). The constitutive kinase 
inactive SIK KI mice were created by conventional gene targeting technologies in the 
C57BL/6NTac genetic background by Taconic Biosciences. Targeting vectors were designed to 
introduce the required point mutation within the genomic locus of the relevant SIK isoform 
via homologous recombination (HR) in murine embryonic stem (ES) cells. Further information 
regarding the targeting strategy, design of targeting vectors and validation is available in the 
following publication (Darling et al., 2017). 
 Firstly, it was important to determine that the TGFb-mediated transcriptional 
upregulation of PAI-1 occurred in MEF cells. Therefore, wild-type MEFs were stimulated with 
recombinant human TGFb1 for different durations over a period of 24 hours and PAI-1 protein 
expression analysed via immunoblotting. As demonstrated in figure 3.4C-A, basal levels of 
PAI-1 protein is virtually undetectable via immunoblotting, however upon TGFb stimulation, 
the expression of PAI-1 is robustly upregulated, with the highest protein expression detection 
after 12 hours of stimulation. Thus, MEF cells are amenable to TGFb-mediated transcriptional 
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induction of the target gene PAI-1 and therefore the impact of genetic inactivation of SIK 
isoforms on this transcriptional response was subsequently investigated. 
 As described in the preceding section, the SIKs, along with AMPK and other members 
of the AMPK-related family of kinases, are activated by LKB1-mediated phosphorylation of 
the conserved threonine residue within the activation loop (Lizcano et al., 2004; Jaleel et al., 
2005) (figure 3.4C-B). Therefore, this residue was selected for mutation to an alanine residue 
as it is essential for the catalytic activity of SIKs (Lizcano et al., 2004). The mice harbouring 
homozygous SIK1T182A and SIK2T175A genotypes were viable and fertile, and phenotypically 
indistinguishable from wild type mice whereas homozygous SIK3T163A mice presented at sub-
Mendelian ratios and were on average smaller compared with wild type or heterozygous 
counterparts. In addition to the generation of individual SIK KI mice, SIK1/SIK2 and SIK2/SIK3 
double KI mice were also generated. As observed with SIK1 KI and SIK2 KI mice, homozygous 
SIK1/SIK2 KI mice were viable, fertile and indistinguishable from wild type. By contrast, 
homozygous SIK2/SIK3 KI was embryonically lethal, with lethality occurring after day E15.5 of 
gestation (Darling et al., 2017). 
 Immunoprecipitation of each endogenous SIK isoform from tissue derived from the 
corresponding KI mice demonstrated that the kinase activity of each SIK isoform was 
completely ablated by the threonine to alanine mutation (Darling et al., 2017). Subsequently, 
it was demonstrated that the phosphorylation of CRTC3 at serine 370 was substantially 
reduced in MEFs derived from SIK2/SIK3 double KI embryos compared with wild type MEFs 
(figure 3.4C-C), confirming that the kinase activity of SIK2 and SIK3 was abrogated in this cell 
line. 
 The TGFb-mediated transcriptional induction of PAI-1 was then analysed between 
wild type and SIK2T175A/SIK3T163A MEF cell lines. Stimulation of wild type MEFs with 
recombinant TGFb1 for 6 hours resulted in the robust upregulation of PAI-1 protein expression 
(figure 3.4C-D). In contrast, the TGFb-mediated upregulation of PAI-1 expression was 
substantially attenuated in SIK2T175A/SIK3T163A MEFs (figure 3.4C-D). This attenuation occurred 
despite the observation of elevated levels of receptor-mediated SMAD3 phosphorylation in 
the SIK2T175A/SIK3T163A MEFs compared with wild type control cells (figure 3.4C-D). Likewise, 
the attenuation of PAI-1 expression was also observed at the mRNA level. Stimulation of wild 
type MEFs with TGFb resulted in a 40-fold increase in PAI-1 mRNA levels whereas the TGFb-
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mediated PAI-1 induction was significantly suppressed in two independent SIK2T175A/SIK3T163A 
MEF cell lines, with approximately 5-fold and 15-fold inductions in PAI-1 mRNA expression 
observed respectively (figure 3.4C-E). 
 This data therefore provides genetic evidence for the role of SIK isoforms in 
modulating the TGFb-mediated transcriptional induction of the target gene PAI-1, supporting 
the observations detailed previously involving the small-molecule kinase inhibitor 
MRT199665 and siRNA-mediated SIK2/SIK3 depletion. However, there are a number of 
outstanding questions to be addressed in future research. Firstly, is the transcriptional 
upregulation of other TGFb target genes in MEFs also influenced by the genetic inactivation 
of SIK2 and SIK3? Secondly, can the attenuation of PAI-1 transcription be rescued via the 
reintroduction of catalytically active SIK2 and SIK3 kinases? It would be also be interesting to 
further analyse individual SIK KI cell lines in order to ascertain whether all three isoforms 
contribute to the modulation of TGFb transcriptional responses or whether it is specific to 
certain isoforms. 
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Figure 3.4C. The TGFb-mediated transcriptional induction of PAI-1 is attenuated in MEFs 
derived from mouse embryos with genetically inactivated SIK2 and SIK3 
(A) Wild type mouse embryonic fibroblasts (MEFs) were stimulated with recombinant human 
TGFb1 (5 ng mL-1) for the durations indicated prior to cell lysis. Cell lysates (12 µg total protein) 
were resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. The 
membranes were subsequently analysed via immunoblotting with the indicated antibodies. 
(B) The serine-threonine protein kinase LKB1, in complex with its regulatory subunits 
STRADa/b and MO25a/b, phosphorylates the invariant activation loop threonine residue of 
AMPK and 12 members of the AMPK-related family of protein kinases. Multiple protein 
sequence alignment was performed in Jalview (version 2.10.5) software (Waterhouse et al., 
2009) using the Clustal Omega sequence alignment programme. Highly conserved amino acid 
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residues are indicated by dark blue shading. (C) Cell lysate samples (800 µg total protein) 
obtained from either wild-type MEFs or SIK2T175A/SIK3T163A MEFs were subjected to 
immunoprecipitation of endogenous CRTC3 using anti-CRTC3 polyclonal sheep IgG 
conjugated to Protein G Agarose resin. Following elution from the antibody-resin, total cell 
lysate (20 µg protein) and IP samples were resolved via SDS-PAGE and transferred to 
nitrocellulose blotting membranes. The membranes were subsequently analysed via 
immunoblotting using the indicated antibodies. (D) Wild type and SIK2T175A/SIK3T163A MEFs 
were either unstimulated or stimulated with recombinant human TGFb1 (5 ng mL-1) for 6 
hours prior to cell lysis. Cell lysate samples (12 µg total protein) were resolved via SDS-PAGE 
and transferred to nitrocellulose blotting membranes. The membranes were subsequently 
analysed via immunoblotting with the indicated antibodies. Immunoblot is representative of 
three independent experiments. (E) Wild type and two independent SIK2T175A/SIK3T163A MEF 
cell lines were either unstimulated or stimulated with recombinant TGFb1 (5 ng mL-1) for 6 
hours prior to lysis and RNA isolation. Complementary DNA (cDNA) was synthesised from the 
isolated RNA and RT-qPCR analysis performed for the indicated TGFb target gene (PAI-1). 
Statistical analysis was performed on data obtained from three biological replicates. 
 
 
3.4.5 Discussion 
In the preceding sections 3.2 and 3.3, evidence for the involvement of SIK isoforms in 
regulating TGFb-dependent transcriptional responses was presented involving the use of the 
small-molecule SIK inhibitor MRT199665. In this section, experiments involving alternative 
methods of disrupting SIK function have been presented that provide more robust evidence 
for the potential novel role of SIKs in TGFb signalling. 
 Firstly, the TGFb-induced transcription of the target gene PAI-1 was analysed in HeLa 
human cervical adenocarcinoma cells, which lack the endogenous expression of the serine-
threonine protein kinase LKB1. LKB1 has been identified as the upstream activating kinase of 
SIK isoforms, along with AMPK and other members of the AMPK-related family (Lizcano et al., 
2004). In HeLa cells stably overexpressing wild type LKB1, both the basal and TGFb-induced 
expression of PAI-1 mRNA and protein were significantly enhanced compared with the levels 
observed in normal HeLa cells. Importantly, the stable overexpression of a kinase inactive 
form of LKB1 (LKB1D194A) failed to mediate the same effect. This therefore provides further 
evidence for the role of SIKs, however it does not exclude the involvement of protein kinases 
which as with the SIKs, are activated by LKB1 and inhibited by the MRT199665 compound, 
such as the four MARK isoforms (Lizcano et al., 2004; Clark et al., 2012). 
 Therefore, in order to further validate that the observed effects on TGFb-mediated 
transcription were occurring through inhibition of the SIKs, experiments were performed in 
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which the protein levels were depletion via RNAi. An important point to state is that, in 
agreement with previous published research, I was unable to identify an antibody that could 
reliably immunodetect endogenous human or murine SIK1. Therefore, it was not possible to 
determine the efficacy of siRNA-mediated depletion of SIK1 protein expression via 
immunoblotting. In cells in which SIK2 and SIK3 protein levels were virtually undetectable by 
immunoblotting, the TGFb-induced upregulation of PAI-1 protein expression appeared to be 
attenuated. However, in cells in which there was only a partial depletion of SIK protein 
expression, PAI-1 expression was comparable to the level observed in control cells. This 
indicated that the virtually complete depletion of SIK protein levels is required in order to 
observe the attenuation of TGFb-induced PAI-1 expression. Despite this, the efficiency of 
siRNA-mediated protein depletion of SIK2 and SIK3 isoforms was inconsistent between 
independent experiments and thus an unreliable method by which to disrupt SIK function. 
 In order to investigate TGFb-mediated transcription using a more robust experimental 
approach, we analysed the ability of TGFb to induce PAI-1 expression in MEFs in which SIK2 
and SIK3 isoforms had been genetically inactivated. In this context, the ability of TGFb 
stimulation to induce the expression of PAI-1 of significantly impaired compared with control 
wild type MEFs. An important subsequent experiment to perform would be to express wild 
type SIK2 and SIK3 proteins in these cells and ascertain whether that is sufficient to restore 
the ability of TGFb to upregulate PAI-1 expression. In addition, analysing TGFb-mediated 
transcription in MEF cell lines in which the individual SIK isoforms have been genetically 
inactivated would facilitate in ascertaining whether the observed effects are mediated by 
specific SIK isoforms or whether there is redundancy. 
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3.5 THE CLINICALLY APPROVED SMALL-MOLECULE INHIBITORS BOSUTINIB 
AND DASATINIB INHIBIT SIK ISOFORMS AND REGULATE TGFβ SIGNALLING 
 
3.5.1 Introduction 
One of the principal recommendations when utilising small-molecule protein kinase inhibitors 
to interrogate cellular signalling pathways is to ensure that the effect observed occurs at a 
concentration similar to that which prevents the phosphorylation of a previously identified 
and validated physiological substrate of the protein kinase being investigated (Davies et al., 
2000; Cohen, 2009). Therefore, the small-molecule inhibitors utilised throughout this thesis 
to inhibit SIK isoforms were always tested in each different cell line employed to ensure they 
effectively prevented the phosphorylation of the bona fide SIK substrate CRTC3 (Clark et al., 
2012; MacKenzie et al., 2013; Lombardi et al., 2016b, 2017; Heap et al., 2017) at the 
concentrations used. Furthermore, it is also important to ensure that the observed effect also 
occurs with at least two structurally unrelated chemical inhibitors (Davies et al., 2000). As 
previously mentioned, the compounds HG-9-91-01 and MRT199665 are structurally distinct 
small-molecule inhibitors of SIK isoforms. However, unfortunately it was not possible to 
employ HG-9-91-01 throughout this thesis due to its off-target inhibition of the type I TGFβ 
receptor kinase. Interestingly, research has reported that the clinically approved small-
molecule protein kinase inhibitors bosutinib and dasatinib are both capable of mediating the 
off-target inhibition of SIK isoforms (Sundberg et al., 2014; Ozanne, Prescott and Clark, 2015) 
and therefore we decided to analyse whether both of these compounds exerted the same 
effect on TGFβ-dependent gene transcription as observed with MRT199665. 
 Bosutinib (Boschelli et al., 2001; Golas et al., 2003, 2005; Vultur et al., 2008; Remsing 
Rix et al., 2009) and dasatinib (Lombardo et al., 2004; Das et al., 2006) are both second-
generation, ATP-competitive tyrosine kinase inhibitors (TKIs) (Weisberg et al., 2007; Zhang, 
Yang and Gray, 2009). Bosutinib has been clinically approved by the US FDA (Food and Drug 
Administration) and EU European Medicines Agency (EMA) for the treatment of adult patients 
with chronic-phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia 
(CML) that is resistant or intolerant to imatinib treatment (Cortes et al., 2011; Trela, Glowacki 
and Błasiak, 2014; Rosti et al., 2017). Dasatinib has also been clinically approved for the 
treatment of patients with imatinib-resistant or imatinib-intolerant chronic-phase Ph+ CML 
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in addition to Ph+ acute lymphoblastic leukaemia (ALL) resistant or intolerant to imatinib 
treatment (McFarland and Wetzstein, 2009; Kantarjian et al., 2010; Keating, 2017; Rosti et al., 
2017). 
 The ability of both bosutinib and dasatinib to inhibit SIK isoforms was initially reported 
in a pharmacological screen aimed at identifying well-characterised small-molecule kinase 
inhibitors that could enhance the production of the anti-inflammatory interleukin-10 (IL-10) 
in murine bone-marrow-derived dendritic cells (BMDCs) (Sundberg et al., 2014). Genetic 
perturbations that result in defective IL-10 signalling have been associated with the 
pathogenesis of inflammatory bowel disease (IBD) (Khor, Gardet and Xavier, 2011). IBD is a 
heterogenous group of idiopathic, chronic and relapsing inflammatory conditions of the 
gastrointestinal tract, the two most common forms of which are Crohn’s disease and 
ulcerative colitis (UC) (Podolsky, 1991; Xavier and Podolsky, 2007). Genetic-linkage analysis 
and genome-wide association studies (GWAS) have identified mutations and single-
nucleotide polymorphisms (SNPs) in genetic loci containing the IL10 gene and the genes for 
its cognate receptor subunits IL10RA and IL10RB that are associated with an increased risk of 
developing Crohn’s disease and UC (Glocker et al., 2009; Jostins et al., 2012). Clinical trials 
have demonstrated that administration of recombinant human IL-10 is safe and well-
tolerated in patients. However, the majority of clinical studies to date have demonstrated 
only a non-significant clinical improvement following recombinant IL-10 treatment and have 
not observed any significant increase in the induction of clinical remission rates compared 
with placebo control treatments (Schreiber et al., 2000; Marlow, van Gent and Ferguson, 
2013). Therefore, research conducted by Sundberg et al (2014) aimed to identify FDA-
approved small-molecule kinase inhibitors which enhance endogenous IL-10 production and 
therefore could be a potential therapeutic approach for the treatment of patients with IBD. 
Bosutinib and dasatinib were amongst the most potent and active compounds that 
enhanced IL-10 production in BMDCs. However, the clinically approved TKI imatinib, which 
like bosutinib and dasatinib targets the ABL tyrosine kinase and is the first-line treatment for 
patients with Ph+ CML or ALL (Trela, Glowacki and Błasiak, 2014), was unable to upregulate 
IL-10 production. This suggested that the IL-10-potentiating effect of bosutinib and dasatinib 
were the result of shared off-target inhibition of other protein kinases. Subsequent analysis 
revealed that SIK isoforms (specifically SIK1 and SIK2) were enriched amongst the high-affinity 
targets of the IL-10-enhancing kinase inhibitors. Furthermore, treatment of BMDCs with 
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increasing concentrations of bosutinib resulted in a dose-dependent decrease in the 
phosphorylation of CRTC3 at the SIK-specific serine 370 (S370) residue. Importantly, short 
hairpin RNA (shRNA)-mediated depletion of endogenous CRTC3 protein expression abrogated 
the ability of both bosutinib and dasatinib to enhance IL-10 production in BMDCs. Collectively, 
the data from this research demonstrated that the clinically approved small-molecule kinase 
inhibitors bosutinib and dasatinib could enhance the production of the anti-inflammatory 
cytokine as a consequence of inhibiting SIK isoforms (Sundberg et al., 2014). 
 
 In vitro IC50 (nM) 
TKI SIK1 SIK2 SIK3 
Bosutinib < 3 < 3 18 
Dasatinib < 3 < 3 10 
Erlotinib - 1600 4000 
Gefitinib - 800 3800 
Imatinib - > 100,000 > 100,000 
Lapatinib - > 100,000 > 100,000 
Sorafenib - > 100,000 > 100,000 
Sunitinib - 400 11,000 
Vandetinib 370 120 740 
 
Table 6. The in vitro IC50 values for nine clinically approved small-molecule tyrosine kinase 
inhibitors (TKIs) against the three SIK isoforms 
The in vitro IC50 (nM) values were determined for nine small-molecule tyrosine kinase 
inhibitors (TKIs) against purified recombinant SIK1, SIK2 and SIK3 serine-threonine protein 
kinases. The data was obtained from (Ozanne, Prescott and Clark, 2015) and the in vitro IC50 
determination was performed as described in (Hastie, McLauchlan and Cohen, 2006) by the 
inhibitor screening team at the MRC International Centre for Kinase Profiling 
(http://www.kinase-screen.mrc.ac.uk). 
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3.5.2 Bosutinib and dasatinib are potent inhibitors of SIK isoforms in vitro and in cultured 
cell lines 
Bosutinib and dasatinib are both type 1 kinase inhibitors that interact with the highly 
conserved nucleotide-binding site of protein kinases through the formation of hydrogen 
bonds and hydrophobic interactions with residues in and around the region occupied by the 
adenine ring of ATP (Liu and Gray, 2006). Type 1 inhibitors constitute the majority of ATP-
competitive kinase inhibitors and function by targeting the active conformation of the protein 
kinase in which the activation loop is phosphorylated (i.e. the conformation that is conducive 
to catalysing ATP phosphate transfer) (Liu and Gray, 2006; Zhang, Yang and Gray, 2009). By 
contrast, type 2 kinase inhibitors such as imatinib recognise the catalytically inactive 
conformation of the protein kinase in which the highly conserved tripeptide Asp-Phe-Gly 
(DFG) motif within the activation loop is folded away from the conformation required for ATP 
phosphotransfer (often referred to as the ‘DFG-out’ conformation) (Müller et al., 2015). The 
DFG-out inactive conformation creates an additional hydrophobic pocket directly adjacent to 
the ATP binding site, frequently referred to as the allosteric binding site (Treiber and Shah, 
2013). Consequently, type 2 kinase inhibitors interact with both the ATP binding site and form 
additional hydrophobic and hydrogen bonding interactions with residues in the allosteric 
binding site. It is proposed that type 2 inhibitors may exhibit higher kinase selectivity because 
the amino acid residues comprising the allosteric binding site are less conserved relative to 
those that form the ATP binding site (Liu and Gray, 2006). Thus, the ability of the activation 
loop of protein kinases to adopt distinctive inactive DFG-out conformations can facilitate the 
development of type 2 inhibitors with greater target selectivity (Schindler et al., 2000). 
 In addition to inhibiting the constitutively active kinase domain of the BCR-ABL 
oncoprotein, bosutinib and dasatinib are potent inhibitors of multiple other protein tyrosine 
kinases including members of the Src family (Src, FGR, FYN, HCK, LCK, LYN and YES (Parsons 
and Parsons, 2004)), tyrosine-protein kinase BTK (also referred to as Bruton’s tyrosine kinase), 
ephrin type-B receptor 4 (EPHB4), Mast/stem cell growth factor receptor KIT and platelet-
derived growth factor receptor (PDGFR) (Das et al., 2006; Bantscheff et al., 2007; Weisberg et 
al., 2007; Rosti et al., 2017). 
 SIKs are unique amongst the AMPK-related family of serine-threonine protein kinases 
in that they possess a small threonine residue at the so termed ‘gatekeeper position’ at the 
periphery of the nucleotide-binding region within the catalytic domain. This is in contrast with 
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all the other members of the AMPK-related family which possess large hydrophobic 
gatekeeper residues. In the context of small-molecule kinase inhibitors, the importance of the 
gatekeeper residue is demonstrated by the observation that one of the most frequent point 
mutations identified in patients which develop imatinib-resistant CML involves mutation of 
the threonine 315 residue at the gatekeeper position (Quintás-Cardama, Kantarjian and 
Cortes, 2007; Weisberg et al., 2007). The substitution of threonine 315 to a hydrophobic 
isoleucine residue (T315I) in the ABL catalytic domain abrogates an important hydrogen bond 
interaction between imatinib and BCR-ABL, resulting in imatinib resistance (Gorre et al., 2001; 
Azam et al., 2008). Therefore, it was hypothesised that various clinically-approved small-
molecule TKIs including bosutinib and dasatinib may also be able to inhibit SIK isoforms due 
to the presence of the small threonine gatekeeper residue (Ozanne, Prescott and Clark, 2015). 
Consistent with the previously published research, kinase inhibitor profiling performed by the 
MRC International Centre for Kinase Profiling at the University of Dundee confirmed that both 
bosutinib and dasatinib are potent inhibitors of SIK isoforms in vitro, with comparable IC50 
values to the clinically relevant target protein tyrosine kinases ABL, BTK and Src (figure 3.5A-
B). Furthermore, bosutinib and dasatinib selectively inhibited SIK isoforms over other AMPK-
related family members. Dasatinib in particular displays high selectivity towards SIK2 and SIK3 
compared with all the other members of the AMPK-related family that were tested. Bosutinib 
appeared to be less selective than dasatinib, as it displayed inhibition of AMPK, MARK3 and 
NUAK1 protein kinases (table 7). However, it was substantially more potent towards SIK2 and 
SIK3. Importantly, neither bosutinib nor dasatinib exhibited any substantial inhibition of the 
type I TGFβ receptor kinase (TGFβR1) in vitro and were therefore considered suitable for use 
in this thesis. 
Therefore, it was subsequently tested whether bosutinib and dasatinib could 
effectively inhibit SIKs in cultured U2OS osteosarcoma cells. As a positive control, wild type 
U2OS cells were incubated with MRT199665 at 1 µM for 1 hour, which as expected inhibited 
the phosphorylation of the physiological SIK substrate CRTC3 at serine 370 (figure 3.5A-C). 
Incubation of U2OS cells with either bosutinib (3.0 µM) or dasatinib (0.3 µM) also resulted in 
a substantial reduction in CRTC3 serine 370 phosphorylation, with levels comparable to those 
observed with MRT199665 treatment (figure 3.5A-C). This data confirmed that both bosutinib 
and dasatinib were capable of inhibiting SIK isoforms under these experimental conditions 
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and in this cellular context and therefore we decided to investigate the effect of these two 
small-molecule kinase inhibitors on TGFβ signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5A. Bosutinib and dasatinib are potent small-molecule inhibitors of SIK isoforms in 
vitro and cultured human U2OS osteosarcoma cells 
(A) The chemical structures of the small-molecule tyrosine kinase inhibitors (TKIs) bosutinib 
and dasatinib. Molecular structures were created using ChemDraw Professional software 
(version 17.0) (PerkinElmer). (B) In vitro IC50 (nM) values for bosutinib and dasatinib against 
the clinically-relevant protein tyrosine kinases ABL, BTK and Src in addition to the three SIK 
serine-threonine protein kinases. The data was obtained from (Ozanne, Prescott and Clark, 
2015) and the in vitro IC50 determination for bosutinib and dasatinib was performed by the 
inhibitor screening team at the MRC International Centre for Kinase Profiling 
(http://www.kinase-screen.mrc.ac.uk). (C) Wild type U2OS osteosarcoma cells were 
incubated with MRT199665 (1 µM), bosutinib (3.0 µM), dasatinib (0.3 µM) or an equivalent 
volume of DMSO for 1 hour prior to cell lysis. Cell lysate samples (800 µg total protein) were 
subjected to immunoprecipitation of endogenous CRTC3 using anti-CRTC3 polyclonal sheep 
IgG conjugated to Protein G Agarose resin. Following elution from the antibody-resin, total 
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cell lysate (20 µg protein) and IP samples were resolved via SDS-PAGE and subsequently 
transferred to nitrocellulose blotting membranes. The membranes were subjected to 
immunoblotting using the indicated antibodies. 
 
 
3.5.3 Bosutinib and dasatinib both negatively regulate TGFβ-dependent gene 
transcription 
As a result of the aforementioned research in which bosutinib and dasatinib were found to 
be potent small-molecule inhibitors of the SIK isoforms, it was decided to investigate whether 
they could recapitulate the effects of MRT199665 on TGFβ-dependent gene transcription. 
Similar to treatment with MRT199665, incubation of U2OS 2G transcriptional reporter cells 
with either bosutinib or dasatinib efficiently impaired the ability of TGFβ to induce the 
expression of GFP. Furthermore, treatment of wild type U2OS osteosarcoma cells with either 
bosutinib or dasatinib attenuated the TGFβ-dependent upregulation of the endogenous 
target gene PAI-1. As with MRT199665 treatment, the effect of bosutinib and dasatinib on 
TGFβ-dependent gene transcription appears to occur downstream of receptor-mediated 
phosphorylation of TGFβ-activated R-SMADs. Incubation of cells with either of the two small-
molecule inhibitors did not substantially impact upon the phosphorylation of SMAD3 in 
response to TGFβ stimulation. 
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Figure 3.5B. The clinically approved small-molecule kinase inhibitors bosutinib and 
dasatinib both abrogate TGFb-induced gene transcription in U2OS osteosarcoma cells 
(A) U2OS 2G transcriptional reporter cells were incubated with SB-505124 (1 µM), bosutinib 
(3 µM), dasatinib (0.3 µM) or an equivalent volume of DMSO and stimulated with 
recombinant human TGFb1 (5 ng mL-1) for 12 hours prior to cell lysis. Cell lysates (12 µg total 
protein) were resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. 
The membranes were subsequently subjected to immunoblotting with the indicated 
antibodies. (B) Wild type U2OS osteosarcoma cells were incubated with SB-505124 (1 µM), 
bosutinib (3 µM), dasatinib (0.3 µM) or an equivalent volume of DMSO and stimulated with 
recombinant human TGFb1 (5 ng mL-1) for 6 hours prior to cell lysis. Cell lysates (12 µg total 
protein) were resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. 
The membranes were subsequently subjected to immunoblotting with the indicated 
antibodies. 
 
 
3.5.4 Discussion 
In this section, it has been demonstrated that the clinically approved small-molecule kinase 
inhibitors bosutinib and dasatinib are capable of inhibiting SIK isoforms in U2OS 
osteosarcoma cells. Furthermore, the inhibition of SIKs by bosutinib and dasatinib displays 
the same suppressive effect on TGFβ-dependent gene transcription as observed with the 
MRT199665 inhibitor and therefore this observation is significant for a number of factors. 
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Firstly, as mentioned previously, it is crucial that any effect observed occurs with at 
least two structurally unrelated inhibitor compounds (Davies et al., 2000; Cohen, 2009). The 
HG-9-91-01 inhibitor is currently the most potent and selective inhibitor of SIK isoforms 
available and is structurally distinct compared with MRT199665. However, it was not suitable 
for use in this thesis due to the off-target inhibition of the type I TGFβ receptor kinase 
discussed in section 3.2. The caveat of only employing the use of a single small-molecule 
inhibitor is that any effect detected could conceivably occur due to inhibition of a protein 
kinase other than the kinase of interest due to inherent off-target effects of kinase inhibitors. 
Therefore, it was important identify alternative small-molecule inhibitors of SIKs with 
contrasting selectivity profiles and investigate whether they exerted the same effect on TGFβ 
signalling as MRT199665.  
The data presented so far has demonstrated that three structurally unrelated small-
molecule inhibitors (MRT199665, bosutinib and dasatinib) all display the same effect on TGFβ 
signalling. As observed with MRT199665, bosutinib and dasatinib both suppress the TGFβ-
induced expression of GFP in the endogenous TGFβ transcriptional reporter cell line and also 
abrogate the upregulation of the endogenous TGFβ target gene PAI-1 in wild type 
osteosarcoma cells. One of the major limitations of the MRT199665 compound is that 
although it potently inhibits the SIK isoforms (SIK2 and SIK3 more than SIK1), it also targets a 
number of other members of the AMPK-related family in addition to AMPK itself. In particular, 
MRT199665 inhibits all four MARK isoforms and NUAK1 with in vitro IC50 values of 2-3 nM. 
Therefore, it would be problematic to draw any conclusions regarding which protein kinase is 
mediating the effects observed. However, because we also observed the same effects with 
both bosutinib and dasatinib, which exhibit different kinase selectivity profiles compared with 
MRT199665, it is therefore possible to eliminate the possibility of certain protein kinases. For 
example, although partial inhibition of the AMPK, MARK, MELK and NUAK1 kinases is 
observed with bosutinib in vitro (mean percentage activity remaining values in the range of 
21-76% at 1 µM inhibitor concentration), it is much more potent towards SIK2 and SIK3 at the 
same concentration (mean percentage activity remaining values of 3% and 2% respectively). 
Furthermore, dasatinib displays no in vitro inhibition of any of the AMPK-related family 
protein kinases aside from SIK2 and SIK3 (mean percentage activity remaining values of 2%). 
An additional control experiment for the use of small-molecule TKIs in this context would be 
to treat cells with imatinib, which like bosutinib and dasatinib inhibits the protein tyrosine 
 161 
kinases ABL and BTK however it does not inhibit SIK isoforms (Bantscheff et al., 2007; Ozanne, 
Prescott and Clark, 2015). Therefore, one would predict that because of this it does not 
suppress the TGFβ-dependent upregulation of target gene transcription. 
Therefore, the data presented in this section has demonstrated that the clinically 
approved small-molecule kinase inhibitors bosutinib and dasatinib exert the same 
suppressive effect as MRT199665 on the TGFβ-mediated induction of the target gene PAI-1. 
Although these three compounds have distinct kinase selectivity profiles, they are all potent 
inhibitors of SIK isoforms. Hence, it is likely that the effects observed on TGFβ signalling occurs 
through SIK inhibition. However, it is still important to verify that the attenuation of TGFβ-
induced gene transcription is indeed mediated via the inhibition of SIK isoforms by using 
inhibitor-resistant SIK mutants. 
 
 Bosutinib Dasatinib 
Protein kinase 0.1 µM 1.0 µM 0.1 µM 1.0 µM 
ABL 1 ± 0 0 ± 0 0 ± 0 0 ± 0 
AMPK 65 ± 4 26 ± 2 107 ± 13 120 ± 5 
BRSK1 101 ± 1 112 ± 5 126 ± 0 123 ± 1 
BRSK2 107 ± 12 120 ± 4 102 ± 14 108 ± 13 
BTK 1 ± 0 1 ± 0 1 ± 0 1 ± 0 
LKB1 84 ± 13 104 ± 15 96 ± 18 100 ± 14 
MARK1 84 ± 5 76 ± 4 115 ± 3 127 ± 3 
MARK2 89 ± 8 68 ± 1 118 ± 4 126 ± 2 
MARK3 74 ± 10 41 ± 3 96 ± 16 104 ± 5 
MARK4 101 ± 7 72 ± 5 105 ± 12 115 ± 24 
MELK 95 ± 10 66 ± 1 112 ± 7 128 ± 7 
NUAK1 63 ± 12 21 ± 2 119 ± 10 118 ± 8 
SIK2 8 ± 0 3 ± 0 4 ± 1 2 ± 1 
SIK3 9 ± 0 2 ± 0 9 ± 2 2 ± 0 
Src 1 ± 0 1 ± 0 1 ± 0 2 ± 0 
TGFbR1 87 ± 14 101 ± 6 103 ± 1 82 ± 5 
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Table 7. Protein kinase profiling of the clinically approved small-molecule inhibitors 
bosutinib and dasatinib 
The small-molecule inhibitors bosutinib and dasatinib were analysed for their ability to inhibit 
a panel of protein kinases in vitro. The panel included the clinically relevant non-receptor 
protein tyrosine kinases ABL, BTK and Src, in addition to the serine-threonine protein kinases 
LKB1, AMPK, AMPK-related family members and the type I TGFb receptor (TGFbR1). The 
results indicate the mean percentage activity remaining ± standard deviation (SD). The data 
was adapted from (Ozanne, Prescott and Clark, 2015) and the in vitro protein kinase profiling 
was performed by the MRC PPU International Centre for Kinase Profiling at the University of 
Dundee (http://www.kinase-screen.mrc.ac.uk). Abbreviations: ABL, tyrosine-protein kinase 
ABL (also referred to as Abelson murine leukaemia viral oncogene homolog); AMPK, 5’-AMP-
activated protein kinase; BRSK, Brain-specific serine/threonine-kinase; BTK, tyrosine-protein 
kinase BTK (also referred to as Bruton’s tyrosine kinase); LKB1, serine/threonine protein 
kinase STK11 (also referred to as liver kinase B1); MARK, MAP/microtubule affinity-regulating 
kinase; MELK, Maternal embryonic leucine zipper kinase; NUAK1, NUAK family SNF1-like 
kinase 1; SIK, Salt-inducible kinase; Src, proto-oncogene tyrosine-protein kinase Src; TGFbR1, 
transforming growth factor-beta receptor type-1. 
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3.6 THE EFFECT OF SIK INHIBITION ON TGFβ-MEDIATED PHYSIOLOGICAL 
RESPONSES 
 
3.6.1 Introduction 
As alluded to previously, TGFβ is a multifunctional cytokine with the ability to regulate a 
diverse array of physiological responses, amongst the most prominent of which are cell 
proliferation, epithelial-mesenchymal transition (EMT), immune regulation and apoptotic cell 
death. From research conducted over the past two decades, it has become increasingly 
apparent that TGFβ signalling is context-dependent and a molecular framework involving the 
cooperation of SMADs with lineage-determining transcription factors (LDTFs), the cellular 
chromatin status and the input of additional signalling pathways has been proposed to explain 
the pleiotropic nature of TGFβ signalling (Massagué, 2012a; Ayyaz, Attisano and Wrana, 2017; 
David and Massagué, 2018). Further elucidation of how these contextual determinants define 
the cellular response to TGFβ signalling is of significant importance, particularly given the 
involvement of aberrant TGFβ signalling in the pathogenesis of multiple human diseases such 
as fibrosis and cancer progression and metastasis (Siegel and Massagué, 2003; Gordon and 
Blobe, 2008; Massagué, 2008a; Drabsch and ten Dijke, 2012). 
The data outlined in the thesis thus far indicated a role for SIK isoforms in the 
modulation of TGFβ-mediated transcriptional regulation of certain target genes such as PAI-
1, CTGF and SMAD7. Whilst this is a novel and interesting observation, it was important to 
also address the functional consequences of SIK activity on TGFβ-dependent cellular 
processes and therefore, the effect of MRT199665 on cellular proliferation and apoptosis was 
investigated. 
 
 
3.6.2 MRT199665 enhances the upregulation of the cyclin-dependent kinase inhibitors 
p21CIP1 and p27KIP1 
The ability of TGFβ to induce a cytostatic response in many different cell types has been 
extensively investigated primarily due to its major contribution to the tumour suppressive 
function of TGFβ signalling (Bierie and Moses, 2006; Massagué, 2008b; Inman, 2011b; 
Drabsch and ten Dijke, 2012). TGFβ-mediated cytostasis has been predominantly studied in 
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epithelial cells and principally occurs through two interconnected transcriptional responses 
(discussed in greater detail in section 1.4.4). Firstly, TGFβ can induce the expression of a 
number of cyclin-dependent kinase (CDK) inhibitors including p15INK4B (Hannon and Beach, 
1994; Reynisdóttir et al., 1995), p21CIP1 (Datto, Yu and Wang, 1995; Reynisdóttir et al., 1995) 
and p27KIP1 (Polyak, Kato, et al., 1994b; Polyak, Lee, et al., 1994) which prevent progression 
through the G1 phase of the cell cycle. Secondly, TGFβ also mediates the transcriptional 
repression of the cell growth-promoting transcription factor c-MYC which has been shown to 
be a critical aspect of the cytostatic response to TGFβ (Alexandrow and Moses, 1995; 
Alexandrow et al., 1995; Chen, Kang and Massagué, 2001; Gomis et al., 2006). 
For the purpose of this thesis project, the cytostatic effect induced by TGFβ was 
analysed in two different epithelial cell types: HaCaT human immortalised keratinocyte cells 
and HuH-7 human hepatocellular carcinoma cells. Stimulation of HaCaT cells with 
recombinant human TGFβ1 over a period of 48 hours rapidly suppressed the protein 
expression of the growth-promoting c-MYC transcription factor whilst concomitantly 
upregulated the expression of the CDK inhibitors p21CIP1 and p27KIP1 (figure 3.6A-A). Similarly, 
stimulation of HuH-7 cells with recombinant TGFβ1 over 48 hours also rapidly suppressed c-
MYC protein expression and upregulated p27KIP1 (figure 3.6A-A). The TGFβ-mediated 
cytostatic response appeared to be weaker in the HuH-7 cell line compared with the HaCaT 
cells, as the expression of p27KIP1 did not increase until the 48-hour time point. In addition, 
unlike the expression observed in HaCaT cells, p21CIP1 protein expression was not detected in 
HuH-7 cells. Thus, HaCaT cells appeared to have a more robust cytostatic response upon TGFβ 
stimulation and were therefore used in the subsequent experiments investigating cellular 
proliferation. The prolonged stimulation of HaCaT cells with recombinant TGFβ over a period 
of 7 days resulted in a significant suppression of cellular proliferation (figure 3.6A-B). The 
proliferation rates of unstimulated control HaCaT cells and those incubated with TGFβ1 
remained comparable until approximately day 5, at which point the unstimulated cells 
continued to proliferate whereas the proliferation rate of TGFβ-incubated cells was 
substantially reduced (figure 3.6A-B). This data confirmed that the HaCaT human keratinocyte 
cell line is a robust model in which to study TGFβ-induced cytostasis and were therefore used 
to analyse the effect of MRT199665 on this cellular response. 
 The stimulation of HaCaT cells with TGFβ resulted in a pronounced induction of the 
CDK inhibitors p21CIP1 and p27KIP1 protein expression, and the simultaneous repression of c-
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MYC transcription (figure 3.6A-C). As expected, both of these TGFβ-mediated transcriptional 
responses were efficiently blocked in cells incubated with the TGFβ type I receptor kinase 
inhibitor SB-505124 (figure 3.6A-C). Interestingly, the incubation of cells with the small-
molecule kinase inhibitor MRT199665 enhanced the protein expression of p21CIP1 and p27KIP1, 
and slightly reduced c-MYC protein expression even in the absence of TGFβ stimulation (figure 
3.6A-C). The simultaneous incubation of cells with recombinant TGFβ1 and MRT199665 
resulted in enhanced transcriptional induction of p21CIP1 and p27KIP1, and further repression 
of c-MYC compared with DMSO control TGFβ-stimulated cells (figure 3.6A-C). The effect of 
the MRT199665 inhibitor on the cellular proliferation of HaCaT cells was subsequently 
analysed, however the cells did not tolerate prolonged incubation with the compound and 
therefore the experiment was unable to be performed. As a result, it would be critical to 
determine whether bosutinib and dasatinib are capable of mediating the same effects as 
MRT199665 on CDK inhibitor and c-MYC expression in HaCaT cells. The effect of SIK inhibition 
on the cellular proliferation of HaCaT cells could then be analysed using either bosutinib or 
dasatinib. This data indicates that SIK inhibition by MRT199665 alone is sufficient to induce a 
cytostatic response in HaCaT cells, which is then augmented via the additional incubation of 
TGFβ. 
Research has reported that TGFβ can concurrently induce apoptosis and EMT in 
cultured cells, which proposed the question of how a single cytokine can produce two distinct 
responses in the same cell type? Subsequent research demonstrated that the ability of TGFβ 
to induce either apoptosis or EMT is highly dependent on the cell cycle stage (Y. Yang et al., 
2006), uncovering an additional contextual determinant of TGFβ signal transduction, and 
suggested that TGFβ-induced growth arrest may function as a precondition for subsequent 
TGFβ-mediated cellular responses (Song, 2007). The data presented in this section indicates 
that there may also be a potential role for SIKs in modulating the cytostatic response in certain 
cell types and therefore in determining how cells respond to TGFβ stimulation. 
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Figure 3.6A. MRT199665 enhances the cytostatic response in HaCaT human keratinocyte 
cells 
(A) HaCaT human immortalised keratinocytes or HuH-7 human hepatocellular carcinoma cells 
were stimulated with recombinant human TGFb1 (5 ng mL-1) for the durations indicated prior 
to cell lysis. Cell lysates (10 µg total protein) were resolved via SDS-PAGE and transferred to 
nitrocellulose blotting membranes. The membranes were subsequently subjected to 
immunoblotting with the indicated antibodies. (B) HaCaT keratinocyte cells were cultured in 
96-well cell culture plates in the absence or presence of stimulation with recombinant human 
TGFb1 (5 ng mL-1) for a period of 7 days. The cellular proliferation of a set of replicate wells 
was analysed every 24 hours. (C) HaCaT keratinocyte cells were incubated with SB-505124 (1 
µM), MRT199665 (1 µM) or an equivalent volume of DMSO and stimulated with recombinant 
human TGFb1 (5 ng mL-1) for 12 hours prior to cell lysis. Cell lysates (12 µg total protein) were 
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resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. The membranes 
were subsequently subjected to immunoblotting with the indicated antibodies. The 
immunoblot is representative of two independent experiments. 
 
 
3.6.3 NMuMG murine mammary epithelial cells undergo TGFβ-induced apoptosis 
TGFβ signalling can either positively or negatively control the process of apoptosis in multiple 
different cell types and as with other physiological processes regulated by TGFβ, it appears to 
be highly dependent on cellular context (Schuster and Krieglstein, 2002; Zhang, Alexander 
and Wang, 2017). Although a coherent understanding regarding TGFβ-regulated apoptosis 
has yet to be established, a number of the proposed underlying molecular mechanisms are 
discussed in greater detail in section 1.4.5. For example, one of the principal mechanisms by 
which TGFβ can promote apoptosis appears to involve the SMAD-dependent transcriptional 
activation of BCL-2 protein family members (Ohgushi et al., 2005; Ramjaun et al., 2007; 
Spender et al., 2009, 2013), critical modulators of the intrinsic (i.e. mitochondrial-dependent) 
apoptotic pathway (Youle and Strasser, 2008; Czabotar et al., 2014). 
The process of apoptosis can be investigated via a multitude of experimental 
techniques however one of the principal biochemical methods for analysing apoptotic cell 
death is the detection of proteins involved in mediating the apoptotic response (Banfalvi, 
2017). The activation of caspase enzymes represents a fundamental event in the early 
apoptotic process (Nuñez et al., 1998; Riedl and Shi, 2004; Li and Yuan, 2008; Taylor, Cullen 
and Martin, 2008; Shalini et al., 2015) and therefore the detection of caspase activation is 
frequently employed to analyse apoptosis. In particular, the proteolytic activation of caspase-
3, which along with caspase-6 and caspase-7 comprise the effector (alternatively termed 
executioner) caspases in mammals, is critical for the initiation of the mammalian apoptotic 
response (Fernandes-Alnemri, Litwack and Alnemri, 1994; Nicholson et al., 1995; Tewari et 
al., 1995). The activation of caspase-3 requires the proteolytic processing of the inactive 
zymogen into large (p17) and small (p12) subunits. The two subunits associate with one 
another to form a caspase monomer, which then subsequently homodimerises via 
hydrophobic interactions with another monomer to form the active caspase enzyme (Riedl 
and Shi, 2004). The cleavage of caspase-3 occurs at the carboxy-terminal side of aspartic acid 
residue 175 (Asp175) and is mediated by the upstream initiator caspases caspase-8 and 
caspase-9 (Fernandes-Alnemri, Litwack and Alnemri, 1994; Tewari et al., 1995; Shi, 2002; 
 168 
Boatright and Salvesen, 2003). Therefore, the immunological detection of the large 17 kDa 
subunit of activated caspase-3 resulting from proteolytic cleavage following the Asp175 
residue is one of the biochemical markers employed throughout this thesis in order to analyse 
apoptosis. 
 Upon proteolytic cleavage and activation, caspase-3 functions as an effector or 
‘executioner’ caspase in the apoptotic programme and cleaves various substrates including 
the protein poly(ADP-ribose) polymerase (PARP) (Slee, Adrain and Martin, 2001; Elmore, 
2007). PARP is a nuclear zinc finger DNA-binding protein that detects and binds to DNA single-
strand breaks (SSBs) and double-strand breaks (DSBs) and has important regulatory functions 
in cellular processes including DNA repair, chromosomal stability and apoptotic cell death 
(D’Amours et al., 1999; Herceg and Wang, 2001). Once bound to the site of DNA strand 
breakage, PARP catalyses the transfer of the adenosine diphosphate (ADP)-ribose moiety 
from the substrate nicotinamide adenine dinucleotide (NAD+) to various protein substrates 
involved in DNA repair (including PARP itself) and chromatin regulation(Oliver et al., 1998), a 
post-translational modification termed reversible protein poly-ADP-ribosylation. The 
importance of PARP-mediated protein poly-ADP-ribosylation in the process of DNA repair has 
been further demonstrated by the observation that catalytic inhibitors of PARP have cytotoxic 
effects on BRCA1- or BRCA2-deficient cells and human tumours (Bryant et al., 2005; Farmer 
et al., 2005; Fong et al., 2009). Breast cancer type 1 susceptibility protein (BRCA1) and breast 
cancer type 2 susceptibility protein (BRCA2; also referred to as Fanconi anaemia group D1 
protein, FANCD1) are important for the repair of DNA double-strand breaks (DSBs) via 
homologous recombination (HR) and therefore critical for maintaining genomic stability 
(D’Andrea and Grompe, 2003; Narod and Foulkes, 2004; Gudmundsdottir and Ashworth, 
2006; Roy, Chun and Powell, 2012). Consequently, BRCA1- and BRCA2-deficient cells are 
unable to efficiently repair DNA DSBs in response to various genotoxic insults and inhibition 
of PARP in these cells results in a high degree of genomic instability and ultimately cell death. 
Thus, multiple PARP inhibitors have been developed as a therapeutic strategy for the 
treatment of various human cancers and are currently undergoing clinical trials (Lord and 
Ashworth, 2008; Rouleau et al., 2010). 
 The proteolytic cleavage of PARP has been identified as an early event to occur during 
the mammalian apoptotic response and one of the principal mediators of PARP cleavage in 
vivo is caspase-3 (Kaufmann et al., 1993; Herceg and Wang, 2001; Slee, Adrain and Martin, 
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2001). PARP contains the caspase-3 tetrapeptide (P4-P3-P2-P1) recognition sequence Asp-Glu-
Val-Asp (DEVD) (Thornberry et al., 1997; Julien and Wells, 2017) and caspase-3 proteolytically 
cleaves the peptide bond between the Asp214 (at the P1 position) and Gly215 residues 
(Lazebnik et al., 1994; Nicholson et al., 1995; Tewari et al., 1995). PARP is comprised of three 
functional domains; an amino-terminal DNA-binding domain (DBD), a central auto-
modification domain (AMD) and a carboxy-terminal catalytic domain (Oliver et al., 1998; 
Rouleau et al., 2010). Specific glutamate and lysine residues within the AMD function as 
acceptors for ADP-ribose moieties, thereby enabling PARP to poly-ADP-ribosylate (pADPr) 
itself (Altmeyer et al., 2009; Tao, Gao and Liu, 2009). This auto-modification of PARP is 
proposed to have two major functions. Firstly, it may function as a scaffold and facilitate the 
recruitment of DNA repair proteins to sites of DNA damage and secondly, the large negative 
charge of the pADPr modification diminishes the affinity of PARP for DNA. Therefore, PARP 
dissociates from the site of DNA damage thereby providing access for the DNA repair proteins 
(Rouleau et al., 2010). The caspase-3-mediated cleavage of PARP occurs within the DNA-
binding domain and results in PARP inactivation. In the context of apoptosis, one of the 
proposed purposes for the cleavage and inactivation of PARP is to prevent unnecessary DNA 
repair from occurring during chromatin degradation. 
 
 
 
 
 
 
 
 
 
 
Figure 3.6B. TGFb induces apoptotic cell death in NMuMG murine mammary epithelial cells 
NMuMG murine mammary epithelial cells were incubated with recombinant human TGFb1 (5 
ng mL-1) for increasing durations. Both adherent and non-adherent cells (i.e. apoptotic cells) 
were lysed and cell lysates (12 µg total protein) were subsequently resolved via SDS-PAGE. 
The separated proteins were transferred onto nitrocellulose membranes which were 
subsequently subjected to immunoblotting with the indicated antibodies. 
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As previously discussed in section 1.4, signalling pathways induced by TGFβ contribute to 
numerous cellular processes including immunoregulation, EMT, cellular proliferation and 
apoptosis in a context-dependent manner. Therefore, we were interested to investigate 
whether the small-molecule kinase inhibitor MRT199665 exerted any effect on some of these 
processes. 
 TGFβ-mediated regulation of cellular processes such as apoptosis is highly dependent 
on the cellular context (Massagué, 2012b). For example, only certain cell types undergo 
apoptotic cell death in response to prolonged stimulation with recombinant TGFβ1 cytokine 
and therefore it is important to utilise the appropriate cell culture system. In order to 
investigate the effect of MRT199665 on the process of TGFβ-induced apoptosis, we employed 
the murine mammary epithelial cell line NMuMG, which have been extensively utilised for 
the interrogation of TGFβ-dependent apoptosis (Yu, Hébert and Zhang, 2002; Ramjaun et al., 
2007; Gal et al., 2008; Viloria-Petit et al., 2009; Avery-Cooper et al., 2014; Liu et al., 2017). 
The addition of recombinant human TGFβ1 ligand to the culture media of NMuMG cells 
caused extensive cell death and induced the proteolytic cleavage and hence activation of the 
effector caspase caspase-3. Immunodetection of the cleaved form of caspase-3 (D175) 
appeared following approximately 9 hours of TGFβ stimulation, with the highest levels 
observed at 24 hours. Concomitant with the cleavage and activation of caspase-3, TGFβ1 
treatment of NMuMG cells also induces the cleavage (and hence inactivation) of the well-
characterised substrate of caspase-3, PARP (Lazebnik et al., 1994; Nicholson et al., 1995; 
Tewari et al., 1995). Protein levels of the full-length form of PARP (with an approximate 
molecular weight of 113 kDa) begin to decrease around 9 hour following 9 hours of TGFβ1 
treatment and the lowest levels of full-length PARP occur after 24 hours of treatment. The 
caspase-3-mediated proteolytic cleavage of PARP occurs within the amino-terminal DNA-
binding domain and results in the separation of the two zinc-finger DNA-binding motifs from 
the automodification domain and the carboxy-terminal pADPr catalytic domain, thereby 
impairing normal PARP function (Lazebnik et al., 1994; Nicholson et al., 1995; Tewari et al., 
1995). PARP cleavage results in the formation of two polypeptides of approximately 89 kDa 
and 24 kDa molecular weight (Herceg and Wang, 2001). The appearance of the large 89 kDa 
fragment of cleaved PARP (D214) is maximal following approximately 12 hours of TGFβ1 
stimulation. This data validates that the NMuMG murine mammary epithelial cell line is a 
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robust model for the investigation of TGFβ-mediated apoptosis in cell culture and in all 
subsequent experiments involving this cell line, cells were stimulated with recombinant TGFβ1 
for either 12 or 24 hours in order to induce the apoptotic cell death process. 
 
 
3.6.4 Treatment of NMuMG cells with MRT199665 enhances the proteolytic cleavage of 
caspase-3 and PARP in response to TGFβ stimulation 
Prior to investigating the effect of MRT199665 on TGFβ-mediated apoptosis, it was necessary 
to demonstrate that treatment of NMuMG cells with MRT199665 could effectively abrogate 
the phosphorylation of the SIK substrate CRTC3. Therefore, endogenous CRTC3 was 
immunoprecipitated from cells following treatment with either MRT199665, HG-9-91-01 or 
DMSO. As expected, both MRT199665 and HG-9-91-01 substantially reduced the 
phosphorylation of CRTC3 at serine 370 compared with DMSO control cells, indicating that 
both of these small-molecule inhibitors were effective at inhibiting SIK isoforms in NMuMG 
cells. Subsequently, we incubated with NMuMG cells with either DMSO, SB-505124 or 
MRT199665 in the presence of TGFβ1 stimulation for 24 hours. In cells treated with DMSO, 
prolonged TGFβ stimulation inducted the process of apoptotic cell death, as indicated by the 
presence of detached cells in the culture media and the immunodetection of the 
proteolytically cleaved and activated form of caspase-3 in addition to the appearance of the 
large 89 kDa fragment resulting from PARP cleavage. Co-treatment of cells with the TGFβ type 
receptor kinase inhibitor SB-505124 completely prevented the apoptotic response from 
occurring. Interestingly, in cells co-incubated with MRT199665, the apoptotic response 
resulting from TGFβ1 stimulation appeared to be dramatically enhanced. Firstly, noticeably 
more detached (i.e. apoptotic) cells were observed in the culture media of cells incubated 
with MRT199665 compared with DMSO control treated cells when visualised via bright-field 
microscopy. Additionally, the immunodetection of the cleaved form of caspase-3 and the 
concomitant proteolytic cleavage of PARP were both substantially enhanced in cells 
incubated with MRT199665 in comparison to DMSO control cells. Consistent with previous 
experiments in different cell lines, MRT199665 exhibited no effect on the receptor-mediated 
phosphorylation of the TGFβ-activated R-SMADs SMAD2 or SMAD3, and SMAD protein 
expression remained consistent between all experimental conditions. Importantly, when 
NMuMG cells were incubated with MRT199665 without the addition of recombinant TGFβ1 
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cytokine, neither the cleaved and activated form of caspase-3 or the large 89 kDa PARP 
fragment were detected. This indicated that treatment of cells with MRT199665 in isolation 
was not sufficient to induce apoptosis and that the observed potentiation of apoptotic cell 
death required both SIK inhibition and activation of the TGFβ signalling pathway.  
 In contrast to the attenuating effect of MRT199665 on the expression of the TGFβ 
target gene PAI-1 in both U2OS human osteosarcoma and A-172 human glioblastoma cell 
lines, incubation of NMuMG cells with MRT199665 did not substantially impact the TGFβ-
mediated induction of PAI-1 protein expression (figure 3.6C-D). It is conceivable that the as 
yet undetermined SIK substrate in the context of TGFβ signalling is not expressed in NMuMG 
cells and therefore incubation with the SIK inhibitor MRT199665 is unable to exert the same 
effect as observed in other cell lines. For example, this discrepancy may be the result of 
different SMAD transcriptional co-regulators being expressed in different cell types and 
further highlights the cell context-dependent nature of TGFβ signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6C. Analysis of the small-molecule kinase inhibitor MRT199665 in the context of 
TGFβ-dependent apoptosis 
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(A) Wild type NMuMG murine mammary epithelial cells were incubated with MRT199665 (1 
µM), HG-9-91-01 (0.5 µM) or an equivalent volume of DMSO for 1 hour prior to cell lysis. Cell 
lysate samples (600 µg total protein) were subjected to immunoprecipitation of endogenous 
CRTC3 using anti-CRTC3 polyclonal sheep IgG conjugated to Protein G Agarose resin. 
Following elution from the antibody-resin, total cell lysate (20 µg total protein) and IP samples 
were resolved via SDS-PAGE and subsequently transferred to nitrocellulose membranes. The 
membranes were subjected to immunoblotting using the indicated antibodies. (B) Wild type 
NMuMG murine mammary epithelial cells were incubated with SB-505124 (1 µM), 
MRT199665 (1 µM) or an equivalent volume of DMSO and stimulated with recombinant 
human TGFb1 (5 ng mL-1) for 24 hours prior to cell lysis. Cell lysates (12 µg total protein) were 
resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. The membranes 
were subsequently subjected to immunoblotting with the indicated antibodies. (C) Wild type 
NMuMG murine mammary epithelial cells were incubated with either MRT199665 (1 µM) or 
an equivalent volume of DMSO, in the presence or absence of stimulation with recombinant 
human TGFb1 (5 ng mL-1) for the indicated durations prior to cell lysis. Cell lysates (12 µg total 
protein) were resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. 
The membranes were subsequently subjected to immunoblotting with the indicated 
antibodies. 
 
 
3.6.5 Treatment of NMuMG cells with MRT199665 increases the percentage of apoptotic 
cells and reduces cellular viability 
The various biochemical and morphological alterations that occur during the process of 
apoptosis can be exploited to discriminate between viable and non-viable (i.e. apoptotic) cells 
and can be utilised to determine the extent of apoptotic cell death that occurs under specific 
experimental conditions. Many of these cellular alterations including the activation of caspase 
enzymes, loss of mitochondrial membrane potential, changes in cellular DNA content and 
redistribution of plasma membrane phospholipids can be measured via flow cytometry 
(Vermes, Haanen and Reutelingsperger, 2000). 
 In normal viable cells, the distribution of various phospholipids is asymmetrical 
between the inner (i.e. intracellular side) leaflet and the outer (i.e. extracellular side) leaflet 
of the plasma membrane. The formation and modification of the plasma membrane 
phospholipid asymmetry is mediated by the concerted function of transmembrane lipid 
transporter enzymes P4-type ATPases, flippases, floppases and scramblases (van Meer et al., 
2006; van Meer, Voelker and Feigenson, 2008; Tanaka, Fujimura-Kamada and Yamamoto, 
2011; Demchenko, 2013). Flippases and floppases belong to the ATP-binding cassette (ABC) 
transporter family and facilitate the ATP-dependent unidirectional translocation of 
 174 
phospholipids between the outer and inner leaflets of the plasma membrane (van Meer et 
al., 2006; Tanaka, Fujimura-Kamada and Yamamoto, 2011). P4-ATPases are a subfamily of the 
P-type ATPases that also mediate unidirectional phospholipid translocation in an ATP-
dependent manner (Andersen et al., 2016). By contrast, the scramblase enzymes catalyse the 
ATP-independent bidirectional translocation of phospholipids between the inner and outer 
leaflets of the plasma membrane. In this way, scramblases randomise the phospholipid 
distribution of the plasma membrane and therefore function to dissipate the phospholipid 
asymmetry (Hankins et al., 2015; Montigny et al., 2016). The dynamic regulation of the 
asymmetrical phospholipid composition of the plasma membrane appears to be critical for 
normal cellular function (Balasubramanian and Schroit, 2003). 
 The dissipation of the phospholipid asymmetry of the plasma membrane is a 
fundamental early event that occurs during the apoptotic process and involves the 
redistribution of the anionic aminophospholipid phosphatidylserine (PS) (Fadok et al., 1992; 
Martin et al., 1995; Erwig and Henson, 2008; Demchenko, 2013). In the majority of viable 
eukaryotic cell types, nearly all PS is sequestered in the inner leaflet of the plasma membrane 
(Ravichandran and Lorenz, 2007), however in cells undergoing apoptosis, PS is translocated 
to the outer plasma membrane leaflet (Fadok et al., 1992; Martin et al., 1995; 
Balasubramanian and Schroit, 2003). Research has indicated that PS translocation is 
facilitated by the activation of an ATP-independent non-specific phospholipid scramblase and 
the concomitant downregulation of an aminophospholipid-specific translocase (Bratton et al., 
1997; Fadok et al., 1998; Segawa et al., 2014; Montigny et al., 2016). 
 The clearance of apoptotic cells is a fundamental process that occurs during 
development, injurious or pathological conditions and normal tissue homeostasis. It is 
critically important to rapidly remove apoptotic cells for the prevention of inflammation or 
autoimmune responses (Ravichandran and Lorenz, 2007; Erwig and Henson, 2008) and the 
principal function of PS translocation to the outer leaflet of the plasma membrane is to 
facilitate the recognition and effective engulfment of apoptotic cells via phagocytosis (Fadok 
et al., 1992, 1998; Koopman et al., 1994; Verhoven, Schlegel and Williamson, 1995). The 
exposure of PS on the apoptotic cell surface is recognised by phagocytic cells such as activated 
macrophages either directly through PS-recognition receptors (Miyanishi et al., 2007; Park et 
al., 2007, 2008; Das et al., 2014) or indirectly via extracellular bridging molecules which 
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simultaneously interact with PS and membrane receptors on the macrophage cell surface 
(Ravichandran and Lorenz, 2007; Erwig and Henson, 2008). 
The cell-surface exposure of anionic PS has been exploited in order to discriminate 
between healthy viable cells and those undergoing apoptotic cell death (Koopman et al., 
1994; Vermes et al., 1995; van Engeland et al., 1998; Vermes, Haanen and Reutelingsperger, 
2000). Surface exposure of PS on apoptotic cells can be detected experimentally via the 
incubation of cell samples with annexin V conjugated to a fluorophore followed by flow 
cytometric analysis. Annexin V (also referred to as Annexin A5, placental anticoagulant 
protein-1 (PAP-1) or vascular anticoagulant alpha (VACa)) is a calcium-dependent 
phospholipid-binding protein which displays a high affinity for the anionic aminophospholipid 
PS (Tait, Gibson and Fujikawa, 1989; Andree et al., 1990; Raynal and Pollard, 1994). 
 In the annexin V affinity staining assay, annexin V is unable to bind to normal healthy 
cells since the anionic PS is constrained to the inner plasma membrane leaflet and annexin is 
not able to penetrate the plasma membrane phospholipid bilayer. By contrast, in dead (i.e. 
necrotic) cells, the integrity of the plasma membrane is compromised and consequently 
annexin V can bind to PS on both the inner and outer plasma membrane leaflet (van Engeland 
et al., 1998). The extracellular exposure of PS occurs during the early phase of the apoptotic 
process in which the integrity of the plasma membrane remains intact. Therefore, in order to 
discriminate between viable cells, early apoptotic cells and necrotic cells, the assay involves 
the simultaneous addition of a plasma membrane impermeable DNA stain to the cell 
suspension samples. Hence, when the cell suspension samples are analysed via flow 
cytometry, intact viable cells remain unstained, early apoptotic cells (retaining plasma 
membrane integrity) are stained by the annexin V fluorophore conjugate, whereas necrotic 
cells are dual stained by the annexin V fluorophore conjugate and the DNA stain (Vermes et 
al., 1995; van Engeland et al., 1998; Vermes, Haanen and Reutelingsperger, 2000). During the 
experimental procedure, the cells are not subject to permeabilisation or fixation and 
therefore only the cells in the later stages of the apoptotic process in which the plasma 
membrane begins to disintegrate and become permeable will be stained with DAPI. 
The treatment of NMuMG cells with recombinant human TGFb1 for 12 hours 
enhanced the appearance of annexin V positive cells, demonstrating an increase in the 
percentage of cells undergoing TGFb-mediated apoptosis (figure 3.6D-A). Annexin V staining, 
and by extension the apoptotic response, was significantly reduced in cells co-incubated with 
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the TGFb type I receptor kinase inhibitor SB-505124. However, when cells were incubated 
simultaneously with both TGFb1 and the small-molecule kinase inhibitor MRT199665, the 
percentage of cells stained with annexin V was significantly enhanced compared to DMSO 
control TGFb stimulated cells (figure 3.6D-A). This indicates that the MRT199665 inhibitor is 
able to potentiate the apoptotic response in response to TGFb stimulation. Furthermore, in 
the same experimental conditions, the percentage of viable intact cells, as determined by 
those cells which are not amenable to DAPI staining, is significantly decreased in cells treated 
simultaneously with MRT199665 and recombinant TGFb1, compared with TGFb-treated 
DMSO control cells (figure 3.6D-B). 
In order to compliment the aforementioned annexin V staining assay, the cellular 
viability of NMuMG cells under various experimental conditions was also analysed using the 
crystal violet staining method. This is based on the observation that when adherent cells in 
culture undergo apoptotic cell death, they become detached from the cell culture plate. The 
adherent cells can be stained using the crystal violet dye which binds to proteins and DNA. 
The apoptotic cells which have lost their adherence are removed from the cell population, 
thereby reducing the amount of crystal violet staining that is subsequently detected 
(Feoktistova, Geserick and Leverkus, 2016). When NMuMG cells were incubated with 
recombinant human TGFb1 for 24 hours, the relative cellular viability decreased by 
approximately 20 percent compared to unstimulated DMSO control cells (figure 3.6D-C). The 
co-treatment of cells with the SB-505124 inhibitor in addition to TGFb stimulation prevented 
the reduction in cell viability. By contrast, when cells with simultaneously incubated with the 
MRT199665 small-molecule inhibitor and recombinant TGFb1, the relative cellular viability 
was significantly attenuated compared to DMSO control cells stimulated with TGFb (figure 
3.6D-C). Collectively, the data presented in this section has demonstrated through a number 
of experimental techniques that the small-molecule kinase inhibitor MRT199665 can 
potentiate the TGFb-mediated apoptotic response in NMuMG cells. In subsequent research, 
it would be important to conduct similar annexin V and crystal violet staining assays in order 
to assess whether the two other small-molecule kinase inhibitors of SIK isoforms used in this 
thesis project, bosutinib and dasatinib, are also capable of potentiating TGFb-induced 
apoptotic cell death in NMuMG cells. Moreover, it would also be imperative to analyse SIK 
inhibition in the context of alternative cell lines that are amenable to TGFb-mediated 
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apoptotic cell death such as the murine hepatocyte cell line AML-12 which has been 
previously used to investigate the process of TGFb-mediated apoptosis (Ramjaun et al., 2007). 
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Figure 3.6D. The small-molecule kinase inhibitor MRT199665 potentiates TGFβ-mediated 
apoptotic cell death in NMuMG cells 
(A) NMuMG murine mammary epithelial cells were incubated with SB-505124 (1 µM), 
MRT199665 (1 µM) or an equivalent volume of DMSO and simultaneously stimulated with 
recombinant human TGFb1 (5 ng mL-1) for 12 hours. Adherent and non-adherent (i.e. 
apoptotic) cells were collected and prepared for flow cytometric analysis using dual-staining 
(Annexin V/DAPI) as detailed in section 2.2.17. (B) NMuMG murine mammary epithelial cells 
were incubated with SB-505124 (1 µM), MRT199665 (1 µM) or an equivalent volume of DMSO 
and simultaneously stimulated with recombinant human TGFb1 (5 ng mL-1) for 12 hours. 
Adherent and non-adherent (i.e. apoptotic) cells were collected and prepared for flow 
cytometric analysis using dual-staining (Annexin V/DAPI) as detailed in section 2.2.17. (C) 
NMuMG murine mammary epithelial cells were seeded in 96-well cell culture plates and 
incubated with SB-505124 (1 µM), MRT199665 (1 µM) or an equivalent volume of DMSO and 
simultaneously stimulated with recombinant human TGFb1 (5 ng mL-1) for 24 hours. Cells 
were subjected to methanol fixation and cellular viability was analysed via crystal violet 
staining assay as detailed in section 2.2.18. 
 
 
3.6.6 Treatment of NMuMG cells with bosutinib enhances the proteolytic cleavage of 
caspase-3 and PARP in response to TGFβ stimulation 
As discussed in section 3.5, the clinically approved small-molecule tyrosine kinase inhibitors 
(TKIs) bosutinib and dasatinib have been shown to inhibit SIK isoforms and both of these 
inhibitors exert the same effect as MRT199665 on TGFβ-dependent transcriptional regulation 
of the target gene PAI-1. As previously discussed, it is important to demonstrate that any 
effects observed occur with multiple structurally unrelated small-molecule inhibitors and 
therefore it was important to investigate whether bosutinib or dasatinib could also potentiate 
TGFβ-mediated apoptosis. Firstly, we wanted to demonstrate that neither bosutinib nor 
dasatinib affected the receptor-mediated phosphorylation of the TGFβ-activated R-SMAD 
SMAD3 in the NMuMG murine mammary epithelial cell model employed for the study of 
TGFβ-induced apoptosis. In NMuMG cells incubated with either bosutinib or dasatinib, 
SMAD3 phosphorylation levels were comparable with the levels observed in DMSO control 
treated cells. Subsequently, we analysed whether bosutinib could recapitulate the 
potentiation of TGFβ-mediated apoptosis that was observed when cells were co-incubated 
with MRT199665. Indeed, in cells co-incubated with bosutinib and recombinant TGFβ1 for 24 
hours, we detected enhanced levels of cleaved (hence activated) caspase-3 and resulting 
cleavage of the caspase-3 substrate PARP, compared to levels observed in DMSO control 
treated cells. Although the levels of cleaved caspase-3 and cleaved PARP were less than those 
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observed with MRT199665 treatment, this provides evidence that two structurally unrelated 
small-molecule kinase inhibitors of SIK isoforms exert a similar effect on the TGFβ-mediated 
apoptotic cell death of NMuMG cells. Subsequent experiments using alternative methods of 
detecting the process of apoptosis (such as annexin V staining and crystal violet staining 
employed previously in this thesis or DNA-fragmentation assay) are required in order to 
validate the effect of bosutinib on TGFβ-mediated apoptosis. Furthermore, it would be 
advantageous to investigate whether dasatinib is also capable of exerting similar effects as 
MRT199665 and bosutinib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6E. The small-molecule TKI bosutinib potentiates the TGFβ-mediated apoptotic 
response in NMuMG cells 
(A) Wild type NMuMG murine mammary epithelial cells were incubated with the small-
molecule kinase inhibitors SB-505124 (1 µ), MRT199665 (1 µM), bosutinib (3 µM) or dasatinib 
(0.3 µM), or an equivalent volume of DMSO and simultaneously stimulated with recombinant 
human TGFb1 (5 ng mL-1) for 1 hour prior to cell lysis. Cell lysates (12 µg total protein) were 
resolved via SDS-PAGE and transferred to nitrocellulose blotting membranes. The membranes 
 181 
were subsequently subjected to immunoblotting using the indicated antibodies. (B) Wild type 
NMuMG murine mammary epithelial cells were incubated with SB-505124 (1 µM), 
MRT199665 (1 µM), bosutinib (3 µM) or an equivalent volume of DMSO and simultaneously 
stimulated with recombinant human TGFb1 (5 ng mL-1) for 24 hours prior to cell lysis. Cell 
lysate samples (12 µg total protein) were separated via SDS-PAGE and transferred to 
nitrocellulose blotting membranes. The membranes were subsequently subjected to 
immunoblotting using the indicated antibodies. The immunoblot is representative of two 
independent experiments. 
 
 
3.6.7 Discussion 
In this section, it has been demonstrated that inhibition of SIK isoforms with the structurally 
unrelated small-molecule kinase inhibitors MRT199665 and bosutinib can potentiate the 
TGFβ-mediated apoptosis of NMuMG cells in culture. Although this is an interesting and novel 
observation, there remains a number of outstanding crucial questions that need to be 
addressed in future experiments. Firstly, despite observing this enhancement of TGFβ-
mediated apoptosis using two distinct small-molecule inhibitors of SIK isoforms (with 
contrasting kinase selectivity profiles), it is still conceivable that the effect observed is 
occurring due to inhibition of an ‘off-target’ protein kinase. This can be somewhat addressed 
by performing the same experiments as presented above but using dasatinib, another 
compound known to inhibit SIKs that is structurally unrelated to either MRT199665 or 
bosutinib. If treatment of NMuMG cells with dasatinib substantiates the effect on TGFβ-
mediated apoptosis, it would provide additional evidence that the effect is occurring through 
inhibition of SIK isoforms. Furthermore, it would also be interesting to investigate the effect 
of imatinib treatment in this context. Imatinib, similar to bosutinib and dasatinib, is a clinically 
approved small-molecule TKI which inhibits a number of the protein kinases that bosutinib 
and dasatinib also target. Importantly however, it is not capable of inhibiting any of the three 
SIK isoforms and therefore one would postulate that it is unable to potentiate the TGFβ-
mediated apoptotic cell death of NMuMG cells. Again, this would provide further evidence 
that this effect is occurring through SIK kinase inhibition. 
 In this thesis, the ability of MRT199665 and bosutinib to potentiate apoptosis 
mediated via TGFβ has only been demonstrated in NMuMG normal murine mammary 
epithelial cells. However, there are numerous other cell lines that have been utilised by 
researchers in order to investigate this process including the AML12 normal murine 
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hepatocyte cell line and multiple Burkitt’s lymphoma (BL) cell lines such as Ramos, BL2, BL40 
and BL41 (Chaouchi et al., 1995; Saltzman et al., 1998; Schrantz et al., 1999; Inman and Allday, 
2000b, 2000a; Ramjaun et al., 2007; Spender et al., 2009, 2013). It would be very important 
and interesting to resolve these problems in order to investigate whether MRT199665 or 
bosutinib are capable of potentiating the TGFβ-mediated apoptotic cell death of these cell 
lines as observed in NMuMG cells. 
 If subsequent research provides robust evidence that the attenuation of SIK catalytic 
activity using small-molecule kinase inhibitors can potentiate TGFβ-mediated apoptosis of 
multiple human cancer cell lines in culture, this would generate interesting therapeutic 
possibilities. The ability of TGFβ to function as both a tumour suppressor or tumour promoter 
depending on the cellular context was previously discussed in detail in section 1.5. In brief, 
TGFβ exerts a tumour suppressive effect in normal premalignant cells however perturbations 
in the signalling pathway, either through inactivation of core components or defects in 
downstream signalling responses, can enable cells to evade the tumour suppressive action of 
TGFβ. Moreover, malignant cells can corrupt TGFβ signalling via mechanisms such as 
induction of EMT and angiogenesis in order to promote cancer progression and metastasis. 
Previous research has demonstrated that TGFβ can induce apoptotic cell death in multiple 
different human B-cell lymphoma cell lines (Chaouchi et al., 1995; Saltzman et al., 1998; 
Schrantz et al., 1999; Inman and Allday, 2000b, 2000a, Spender et al., 2009, 2013). Thus, the 
ability of small-molecule inhibitors of SIKs to potentiate TGFβ-mediated apoptosis may 
represent a novel potential therapeutic approach to the targeted treatment of specific forms 
of lymphoma and for this reason, it would be of immense interest to investigate the ability of 
SIK inhibitors to augment TGFβ-dependent apoptosis in an in vivo murine model. 
Understandably, there would be numerous additional factors to consider for this potential 
approach to be efficacious. For example, it would only specifically be of therapeutic value for 
tumour cells that are responsive to TGFβ signalling and furthermore, tumour cells that are 
amenable to TGFβ-induced apoptosis. Additionally, there may be a requirement for 
administration of recombinant human TGFβ1 if the circulating plasma concentration is 
insufficient to induce apoptotic cell death. The viability and safety of this would require 
extensive research, particularly with the knowledge that TGFβ can function as a tumour 
promoter in certain cellular contexts. However, the observation that bosutinib and dasatinib 
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are both potent inhibitors of SIK isoforms suggests that specific and potent small-molecule 
SIK inhibitors will be tolerated in humans. 
 Recent research has sought to optimise the small-molecule SIK inhibitor HG-9-91-01 
to develop analogs that have improved protein kinase selectivity and that are suitable for use 
in vivo (Sundberg et al., 2016). Although HG-9-91-01 is a potent inhibitor of SIK isoforms, it is 
known to mediate the ‘off-target’ inhibition of other kinases, including the TGFβ type I 
receptor serine-threonine kinase as demonstrated in this thesis project. Furthermore, it 
exhibits poor pharmacokinetic (PK) properties, with a high degree of plasma protein binding 
and rapid degradation rendering it unsuitable for in vivo use. The research conducted by 
Sundberg et al reported the development of a novel SIK inhibitor YKL-05-099 that displays an 
increased selectivity for SIK isoforms versus other protein kinases and improved PK properties 
that enable it to be used for in vivo study. However, despite the improvements to the kinase 
selectivity profile, I have analysed the effect of YKL-05-099 on TGFβ signalling and observed 
that it attenuates the receptor-mediated phosphorylation of SMAD3, most likely as a result 
of inhibition of the TGFβ type I receptor kinase as observed with HG-9-91-01. Therefore, 
neither HG-9-91-01 or YKL-05-099 are suitable for the in vivo investigation of SIK inhibition in 
the context of TGFβ signalling regulation. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In conclusion, the main discovery of this doctoral project has been the identification of salt-
inducible kinases (SIKs) as novel protein kinase regulators of the TGFβ signalling pathway. The 
data presented within this thesis provides evidence for the involvement of SIKs in modulating 
specific transcriptional responses and cellular functions downstream of TGFβ pathway 
activation. Perturbation of the catalytic activity of SIKs, either by the use of small-molecule 
kinase inhibitors or via genetic inactivation, attenuates the TGFβ-mediated transcriptional 
induction of certain target genes. Moreover, this modulation of TGFβ-dependent 
transcriptional responses does not involve the abrogation of receptor-mediated 
phosphorylation of SMAD transcription factors nor the disruption of SMAD nuclear 
translocation in response to TGFβ stimulation. 
 The research conducted for this thesis project has demonstrated that the endogenous 
2G TGFβ-dependent transcriptional reporter cell line previously developed via collaboration 
between the Hay and Sapkota research groups (Rojas-Fernandez et al., 2015) is a valuable 
research tool and can be effectively exploited for high-throughput screening (HTS) methods. 
Following on from the validation that the endogenous transcriptional reporter cell line is a 
robust system in which to perform HTS, it would be interesting in future research to perform 
pharmacological screening using more extensive small-molecule inhibitor libraries. This 
would allow for greater coverage of the human kinome and to pharmacologically target other 
classes of enzymes involved in cellular signalling such as E3 ubiquitin-protein ligases and 
DUBs. Additionally, due to dual-reporter nature of the cell line, it would be beneficial to 
perform dual-screening using both GFP fluorescence and luciferase enzyme activity in order 
to improve the robustness and reliability of the data. 
 The methodology employed to generate the endogenous 2G TGFβ-dependent 
transcriptional reporter cell lines can also be used to create endogenous transcriptional 
reporter cell lines for other signalling pathways. For example, the Sapkota research group has 
also recently generated an endogenous 2G transcriptional reporter cell line for the BMP 
signalling pathway (Hutchinson et al., 2019). In this cell line, the dual-reporter cassette was 
inserted in-frame and downstream of the endogenous promoter region for the BMP-
responsive target gene DNA-binding protein inhibitor (alternatively referred to as inhibitor of 
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DNA-binding 1 or inhibitor of differentiation 1) ID-1 (Hollnagel et al., 1999; Katagiri et al., 
2002; López-Rovira et al., 2002; Ying et al., 2003). ID-1 is a transcriptional regulator that 
interacts with and negatively regulates basic helix-loop-helix (bHLH) transcription factors 
(Benezra et al., 1990; Ruzinova and Benezra, 2003). The stimulation of HaCaT cells with 
recombinant human BMP2 enhanced the relative luciferase activity 1.5-fold compared to 
unstimulated control cells. Co-incubation with the BMP type I receptor kinase small-molecule 
inhibitor LDN193189 (Cuny et al., 2008; Yu et al., 2008) attenuated the induction of luciferase 
activity, indicating that the transcriptional reporter cell line is dependent on BMP stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4A. The generation of an endogenous 2G BMP-dependent transcriptional reporter 
cell line 
HaCaT 2G BMP transcriptional reporter cells were incubated with LDN193189 (100 nM), SB-
505124 (1 µM) or an equivalent volume of DMSO and simultaneously stimulated with 
recombinant human BMP2 (6.25 ng mL-1) for 8 hours prior to cell lysis and luciferase assay 
analysis. The experiment was performed three times and the luminescence values were 
normalised to the total protein concentration of the respective cell lysate sample. Error bars 
represent the standard error of the mean (SEM). 
 
 
In the data presented throughout this thesis, it has been demonstrated that three 
structurally unrelated small-molecule kinase inhibitors (MRT199665, bosutinib and 
dasatinib), that are known to potently inhibit SIK isoforms, all have the capability to modulate 
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TGFβ-mediated transcriptional responses. Furthermore, the effects of these kinase inhibitors 
occur at the same concentrations required to prevent the phosphorylation of the previously 
established physiological substrate of SIKs, the transcriptional coactivator CRTC3. The ability 
to demonstrate that an observed effect occurs with at least two structurally unrelated kinase 
inhibitors and at the appropriate inhibitor concentrations are both essential criteria for the 
use of pharmacological protein kinase inhibitors in the study of cellular signalling (Davies et 
al., 2000; Cohen, 2009). Nevertheless, it remains conceivable that the modulatory effect on 
TGFβ signalling is occurring through inhibition of protein kinases other than the presumed 
targets of SIK isoforms. As such, one of the most rigorous experiments that can be conducted 
in order to ascertain that the observed effects of a pharmacological inhibitor are mediated 
via the inhibition of the presumed target kinase, and not by any ‘off-target’ inhibition, is to 
demonstrate that the effects of the inhibitor disappear when an inhibitor-resistant mutant of 
the protein kinase is expressed. As previously referred to in section 3.5.2, SIK isoforms are 
unique amongst the AMPK-related family of protein kinases in that they possess a threonine 
residue at the ‘gatekeeper position’ within their kinase domain. Threonine contains a 
relatively small amino acid side chain and as a consequence, HG-9-91-01 is selective for SIKs 
over other members of the AMPK-related family because it targets a hydrophobic pocket 
formed by the presence of the small threonine gatekeeper residue. Therefore, in principal, 
mutation of the gatekeeper threonine residue to an amino acid residue with a comparatively 
larger side chain would abrogate the ability of HG-9-91-01 to inhibit SIK isoforms. Indeed, 
research has elegantly demonstrated that the replacement of the gatekeeper threonine 
residue of SIK2 (Thr96) with a glutamine residue (T96Q) abolishes the ability of HG-9-91-01 to 
inhibit SIK2 in vitro (Clark et al., 2012). Moreover, overexpression of SIK2T96Q in macrophages 
prevented the ability of HG-9-91-01 to induce an anti-inflammatory macrophage phenotype 
characterised by enhanced levels of the anti-inflammatory cytokine IL-10 (Clark et al., 2012). 
Although mutation of the gatekeeper threonine residue in SIK isoforms abolishes the 
inhibitory action of HG-9-91-01, it does not render them resistant to MRT199665. Subsequent 
research however demonstrated that SIK2T96Q is resistant to both bosutinib and dasatinib 
(Ozanne, Prescott and Clark, 2015). As demonstrated in this thesis, both bosutinib and 
dasatinib can recapitulate the effects observed with the MRT199665 compound on TGFβ-
mediated transcriptional responses. Consequently, investigating whether the expression of 
the SIK2T96Q inhibitor-resistant mutant can prevent the attenuation of TGFβ-induced target 
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gene transcription caused by bosutinib and dasatinib would be a critical experiment by which 
to experimentally validate the role of SIKs in TGFβ signal transduction. 
Although the precise molecular mechanisms by which SIKs modulate the TGFβ 
pathway remain to be elucidated, I hypothesise that SIKs may function at the level of 
transcriptional regulation. Since the discovery of SIK1 in 1999 (Wang et al., 1999), followed 
by the identification of SIK2 and SIK3 in the early 2000s (Horike et al., 2003), substantial 
progress has been made on illuminating the cellular functions of SIKs. Thus, it has become 
apparent that SIK isoforms have important regulatory functions in metabolism (Sakamoto, 
Bultot and Göransson, 2018) and the innate immune system, specifically macrophage 
polarisation (i.e. the interconversion of inflammatory and anti-inflammatory phenotypes of 
macrophages) (Clark et al., 2012; MacKenzie et al., 2013; Lombardi et al., 2016b; Darling et 
al., 2017). SIKs primarily function to regulate target gene expression through the modulation 
of transcriptional co-regulators. 
At present, the most well-characterised physiological SIK substrates are the 
transcriptional coregulators CREB-regulated transcription coactivators (CRTCs) (Altarejos and 
Montminy, 2011; Clark, 2014; Sakamoto, Bultot and Göransson, 2018) and class IIa histone 
deacetylases (HDACs) 4 and 5 (Berdeaux et al., 2007; Mihaylova et al., 2011; Wang et al., 
2011; Patel et al., 2014; Henriksson et al., 2015; Sakamoto, Bultot and Göransson, 2018). 
Phosphorylated SMAD3 has been reported to interact with and recruit the class IIa HDACs 
HDAC4 and HDAC5 to mediate transcriptional repression (Kang et al., 2005; Massagué, 
Seoane and Wotton, 2005; Ross and Hill, 2008; Hill, 2016). Therefore, it is conceivable that 
the role of SIKs in modulating TGFβ-mediated transcriptional responses is occurring through 
the regulation of activated SMAD3-HDAC4/HDAC5 transcriptional complexes. One potential 
method by which to investigate this possibility is by assessing whether the small-molecule 
inhibition of SIK kinases affects the interaction of SMAD3 with HDACs via co-
immunoprecipitation analysis or whether the histone acetylation status of target gene 
promoter regions is affected by performing chromatin immunoprecipitation experiments 
using antibodies that recognise acetylated histone H3 or H4 followed by RT-qPCR analysis 
using primers that amplify specific promoter sequences. Although the observations reported 
in this thesis project identify a novel function for SIKs in the regulation of TGFβ-mediated 
transcriptional responses, previous research has implicated a role for the SIK1 isoform in the 
TGFβ signalling pathway. Kowanetz et al reported that SIK1 is a direct transcriptional target 
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of SMAD-dependent TGFβ signalling and that upon induction, interacts with the inhibitory 
SMAD7 and functions to down-regulate the activated TGFβ type I receptor kinase (Kowanetz 
et al., 2008). Consistent with the data presented in this thesis whereby small-molecule kinase 
inhibition of SIK isoforms enhances the transcriptional induction of the CDKIs p21CIP1 and 
p27KIP1 in response to TGFβ stimulation, Kowanetz et al observed that the TGFβ-induced 
upregulation of p21CIP1 and p15INK4B is enhanced upon siRNA-mediated knockdown of SIK1. 
However, contrary to the data presented in this thesis, depletion of SIK1 also resulted in the 
enhancement of TGFβ-induced PAI-1 and SMAD7 mRNA expression (Kowanetz et al., 2008). 
This suggests that the precise nature of SIK function in the TGFβ signalling pathway may be 
dependent on cellular context and therefore further investigation is required in order to 
ascertain how SIKs regulate TGFβ signalling in different contexts. 
 In attempting to elucidate the mechanism by which SIKs regulate TGFβ signalling, one 
of the most intriguing observations made during the course of this thesis project is that SIK2, 
and to a lesser extent SIK3, are able to robustly phosphorylate SMAD3 in vitro. It is possible 
that SIK-mediated phosphorylation of SMAD3 may function to regulate the interaction of 
SMAD3 with DNA promoter sequences or transcriptional regulatory partners. As a result, 
subsequent research will concentrate on using mass spectrometry-based approaches to 
identify the potential SIK-dependent phosphorylation sites on SMAD3 and investigate the 
functional and physiological relevance of these phosphorylation sites. 
 In addition to determining the molecular target of SIKs in the context of TGFβ 
signalling, one of the critical outstanding questions that remains to be addressed is the extent 
to which SIKs may regulate TGFβ-mediated transcriptional responses. Are SIKs involved in the 
regulation of a specific subset of TGFβ target genes, or do they regulate the global TGFβ-
dependent transcriptome? We sought to address this question by performing RNA 
sequencing (RNA-seq) using wild type MEFs and two independent SIK2/SIK3 mutant MEF cell 
lines. However, the data obtained from this analysis revealed a substantial degree of variation 
in the gene expression profiles of the basal unstimulated states between each of the three 
MEF cell lines such that it was challenging to generate any meaningful conclusions. The 
transcriptomic differences observed between these MEF cell lines may have been a 
consequence of the immortalisation procedure. Primary cell lines are of significant value in 
research because they have not been extensively passaged in culture and thus possess the 
same genetic composition as the animal from which they were derived. However, the major 
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limitation of primary cells is that they can only be passaged a limited number of times in 
culture before they undergo growth arrest and cellular senescence. In order to circumvent 
this limitation, primary cells can be subjected to cellular transformation via the retroviral-
mediated transduction of the SV-40 large T antigen, which then allows the cells to be 
propagated in culture indefinitely. However, cellular transformation using the SV-40 large T 
antigen is known to perturb multiple cellular signalling pathways (Ahuja, Sáenz-Robles and 
Pipas, 2005) and it is plausible that this has contributed to the transcriptome variations 
observed in the MEF cell lines used for the RNA-seq analysis. Moreover, one of the principal 
disadvantages of using primary cell cultures is the possibility that they may consist of multiple 
different cell types, a factor which may also contribute to the differences observed in the 
transcriptome of the three MEF cell lines. Therefore, an alternative approach using SIK 
inhibitors in cultured human cancer cell lines may be a possibility in any future transcriptomic 
analysis experiments, although this approach would inevitably possess considerable 
limitations such as kinase inhibitor selectivity. Moreover, the generation of SIK isoform knock-
out (KO) cell lines using CRISPR-Cas9 would be an incredibly valuable tool in which to analyse 
the effect of SIKs on the TGFβ-dependent transcriptome. 
 One of the key findings arising from this thesis project is that the inhibition of SIKs 
using either one of the small-molecule kinase inhibitors MRT199665 or bosutinib is capable 
of potentiating the TGFβ-mediated apoptotic cell death of NMuMG cells. The ability of TGFβ 
to induce apoptosis is considered to be one of the crucial mechanisms by which TGFβ 
functions as a tumour suppressor (Massagué, Blain and Lo, 2000; Bierie and Moses, 2006; 
Massagué, 2008b; Inman, 2011b). If the observation that SIK inhibition results in the 
potentiation of TGFβ-induced apoptosis can be substantiated in a cancer cell model, this 
raises a novel and interesting therapeutic potential. The majority of pharmacological 
interventions targeting the TGFβ pathway have focused upon inhibiting the pathway, for 
example by using anti-sense oligonucleotides or antibodies directed against TGFβ ligands or 
small-molecule kinase inhibitors of the TGFβ type I receptor (Akhurst and Hata, 2012; Akhurst, 
2017). However, these strategies may be hindered by the potential of impeding the tumour 
suppressive effects of TGFβ in addition to disrupting its numerous homeostatic functions. 
Hence, targeting specific facets of the pathway as opposed to the complete inhibition may be 
a more advantageous therapeutic approach. Consequently, in specific tumour types which 
depend on TGFβ signalling, SIK inhibition may be a potential therapeutic approach by which 
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to promote apoptotic cell death of those tumour cells. Previous published research, along 
with research conducted during the course of this thesis project, has demonstrated that the 
clinically approved small-molecule inhibitors bosutinib and dasatinib are potent inhibitors of 
SIK isoforms (Sundberg et al., 2014; Ozanne, Prescott and Clark, 2015). Both bosutinib and 
dasatinib have been successfully used for the treatment of patients with imatinib-resistant or 
imatinib intolerant chronic phase Ph+ CML or ALL, therefore this indicates that inhibiting SIKs 
for therapeutic purposes can be tolerated in patients. 
Overall, the experiments presented throughout this thesis project have provided 
evidence for the identification of the protein kinases SIKs as novel regulators of the TGFβ 
signalling pathway. Although the precise molecular mechanisms underlying this finding 
remain to be elucidated, the data indicates that SIKs are an additional regulatory component 
of TGFβ signalling and the results presented may contribute toward the further 
understanding regarding the contextual determinants of TGFβ signalling in normal and 
pathological conditions. 
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